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Abstract 
The concept of bioreductive prodrug chemotherapy is introduced in chapter I. Tumour cell 
hypoxia is a significant factor in limiting tumour growth control with conventional radio-
therapy and some chemotherapeutic agents. Following therapy these cells can repopulate and 
cause a relapse of the cancer. On the other hand, hypoxia is unique to tumours, and is 
therefore potentially exploitable. Bioreductive prodrugs are compounds in which a oxygen 
inhibited redox-based bioactivation step triggers a reaction leading to a lethal intermediate. 
The concept of bioreductive DNA alkylators and DNA topoisomerase 11 inhibitors is 
discussed. 
The synthesis of model thiazolylindole compounds based on the natural product BE \0988 
are discussed in chapter 2. Two strategies were employed for the construction of the 
thiazolylindoles: the Hantzsch reaction; and nucleophilic substitution on 2-bromothiazole by 
an indolyl anion. 
The synthesis of thiazolylindolequinone compounds are discussed in chapter 3. The quinone 
C(5) position of the thiazolylindolequinone analogues was elaborated to provide a series of 
cyclic and acyclic C(5)-amino derivatives. 
Synthetic strategies towards the synthesis of indole-2-carboxylates are discussed in chapter 4. 
The Moody-Rees and Cadogan-Sundberg reactions were employed to provide a synthesis of 
the useful highly substituted indole [154]. 
The Brederek imidazole reaction (i.e., the reaction of a amidine and a-halo ketone) is 
discussed in chapter 5. Application of the Brederek reaction was employed towards the 
construction of the bisindole imidazole natural compounds, the nortopsentins. 
The biological properties of the compounds of the compounds synthesised are discussed in 
chapter 6. The compounds were tested for DNA topoisomerase 11 inhibitory activity and 
cytotoxicity under a hypoxic environment. 
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"What have you lost, Mulla ?" 
"My key," said Nasrudin. 
"Where did you drop it ?" 
"At home." 
"Then why, for heavan's sake, are you looking for it here ?" 
"There is more light here." 
a Sufi parable 
Chapter 1 
Introduction. 
- -------------
1. 1ntroduction 
The late John Wayne refered to cancer as "the big C'" and indeed it is a big disease, roughly one 
person in five in the prosperous countries in the world will die from it. In the US the death rate 
from cancer has increased by 7% between 1975 and 1990, and this number has been adjusted 
to compensate for changing size and composition of the population with respect to age, so the 
increase can't be blamed on people dying less often from other diseases. l The challenge to find 
a cure for this disease has not been taken lightly, it has been estimated that since president 
Richard M. Nixon initiated the US "war on cancer" in 1971 over $25 billion has been spent on 
research in the US alone. 
1.1. What are cancers? 
Cancers arise when a cell acquires multiple genetic mutations that together cause the cell to 
escape from normal controls on replication and migration.2 As the cell and its offspring 
multiply uncontrollably, they can invade and damage nearby tissue. Some may also break 
away and travel to parts of the body where they do not belong, establishing new malignancies 
(metastases) at different sites.3 
The clearest definition of cancer is to describe it as a micro evolutionary process4 The body of 
an animal can be viewed as a society or ecosystem whose individual members are cells, 
reproducing by cell division and organised into collaborative assemblies or tissues. In a 
healthy body, self sacrifice, rather than competition is the rule for almost every class of cell. 
All somatic cell lineages are committed to die, leaving no progeny but dedicating their existence 
to support germ cells, which alone have a chance for survival. The cells of multicellular 
organisms are committed to collaboration. Any mutation that gives rise to non altruistic 
behaviour by individual members of the co-operative will jeopardise the future of the whole 
enterprise. Thus mutation, competition and natural selection operating within the population of 
somatic cells are ingredients for a disaster. Cancer is a disease in which individual cells begin 
by prospering selfishly at the expense of their neighbours but in the end destroy the whole 
cellular society and die. 
1.1.1. Strategies involved in cancer therapy 
A major problem in finding a cure for cancer lies in the very nature of the disease. Cancer is a 
disease in which an organisms own cells deviate from normality and eventually cause death. 
The paradox lies in being able to differentiate between "normal" healthy and cancerous cells. 
Successful cancer treatment must rely on the exploitation of consistent and significant biological 
differences between normal and malignant tissues. Three main lines of attack are used in 
contemporary cancer treatment: surgery; radiotherapy; and chemotherapy.4 For cancer 
treatment to be successful the following criteria must be met: 
i) will the treatment prolong the period of useful life ? 
ii) will the quality of life be acceptable? 
iii) will the patient be able to work, to care for itself and to be in less pain? 
The success of surgery in treating localised primary tumours depends on differences in 
topography. The primary tumour is a discrete lesion and, if dissemination has not occurred, 
then surgery exploits this topographical difference and is successful. Once malignant tissue has 
appeared beyond the discrete primary tumour, ie. after metastasis, surgery, in the long term, 
fails. 
Radiotherapy treatments also primarily exploit differences due to locale. If the tumour mass is 
localized, with no distant spread and is not located within or close to highly radiosensitive 
tissues or organs then it may be curable. Intrinsic cellular and tissue differences in 
radiosensitivity of cells to radiation may also determine response to treatment. The 
radiosensitivity of cells depends in part on the oxygen tension (p02) present in the tissue at the 
time of irradiation, refered to as the oxygen effect. Cells in air saturated environments are 
about three times as sensitive to radiotherapy as cells in an oxygen-free environment. Solid 
tumours that contain high proportions of hypoxic (oxygen deficient, low p02) cells are usually 
resistant to attack by radiotherapy5 
Most of the drugs that are used in cancer chemotherapy are antiproliferative agents. DNA 
replication is a necessary precondition for cell division and it contributes a vulnerable target for 
the action of cytotoxic drugs intended to block the multiplication of malignant cells. Two main 
classes of cytotoxic agents will be discussed: the DNA alkylators, drugs that form covalent 
bonds with DNA; and topoisomerase inhibitors, drugs that effect the action of the 
topoisomerase enzymes, enzymes which play a vital role in DNA metabolism. 
A recurring theme in cancer therapy is the need to differentiate between healthy and diseased 
cells. Hypoxic cells are a significant factor in limiting tumour growth control with conventional 
radiotherapy and some chemotherapeutic agents. Following therapy these cells can repopulate 
and cause a relapse of the cancer. On the other hand, hypoxia is a condition unique to tumours, 
and is therefore potentially exploitable. 
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A field of growing importance in cancer treatment is bioreductive prodrug chemotherapy,6 
whereby the hypoxic chemical environment is used to the advantage of the clinician, in that it 
provides a means for the chemical activation of an inert prodrug into a cytotoxic species. These 
bioactivated prodrugs can be used in combination with radio-therapy and conventional 
chemotherapeutic agents. Before discussing the field of bioreductive prodrugs in more detail a 
brief description of the events leading to hypoxia will be mentioned. 
1.1.3. Vasculisation of tumours and the events leading to hypoxia 
Malignant growths are not merely clusters of proliferating cells, often less than half the volume 
of the tumour consists of cancerous cells'? One to ten percent of the volume is contributed by 
blood vessels weaving through the tumour mass. The remaining space is filled, primarily by 
an abundant collagen rich matrix, the interstitium, that surrounds the cancer cells and can 
separate them from the vasculature. The clinical event that converts a self contained pocket of 
aberrant cells into a rapidly growing malignancy comes when the tumour becomes 
vascularised, a process called angiogenisis. This event is triggered when the tumour cells 
release a substance named tumour angiogenisis factor (T AF). This has the capacity to stimulate 
nearby blood vessels to send out new capillaries that grow towards the small colony of tumour 
cells and finally penetrate it. Fresh nutrients pour in and wastes are speedily removed. The 
vascular system of tumours can be highly disorganised, both in its structure and operation. 
The capillaries grow in unpredictable directions that can change from day to day. Consequently 
some areas of the tumour may be well vascularised, whereas others have little or no blood 
supply. Tumour cells in those blood-starved areas may seem, on inspection to be dead, but 
they frequently revive if nourishment returns. 
From the differences in the vascular supply within the tumour mass two different classes of 
tumour microenvironment can be described: those cells nearest the blood supply, well 
oxygenated and well nourished, are the cells most likely to survive and proliferate (oxic cells); 
and hypoxic cells, in which the cellular oxygen tension is depleted, they are poorly nourished, 
are bathed in their own excretion products and they have low proliferation rates.8 Due to poor 
nutrition, hypoxic cells are found which supply their energy requirements by anaerobic 
glycolysis and hydrolysis of ATP. The increased production of protons (by the dissociation of 
the lactic acid produced) during these metabolic processes causes an acidic microenvironment. 
The intracellular pH of hypoxic cells is maintained close to neutral by membrane pumps to 
efflux the protons, thus, resulting in chronic acidification of the extracellular compartment. 
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1.2. The DNA Alkylating Agents 
The alkylating agents are a class of compounds that are capable of reacting in a manner such 
that an alkyl group or a substituted alkyl group becomes covalently linked to cellular 
constituents.9 The main property required by alkylating agents is that they proceed via an 
electrophilic intermediate which will then form a covalent bond with nucleophilic groups on 
cellular constituents such as the nucleic acids, DNA and RNA and proteins. 
Two broad classes of DNA alkylating agents can be described: monofunctional alkylating 
agents; and bifunctional alkylating agents. Monofunctional alkylating agents form a covalent 
bond with a single strand of DNA. A possible consequence of monofunctional alkylation is the 
mispairing of bases in DNA. Such mispairing could lead to miscoding and mutation. I 0 
Bifunctional alkylating agents result in interstrand cross-linking of DNA, this leads to impaired 
template function for further DNA replication. I I Rapidly proliferating cells are supposed to be 
more sensitive to DNA cross-linking than normal cells, because they are not able to repair 
damaged DNA.12 
1.2.1. The nitrogen mustards 
The first alkylating agents to be used in the clinic were the nitrogen mustards ego melphalan [1] 
and chlorambucil [2], which were originally designed from the nitrogen mustard 
mechlorethamine [3], which was synthesised in 1942 and primarily developed as a chemical 
warfare agent. However, on closer inspection into the toxicity of mechloroethamine and related 
compounds it was found that the toxicity was most pronounced in rapidly dividing cells. This 
led to clinical studies throughout the early 1940's into the clinical efficacy of the mustards as 
antitumour agents, however, because of wartime secrecy surrounding all work on nitrogen 
mustards, information about the clinical trials was suppressed until 1946. 13 
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[1] melphalan 
Cl 
HO~r 
I ~_ ~
[2] chlorambucil 
~CI 
H C-N 3~ 
Cl 
[3] mechlorethamine 
Cl 
The proposed mechanism of action of the mustards is shown, Scheme 1, one of the 
chloroethyl side chains undergoes a cyclisation, releasing a chloride ion and forming an 
aziridinium ion intermediate [4],14 in some cases the reaction may proceed via the formation of 
a carbonium ion intermediate [5]. Both the intermediates [4] and [5] are labile towards 
nucleophilic attack by nucleic acids or groups such as amino, carboxyl, sulfhydryl or imidazole 
moieties in proteins. One favoured reaction, of major importance to the cytotoxic effect of the 
mustards, is the formation of a covalent bond between the mustard and the N(7)-nitrogen group 
of a guanine nucleotide [6]. After forming a covalent bond with one DNA strand, the 
bifunctional alkylating agents can then undergo a similar cyclisation of the second side chain 
and form a covalent bond with another nucleophilic group. This second reaction could involve 
the N(7)-nitrogen of another guanine or some other nucleophilic moiety. This may result in the 
fOlmation of drug DNA cross-links [7], or in the binding of DNA to a protein. 
Some of the problems associated with the clinical use of mechlorethamine [3] are due to its 
high chemical reactivity. At physiological pH, this compound can rapidly cyclise to react with 
water or blood and tissue constituents. Replacement of an aromatic ring adjacent to the 
nitrogen as in melphalan [1] and chlorambucil [2] reduces the nucleophilicity of the nitrogen, 
this is due to the electron withdrawing effect of the aromatic ring, and so the rate of cyclisation 
to form the reactive aziridinium ion species is reduced. This decreased reactivity allows time 
for absorption and wide distribution before extensive alkylation occurs. Thus melphalan [1] 
and chlorambucil [2] can be given orally, whereas mechloethamine [3] can only be given 
intravenously. 
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[6) 
Repeat sequence 
CH 3 I 
OH ~N~ OH N~N0 eN~N 
[5) 
A .. Jl ~ ~ Jl .. A 
H2N:--'N ~ [7) ~ N/- NH2 
R R' 
Scheme 1: Proposed mechanism of action of the nitrogen mustard mechloroethamine 
A number of modified mustards have been synthesised in an attempt to obtain an anticancer 
drug that will preferentially localise in a particular tissue. Melphalan [1] is an example of such 
a compound. Since phenylalanine is a precursor of melanin, it was postulated that a 
phenylalanine mustard might preferentially accumulate in melanomas and thereby produce a 
selective effect. 15 
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1.2.2. Bioreductive alkylating agents 
Denny et al. have designed a series of nitrogen mustards which are specifically activated in 
hypoxic environments. 16 As mentioned previously in this chapter, solid tumours are difficult 
to eradicate by conventional techniques because of tumour hypoxia. The dinitrobenzamide 
mustard [8] (NSC 646392) is a poor alkylating agent due to conjugation of the lone pair of 
electrons of the nitrogen mustard with the two nitro groups on the aromatic ring, Scheme 2. 
[8] NSC 646392 
Thus, electron delocalisation reduces the formation of the reactive aziridinium ion intermediate 
to such an extent that the mustard can be considered unreactive. Cellular enzymatic reduction 
of one or both nitro groups will therefore increase the nucleophilicity on the nitrogen and hence 
increase the formation of the reactive aziridinium ion intermediate. However, enzymatic 
reductions of nitro groups are normally oxygen inhibited and so only in hypoxic cells (low 
p02) will there be a build up of the reactive species. In preliminary studies NSC 646392 [8] 
displayed hypoxic selectivity ratios of 10 to 60 fold in vitro cytotoxic assays using a range of 
mammalian cell lines, while separate DNA elution studies showed that more soluble analogues 
based on [8] were activated under hypoxia to form DNA-crosslinking agents. 
Scheme 2: Conjugation of the lone pair of electrons with the nitro groups, greatly reduces the 
nucleophilicity of the mustard nitrogen 
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Bioactivated prodrug therapy offers a unique opportunity for rational drug design within the 
strict criteria dictated by the biological environment. To fully exploit the small proportion of 
fully hypoxic cells present in most solid tumours, bioreductive drugs (BD) must be engineered 
to do three things: 
i) distribute efficiently to the hypoxic regions in tumours; 
ii) undergo selective (oxygen inhibited) metabolism in these hypoxic regions; 
iii) be thus converted to very toxic species. 
Denny has defined BD nicely as being comprised of three domains, namely trigger and effector 
units joined by a linker mechanisml7 While it is not always possible to separate these 
functions clearly, this concept allows independent consideration of the types of structures most 
suitable for each process, and criteria which they must meet. 
The trigger is where selectivity resides. For drugs designed to be reduced by the "background" 
of reductase enzymes in cells, the reduction potentials need to be within a narrow range, to 
J 
ensure appropriate rates of both the forward-reduction and the back-oxidation of the resulting 
one-electron species by oxygen in oxygenated cells, Scheme 3. 
Enzyme 
BD ----' .. ~ Cytotoxic Products 
Scheme 3: One electron reduction of a BD to the corresponding radical anion, and hence to a 
cytotoxic species 
The bioreductive drug (BD) is reduced by a one electron process to the radical anion [9]. Any 
residual oxygen within the cell will reoxidise [9] back to the original drug and form the reactive 
oxygen species (ROS) superoxide (Oy). Oxygen readily accepts electrons from other 
molecules to form oxygen-derived free radicals. It is this property that makes it toxic to cells. 
Many intracellular reactions, including respiration, reduce oxygen to superoxide or hydrogen 
peroxide. These molecules are only moderately reactive with other biological molecules, but 
they can form a hydroxyl radical ("OH), which is highly reactive and might be directly 
responsible for most of the oxidative damage from ROS in biological systems. Aerobic cells 
are endowed with extensive antioxidant defence mechanisms to counteract the damaging effects 
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of ROS, and can be viewed as being under a continual state of "oxidative siege", their survival 
depending on a balance between ROS and antioxidants. 
Moieties which have proved useful as triggers for BD include: nitroaromatics [8],16 quinones 
[10],18 transition metal complexes [11],19 aromatic [12]20 and aliphatic N-oxides [13]21 , 
shown below. 
0 OCONH2 
H2N 
H3C NH 
0 
[10] MMC 
[12] SR 4233 Tirapazamine 
+ 
CH 
"'y} o CH3 
H3C IP ~CI '1:;o-C~Q 
'1 N~ 
H3C ~2N~ Cl 
H3C [11] SN 24771 
OH 0 
0-
OH 0 1+ HN~~-CH3 
CH 3 
[13] AQ4N 
The effector, when released or activated must be much more toxic than both the parent prodrug 
and any ROS generated by futile cycling in oxygenated cells. It should be effective against 
cells in a variety of pH environments and proliferative states and particularly against non-
cycling cells. A further advantage is an ability (defined by half life and reversible binding to 
cell components) to back-diffuse a limited distance from the hypoxic cells in order to kill 
surrounding oxygenated tumour cells. Moieties which have proved useful as effectors for BD 
include: the nitrogen mustards [8] and [11], quinone methides [10], DNA cleaving agents 
such as free radical species [12] and topoisomerase 11 inhibitors [13]. 
The linker mechanism is harder to define physically, and consists largely of mechanistic 
concepts. One widely exploited is activation of an attached mustard by electron release 
following reduction of a nitro aromatic, ego the dinitrobenzamide mustard [8]. Also the 
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indolequinone anticancer compounds, of which mitomycin C (MMC) [10] is a archetypical 
example, can be categorised in terms of the linker mechanism. Reduction of the quinone 
moiety results in the formation of a intermediate species, in which the indole nitrogen is no 
longer in conjugation with the quinone, this leads to formation of a highly electrophilic quinone 
methide intermediate which can alkylate cellular constituents. The indolequinone moiety, as in 
MMC [10], has proved to be an attractive generic scaffold for the synthesis of many novel 
bioreducti ve prodrugs. 
1.2.3. The mitomycins 
The mitomycins were first discovered in 1956 by workers at Kyowa Hakko Kogyo Co., a 
Tokyo'drug company, among fermentation products of Streptomyces caespitosus.22 
Commercial production of large batches of MMC by fermentation of Streptomyces caespitosus 
has allowed its development as a clinical anticancer agent. Despite its toxicity, this 
chemotherapeutic agent was introduced in Japan (1960) and later in the US (1974) for treatment 
of several types of tumours. A compromise between potency and toxicity established MMC 
[10] as the best candidate within the naturally occurring mitomycins for clinical use23 MMC 
has proven to be an effective drug for stomach, breast, and colon cancers and to a lesser extent 
for pancreatic and lung cancers. 
o 3 
Szybalski and Iyer first proposed that MMC acts an alkylating agent that is unmasked following 
reductive activation24 Two latent functionalities, the carbamoyl group and the aziridine, under 
appropriate circumstances are transformed into electrophilic species, a process termed 
bioelectrophilicity. Biochemical investigations have demonstrated that upon reductive 
activation MMC first reacts at C(I) and then at C(10) with the nucleophilic 2-amino residue in 
deoxyguanosines located on complimentary DNA strands, thus allowing the formation of a bis-
DNA cross-linked adduct. 25 ,26 It has been suggested that the formation of intrahelical 
interstrand DNA-MMC adducts inhibits DNA replication, resulting in cessation of cell division. 
The proportion of cross-linked DNA is only about 10% of the mono-alkylation, suggesting that 
there might be a minor pathway with different factors controlling the product outcome.27 
Enzymatic rcduction of a quinone moiety can proceed either by a one electron reduction 
pathway or a two electron reduction, Figure 1. The hypothetical quinone [A] can be reduced 
ID 
by a one electron reduction to the semiquinone radical anion [B] , for example by an enzyme 
such as NADPH: cytochrome P450 reductase, the radical anion [B] can also be further reduced 
to the hydroquinone [Cl. In the presence of oxygen the radical anion [B] will be oxidised to 
the quinone [A]. However, the quinone [A] can also be reduced by an obligate two electron 
reduction, for example by NAD(P)H: quinone oxidoreductase (DT-diaphorase), to the 
hydroquinone [Cl. Danishefsky and Ciufolini have shown that treatment the hydroquinone 
form of MMC with oxygen results in the imediate regeneration of MMC28 The ease of 
bioreduction of a given quinone containing drug will depend on: (i) the ability of the drug to act 
as a substrate for the enzyme(s); and (ii) the expression levels of these enzymes in a particular 
cell type. 
+ 2e' 
0 O· O· 
"))( " ':<r "' "':<r"' + 1 e' .. r-- I + 1e-... r-- I R2 R4 R2 ~ R4 R2 ~ R4 
0 O. 0-
[A] [B] [Cl 
Figure 1: Reduction of a quinone moiety to either a semiquinone radical anion or a 
hydroquinone species 
MMC mechanism of reaction with DNA remains fertile ground for investigation. Attempts to 
model the biological reductive process in the absence of DNA have provided information 
concerning this mechanistic scenario. The focus for debate surrounds the initial reductive 
activation step. The reduction can proceed either by an initial one electron reduction, thus 
forming a mitosene semiquinone radical anion or by a two electron reduction process to provide 
a mitosene hydroquinone. 
It has been proposed that a two electron reduction of MMC to a hydroquinone [14] 
(leucomitomycin Cl would lead to localization of electron density on nitrogen, triggering the 
loss of methanol and resulting in increased electrophilicity of centres CCI) and CC I 0), Scheme 
4.24. This mechanism explains mitomycin's requirement for reductive alkylation and its DNA 
cross-linking. The lone pair of electrons, on the indoline nitrogen, are no longer in conjugation 
with the quinone moiety and are therefore "unleashed", such that ~-elimation of the methoxy 
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substituent is facilitated by neighbouring-group participation, resulting in the indole species 
leucoaziridinomitosene [15], the thermodymamic driving force being the resonance 
stabilisation energy of the aromatic indole nucleus. Release of the high ring strain energy in the 
aziridine ring, thus provides the quinone methide [16]. The quinone methide can then undergo 
electrophilic attack by a proton to form 2,7-diaminomitosene [17], path A. Thus resulting in a 
species unable to covalently bond with DNA at the C(I) position. Conversely, nucleophilic 
attack by a species such as the 2-amino residue in deoxyguanosine affords the C(I) drug-DNA 
adduct [18], path B. Ross et al. have demonstrated the formation of 2,7-diaminomitosene 
[17] as the principal metabolite after administration of MMC to HT-29 human colon carcinoma 
cells and rat hepatic DT -diaphorase. 29 
Schiltz and Kohn have shown that leucoaziridomitosene [15] in water in the absence of an 
external nucleophile undergoes principally electrophilic substitution at C(l), to provide 2,7-
diaminomitosene [17], either at pH 5.5 or 8.5.30 However, in the presence of aniline, as an 
external nucleophile, C(I) nucleophilic adducts predominated at pH 5.5 (path B), while at pH 
8.5 the C( I) electrophilic adduct [17] predominated (path A). The sensitivity of reductively 
activated MMC transformations to both pH and added nucleophile suggested that in MMC in 
vivo processes DNA bonding will not efficiently proceed unless select interactions between the 
activated drug and the DNA surface exist, thereby allowing proper alignment of the activated 
drug in the minor groove. Under conditions where this does not occur, self-destruction of the 
activated drug by primary C( I) electrophilic transformations proceed to yield 2,7-
diaminomitosene [17]. This process prevents indiscriminate drug-DNA bonding and is 
expected to contribute to the overall DNA sequence selectivity observed in MMC-DNA 
transformations. 
MMC, unlike many naturally occurring anticancer drugs, is a small, compact compound. 
Despite what seems to be a structural deficit MMC preferentially bonds to specific DNA 
sequences31 It has been demonstrated that in vitro MMC mono-alkylation transformations 
proceed only at guanine (G*) sites, with 5'CG* dinucleotide sequences being modified at 
appreciably higher levels than 5'AG*, 5'GG*, and 5'TG* sequences and that in vitro and in 
vivo MMC DNA bis-alkylation, interstrand cross-linking processes occur within 
complementary 5'CG* sequences rather than at 5'G*C sequences.32 Kohn et al. have shown 
that MMC monoalkylation reactions at 5'CG* .5'CG sequences are facilitated, in part, by the 
formation of a hydrogen bond between the carbonyl oxygen of the carbamoly group of the 
activated mitomycin species and the N(2)-amino proton on the guanine (G) of the non bonding 
strand)3 This arrangement is expected to promote monoalkylation of DNA by positioning the 
activated drug near a guanine (G*) present on the bonding strand. 
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p-Elimination of the methoxy substituent to form leucoaziridinomitosene [15] has been shown 
to be enhanced under acid catalysis (i.e., methanol is a better leaving group than methoxide). 
There are two mechanisms for methoxy elimination: firstly, specific acid-catalysed elimination 
assisted by the protonated aziridine; and secondly, non-specific elimination.34 The pKa for the 
aziridine functionality in leucomitomycin C [14] is 9.1, therefore, at physiological pH the 
aziridine functionality will exist excessively in the protonated form. The protonated aziridino 
nitrogen can act as an internal general acid, thus facilitating the specific elimination of methanol 
(rate constant kt), Scheme 5. 
- MeOH -H+ 
--_I [15] 
NH 
/0 
H MMCredH+ 
Scheme 5 
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The protonated leucomitomycic species can also facilitate the loss of methanol by a spontaneous 
elimination process (rate constant k2), Scheme 6. Skibo and Boruah reported the rate 
constant for the specific acid-catalysed elimination of methanol (kIl to be 1.5 x 105 M-I s-I 
and for spontaneous elimination of methanol (k2) to be 0.015 M-I s-I)4 The authors also 
reported a 100,000-fold increase in the rate constant (kIl upon reduction of MMC to 
leucomitomycin C [14]. 
H OCONH2 
H OCONH2 0/ 0/ 
H2N (o~W H2N .' H 
-H+ 
.. ' - MeOH 
• [151 
,H .. ~ + H3C N..<±> H3C NH2 H 
/0 MMC,edH+ /0 H H 
Scheme 6 
MMC can also be rendered electrophilic at the CC I 0) position, in the case of the the CC I) drug-
DNA adduct [18], a bis-DNA adduct will be formed [19], Scheme 7. Several mechanisms 
have been proposed for mitomycin C(lO) transformations. In 1981 Moore and Czerniak 
suggested that C(lO) nucleophilic processes occured by an SN2 pathway, path A,35 while in 
1987, Kohn and Zein proposed that C(lO) nucleophilic reactions could proceed via an iminium 
ion [20], which can either undergo nucleophilic attack by DNA to provide the bis-DNA adduct 
[19] or by water to form the mono-DNA adduct [21].36 
14 
Scheme 7 
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Tomasz et at. have proposed a mechanism for monofunctional and bifunctional alkylation of 
DNA by MMC, Scheme 8.37 The monofunctional adduct [18] may react by either of two 
pathways: i) electron transfer (analogous to the mechanism proposed by Peterson and Fisher 
for autocatalytic activation of MMC38) with unreacted MMC or oxygen, thereby losing its 
activated state and giving the monoadduct [22] as the end product, or ii) elimination the C(lO) 
carbamoyl functionality to form the iminium species [20], which is receptive to a second 
nucleophilic attack giving bifunctionally alkylated end product [19]. However, in DNA only a 
fraction of the guanines are at cross-linking distance from another guanine, i.e., those in a 
G*C, CG* or G*G sequence; only that fraction can give the cross-linked adduct [19] upon 
reaction with the iminium ion [20]. Any iminium ion [20] bound to other guanines will react 
with H20 at the activated C(lO) position, therefore forming the mono-alkylated product [21]. 
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Ross et at. studied,the reductive activation of MMC in a cell free system, in order to confirm the 
role of individual reducing enzymes in the process.39 Glutathione conjugates and also binding 
to DNA with interstrand cross-linking were observed during DTD-mediated activation. The 
major metabolite formed was 2,7-diaminomitosene [17]. However, it was discovered that 
increasing amounts of DNA cross-linking were observed during DTD-mediated reductive 
activation of MMC, as the pH was lowered from 7.8 to 5.8. Therefore, at high pH, activation 
of MMC resulted in the non cross-linking 2,7-diaminomitosene [17], whereas at low pH 
MMC was activated to form a cross-linking species. These results were in agreement with an 
earlier report that MMC DNA cross-linking processes were promoted at lower pH. Schiltz and 
Kohn have speculated that with increasing pH a significant amount of the conjugate base [23] 
of the quinone methide [16] is formed, Scheme 9. Formation of [23] should promote C(I) 
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electrophilic processes at the expense of CC I) nucleophilic reactions.30 Although the 2,7-
diaminomitosene [17] formed can be activated to form a C(10) mono DNA adduct it is unable 
to form a cross-linking species. The formation of 2,7-diaminomitosene [17] leads to a net 
increase in electrons, thereby increasing the likelihood of redox transformations with any 
mitomycin hydroquinone species present. 
Quinone methide [16] 
Scheme 9 
[23] 2,7-diaminomitosene [17] 
Evidence has accumulated suggesting that the mitomycin semiquinone radical anion [24] is 
sufficiently activated to trigger the events that lead to the formation of a bis-alkylating 
agent.28,36,40-42 A proposed mechanism of MMC proceding via one electron reduction to the 
semiquinone radical anion is shown, Scheme 10. The basic mechanisms leading to CCI) and 
C(10) activation are generally similar to the hydroquinone pathway (Schemes 4, 7 and 8). 
The initial step is single electron reduction of MMC to the semiquinone radical anion [24], 
which then readily loses methanol. The activated mitosene semiquinone formed [25] is now 
rendered electrophilic both at C(l) and C(10) by opening of the aziridine ring which is assisted 
by the radical anion and by elimination of the carbamate group assisted by the push from the 
indole nitrogen, respectively. However, the first alkylation of DNA is thought to occur at 
CCI). Evidence for this comes from the isolation, after oxidation, of the C(1) mono-DNA 
adduct [28], but not a C(10) mono-DNA adduct. Hence subsequent protonation and aziridine 
ring opening affords the quinone methide species [26] capable of alkylation at CC I). The 
resulting C(1) mono-DNA adduct [27] can then be oxidised to the quinone mono-DNA adduct 
[28], or since it is still a semiquinone radical it can readily lose the carbamoyloxy substituent to 
afford the iminium compound [29] which can cross-link to give the bis CC I)lCC ID) bis-DNA 
adduct [30]. The products [27] and [30] are probably reoxidised to the quinones [28] and 
[31] respectively during isolation and I or by electron transfer between various quinones and 
semiquinone radical anions. The CCI) mono-DNA adduct [27] can be deactivated to the 
unreactive quinone species [28] in a mechanism similar to the hydroquinone pathway, 
Scheme 8, by a redox reaction between oxygen or a quinone species. 
However, the semiquinone radical anion [24] can also be reduced to leucomitomycin [14], 
either by further enzymatic reduction or by a redox reaction with another semiquinone radical 
anion. The hydroquinone [14] can then follow the reactive pathway previously mentioned for 
the mitomycin hydroquinone species, Schemes 4, 7 and 8, to form C(1) mono- or bis 
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C(1)/C(IO) bis-DNA adducts. The mitosene semiquinone [25] may also be further reduced to 
leucoaziridomitosene [15], by a similar mechanism. 
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Scheme 10: A proposed mechanism for the mode of action of MMC 
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Various reductases have been implicated in the in VIVO activation of MMC, including 
NAD(P)H: quinone oxidoreductase (DT-diaphorase (DTD), NADPH: cytochrome P4S0 
reductase (P4S0R), NADH: cytochrome bS (BSR), xanthine oxidase (XO) and xanthine 
dehydrogenase (XDH).43-47 MMC activation by P4S0R, BSR and XO is a one-electron 
reduction while activation by DTD and XHD is a two-electron reduction. 
In toxicity experiments with cell lines high with DTD activity, it has been shown that toxicity of 
MMC is essentially unchanged under hypoxic verses aerobic conditions48 Conversely, with 
cell lines that are deficient in DTD, toxicity is markedly enhanced under hypoxic conditions. 
This suggests that DTD is the major activating enzyme in cells with high DTD expression under 
both aerobic and hypoxic conditions, but a one electron reduction is the major activating 
enzyme in DTD deficient cells. Although there still remains controversy as to the exact nature 
of the initial activation of MMC, what is for certain is that reduction of the quinone provides the 
driving force for the subsequent formation of electrophilic quinone methide species, and hence 
cytotoxic products. 
Despite the therapeutic value of MMC, adverse toxicity prohibits its prolonged use. This has 
led to an intense effort to develop semisynthetic variants with improved efficacy and decreased 
toxicity. The high level of functionality within MMC exacerbates chemical synthesis, to date 
only two complete synthesis of MMC have been accomplished. The problems associated with 
the need to accommodate highly interactive functionality in a rather complex matrix have been 
nicely summarised by Danishefsky "the synthesis of a mitomycin is the chemical equivalent of 
walking on egg shells"49 However, the indolequinone nucleus appears an attractive target for 
the construction of bioreductive prodrugs. Compounds based upon reactive intermediates 
derived from the mechanistic pathways of MMC activation as well as MMC analogues will be 
briefly discussed. 
1.2.5. Synthetic analogues based on the indolequinone moiety of the 
mitomycin natural products 
The so called cyclopropamitosenes [32] are a series of compounds which contain the overall 
shape of the mitomycins, but the electrophilicity at the C( I) position is greatly reduced, by the 
substitution of the aziridine ring for the cyclopropane.50,51.52 It has been suggested that 
reduction of the quinone moiety provides a species in which the indole nitrogen lone pair of 
electrons are "unleashed". This is thought to cause the subsequent elimination of the 
carbamoyloxy group to provide a iminium species which is receptive to nucleophilic attack by 
DNA. The aziridino C(7) substituted cyclopropamitosene [33] shows under anaerobic in vitro 
studies in V79 cells 100 times more potentcy than MMC. 
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MeO 
o 
[32] 
o 
[33] 
E09 [34] is the leading compound in a novel class of indolequinones.53 E09 is considerably 
more active than MMC under both aerobic and anaerobic conditions and it does not cause the 
unwanted side effect myelosuppresion. Reduction of the quinone is thought to activate the 
hydroxyl leaving groups and the aziridine, which gives a total of three reactive centres per 
molecule. Workman et al. have shown that E09 is metabolised by DTD and so initial reduction 
of E09 can be considered to result in the formation of the corresponding hydroquinone.54 
o 
[34] 
OH 
OH 
1.2.6. Analogues based on the mitomycin natural products 
BMY-2506? [35]55 and KW-24l9 [36]56 are analogues of MMC which bear a substituted 
disulfide substituent attached to the C(?) position. They have been found to be superior to 
MMC as anticancer agents and both are presently under clinical trials. 
o 
o 
R = p-nitrophenyl [35] 
BMY-25067 
NH R= H02C(NH2)CH(CH2}zCONHCH2 [36] KW-2149 
Each was designed on the basis of the hypothesis that their disulfide group may mediate 
nonenzymatic reduction of the quinone, initiated by thiols such as glutathione CGSH). Tomasz 
et al. have shown that cleavage of the disulfide by GSH resulted in a sulfoxy anion species 
which can undergo an intramolecular conjugate addition onto the quinone moiety. 57 The 
intermediate species can then undergo an internal redox reaction to yield a semiquinone radical 
anion, a species reminiscent to the semiquinone radical anion [25], Scheme 10. A reactive 
20 
pathway similar to the semiquinone radical anion [25] is believed to result in the cytotoxicity of 
these compounds. However, Kohn and Wang have proposed a novel ionic, nonreductive 
activation pathway for these mitomycins.58 
1.3. DNA topoisomerase enzymes 
Both the extraordinary length of DNA in individual chromosomes and its double helical nature 
present a challenge in terms of accessibility, organisation and segregation of the genome in a 
dense intracellular environment, for example during transcription a copying protein, RNA 
polymerase remains somewhat stationary while the DNA screws through it, Figure 2.59 If 
you have ever been fishing, and the current twists your bait around the end of your line, you 
will know that there would be an unholy mess, likewise it would cause big trouble if Nature 
did not find some way to relieve the twisting stress of DNA during its passage through a 
pol ymerase. 
Figure 2: During DNA transcription the DNA screws through the RNA polymerase 
Regulation of DNA topology is, thus, of critical importance to normal cellular function, and 
one of the principle means by which the cell accomplishes this is the DNA topoisomerase 
enzymes.60 Topoisomerase enzymes cut either one or both of the two sugar-phosphate chains 
to allow some kind of motion in the DNA to relieve the tortional stress; they then re-connect the 
broken parts and thus leave an intact but relaxed DNA. Repeated application of this process to 
a tangled-up piece of DNA will eventually unravel it. By opening transient gates in the DNA 
backbone, DNA topoisomerases assist in solving helical winding and tangling problems of 
DNA during its replication, transcription, recombination and repair. 
DNA topoisomerases can be classified into three evolutionary independent families or types: 
type 1-5', type 1-3', and type 11.61 All known DNA topoisomerases share two characteristics. 
The first is their ability to cleave and reseal the phosphodiester backbone of DNA in two 
successive transesterification reactions. During the transient DNA cleavage stage, a covalent 
DNA-protein intermediate is formed between a tyrosine hydroxyl group of the topoisomera~e 
and a DNA phosphate break site. Because the bond energy is conserved in the protein-DNA 
intermediate, no energy cofactor is required for this DNA breakage and rejoining activity. The 
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second characteristic is that once a topoisomerase-cleaved DNA intermediate is formed, the 
enzyme allows the severed DNA ends to come apart, opening a gate for the passage of single-
or double-stranded DNA segment. 
Type 1-5' topoisomerases bind, cleave and open transient gates in single stranded DNA 
segments, in order to allow the passage of another single strand- or double-stranded DNA 
segment. In the DNA cleavage stage, the protein-DNA covalent intermediate is formed 
between a tyrosyl residue and the 5'-phosphate at the DNA break site. Type 1-3' 
topoisomerases bind preferentially to double-stranded DNA, and cleave one of the DNA 
strands of the duplex by forming a protein-DNA covalent intermediate between a tyrosyl 
residue and the 3'-phosphate at the break site. During the DNA cleavage stage, the unbroken 
strand can pass through this enzyme-operated nick and release the twisting stress of a DNA 
double helix 
Unlike type I topoisomerases, type Il topoisomerase (topo Il) is ATP dependent and functions 
as a paired molecule. In eukaryotes, the two halves of the enzyme are formed by two identical 
polypeptide chains, ranging from 160 to 180 kDa each. Harrison et al. have recently reported 
the X-ray crystal structure of a large fragment of yeast DNA topo Il, which reveals a heart-
shaped dimeric protein with a large central hole.62 A molecular model of the enzyme has been 
posulated, whereby topo Il acts as an ATP-modulated clamp with two sets of jaws at opposite 
ends, connected by multiple joints. An enzyme with bound DNA can admit a second DNA 
duplex through one set of jaws, transport it through the cleaved first duplex, and expel it 
through the set of jaws, like a boat passing through a lock. 
The two-gate mechanism of type II DNA topoisomerases is shown, Figure 3. In (a) the 
enzyme is in the form of an open clamp, and is bound to a DNA duplex, which will become the 
DNA gate (the G-segment). A second DNA duplex (the T-segment) can go in and out of the 
G-segment-bound enzyme so long as the clamp remains in the open conformation. In (b) 
binding of ATP closes the protein gate composed of the amino-terminal domains of each half of 
the homodimer. If closure results in the capture of the second DNA duplex, it will pass 
through the entire interface between the two halves of the topoisomerase, cross the transiently 
broken G-segment of DNA and exit through a second protein gate located at the opposite site of 
the entrance gate. In (c) once the T-segment is outside, this second gate closes and the rejoined 
G-segment remains trapped inside the protein clamp. The enzyme returns to the open-clamp 
form, bound to a G-segment, after ATP hydrolysis and release of the products. The black dots 
in (b) indicate the DNA 5'-phosphodiester linkages between the G-segment of DNA and the 
topoisomerase, and the (N) denotes the amino-terminal domains of the enzyme. If the G- and 
T-segments reside in the same DNA molecule, the topoisomerase may either eliminate DNA 
supercoils or interconvert knotted forms in such a DNA molecule. If the G- and T -segments 
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belong to different DNA molecules, ,the topoisomerase will catalys~ their catenation or 
-. __ . _ .. ~deca~na~on. T ----
" .111.~ • 
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Figure 3: The two gate mechanism of topo 11 
The addition of a strong detergent such as sodium dodecyl sulfate (SDS) to a topo II reaction 
results in the cleavage of a small proportion of the DNA molecule and the CDvalentlinking of a 
topoisomerase polypeptide to the 5'-phosphoryl end of each broken DNA strand.63 Both 
single- and double-strand DNA breaks are produced. The cleavage reaction is rapid and can be 
. reversed by the addition of 0.5 M NaCl priorto detergent addition. DNA remains superhelical 
after salt reversal, suggesting that no free ends are generated in this partial reaction.b3 A simple 
.. 'two state model has been proposed for this partial reaction, Figure 4. A topoiso;nerase U-
. DNA cleavable complex (C), the presumed key covalent intermediate ill the strand-passing 
reaction, is proposed to be in equilibrium with at least one other to po II-DNA complex, the 
non-cleavable complex (B).64 Exposure of the cli,!avable complex to a protein denaturant, such 
".' '.' "~ a strong detergent, results in DNA cleavage and the covalent linking of a topo 1I subunit to 
. the 5'-phosphoryl end of the broken strand. Interaction of a second DNA segment with the 
cleavable complex presumably triggers the strand passing reaction (DJ. 
,. 
: 
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Figure 4: A schematic representation of the mechanism of topo II 
1.3.1. DNA topoisomerase inhibitors as anticancer agents 
Studies have shown that both proliferating "normal" and tumour cells contain high levels of 
topo IT, however, topo II is regulated very differently in tumour cells.65 In tumour cells high 
topo IT activity is important for cell proliferation and in turn tumour cells have been shown to be 
sensitive to topo II poisons. Oestrogen stimulation of human breast cancer cells enhances the 
induction of DNA cleavage by such topo IT poisons, and the increased DNA cleavage correlates 
with enhanced cytotoxicity. Since proliferating tumour cells exhibit higher levels of both topo 
II and hormone receptors than do "normal" cells, rational new strategies for the selectivity and 
efficacy of a systemic therapy in hormone-dependent malignancies, such as breast, prostate and 
testicular cancer, have been suggested66 
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1.3.2. DNA illtercalators as topo 11 illhibitors 
Many DNA intercalators have been shown to have antitumour activity, among them acridines 
and anthracyclines have been studied most extensively67 DNA intercalators are flat aromatic 
molecules which can insert between two adjacent layers of base pairs and are held there 
primarily through van der Waals forces. However, despite extensive effort in analogue 
synthesis the antitumour activity of these intercalators was not understood. No single known 
parameter of these drugs, e.g. DNA binding strength, drug hydrophobicity or ability to inhibit 
ON A synthesis correlated with drug cytotoxicity. A good example of this is the pair of 
isomeric acridines m-AMSA [37] and o-AMSA [38], both compounds intercalate with DNA 
but only m-AMSA showed strong antitumour activity.68 
[37] [38] 
~NHS02CH3 
HN~OCH3 
~ ~ 
The clue that DNA damage might be responsible for antitumour activity came from studies of 
m-AMSA [37], which induced limited fragmentation of chromosomal DNA in cultured 
mammalian cells, in addition protein-DNA cross-links were also observed.69 The DNA strand-
breaks and protein-DNA cross-links seemed to derive from the same DNA damage since they 
were produced synchronously at a molar ratio close to unity. The disappearance of the DNA 
strand-breaks and protein-DNA cross-links upon removal of [37] from the culture media 
followed a similar pattern. This suggested that one terminus of the broken strand might be 
linked to a protein 70 
It was rationalised that the protein-associated breaks were produced by a nuclease. Using 
exonucleases, Marshall et al. demonstrated that the 5' termini of DNA fragments produced in 
cells exposed to [37] were blocked by a protein71 The similarity between m-AMSA [37] 
induced DNA damage and topo II linked DNA breaks in a partial topo II reaction, Figure 4, 
led to the initial testing of [37] using purified mammalian topo 11 m-AMSA [37] but not the 
inactive isomer o-AMSA [38] was shown to stimulate topo II-mediated DNA damage, ATP 
stimulated the reaction several fold. Topo 11 was covalently linked to the 5' phosphoryl end of 
each broken DNA strand via a phosphoryltyrosyl linkage. Nelson et al. proposed that m-
AMSA [37] interfered with the breakage-reunion reaction of topo 11 by trapping the key 
reaction intermediate, the cleavable complex.72 m-AMSA is thought to stabilise the cleavage 
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complex by fonning a non-productive drug-enzyme-DNA ternary complex. Studies with other 
intercalative antitumour drugs, such as adriamycin [39] and ellipticine [40], produced similar 
results,?3 
The results imply that it is formation of the cleavable complex and not the subsequent loss of 
topo II activity which is responsible for lethality. The putative role of topo II in mediating 
antitumour activity is a somewhat novel one in cancer phannacology, namely that the drug 
action does not result from blocking a normal enzyme function but rather by subverting it in 
such a way as to render the enzyme a lethal instrument. In a sense, the enzyme becomes a 
required co-factor for drug action. 
There is little infonnation in mammalian cells regarding the mechanism by which the cleavable 
complex results in cell death. Inhibition of cell division, DNA synthesis and DNA degradation 
have all been shown to be associated with topo II poisons,?3 It has been speculated that 
increased sensitivity to oncogenes, expressed in malignant cells, could contribute to the 
specificity of these antitumour agents. 
1.3.3. DNA topoisomerase inhibitors 
Due to the increasing importance of DNA topoisomerase the search for compounds which have 
a high inhibitory effect has been initiated. This search has followed screening of new natural 
products that have been elucidated as well as synthetic analogues derived from known topo II 
inhibitors. 
Of the naturally occurring compounds the indolequinones, makaluvamine A [41] and 
makaluvamine F [42] have been shown to be potent inhibitors of topo n. The malaluvamines 
where discovered from the Fijian marine sponge Zyzzya sp,?4 
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Also recently described is the natural product BE 10988 [43], which was isolated from culture 
broths by Japanese workers, which has been claimed to be a potent inhibitor of topo rr.?5 Of 
the synthetic topo II inhibitors etoposide [44] (VP 16, 'Vespesid') is the most promising to 
date, this agent is a semisynthetic analogue of the natural compound podophylotoxin. 
Etoposide seems to be of most clinical value in non-small-cell lung cancer and certain types of 
testicular cancer resistant to other therapies.?3 
o 
[43] 
Macdonald et al. have hypothesised in the ternary drug-DNA-enzyme 'cleavable complex' the 
principle interaction of the drug is with DNA and that drug-DNA complexation distorts the 
DNA duplex in a fashion similar to an intermediate in the enzymes catalytic cycle.?6 The model 
postulates three domains: the first, an aromatic domain proposed to be involved in DNA 
intercalation or 'intercalation like' DNA association; second, a substituent appended to the 
planar domain, which has hydrogen bonding functionality and is proposed to interact with the 
DNA minor groove; and thirdly, a domain of considerable structural diversity, which extends 
above the intercalation region and is also proposed to lie in the DNA minor groove. Macdonald 
et al. have used this model to synthesise hybrid molecules which are composed of subunits of 
existing topo 11 active agents. Azatoxin [45] is a unique topo II-directed agent which 
represents a hybrid of the ellipticine [40] and etoposide [44] nuclei.?? 
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The molecular model for the interaction of drugs with topo II and DNA has been refined by 
Capraico, who has suggested that topo n inhibitors intercalate between the base pairs in the 
enzyme-DNA complex and that this intercalation interferes with the enzyme's activity and 
prevents the resealing of DNA.78 
1.3.4. Bioreductive prodrugs of topo 11 inhibitors 
As mentioned previously the need for selective anticancer agents is a crucial factor in the 
synthesis of novel compounds. Patterson et al. have applied the idea of a bioreductive prodrug 
to a topo n inhibitor, Scheme 1121 The alkylaminoanthrquinone [13] (AQ4N) is a synthetic 
DNA affinic agent broadly based on the anthracycline antibiotics. AQ4N [13] is metabolised 
to AQ4 [46] which is a potent topo II inhibitor in a 4 electron process, possibly by cytochrome 
P450. 
OH 0 
O' 
/'-... /'-... 1 M e HN- """"-/ -N:;: 
1 
Me 
O' 
1+ 
OH 0 HN~~'Me 
AQ4N [13] Me 
Scheme 11 
OH 0 
Me 
1 
OH 0 HN~N'Me 
AQ4 [46] 
Denny et al. have also applied the postulate of a bioreductive prodrug to a topo n inhibitor, and 
again the reduction of an aliphatic N-oxide provided the bioreductive focus, Scheme 12. 
DACA [48] is a potent cytotoxin, a DNA intercalator, and an inhibitor of topo n. It shows 
strong activity against some murine solid tumours, and is currently in phase I clinical trials as 
an anticancer agent. DACA N-oxide [47] was designed as a non-toxic prodrug which can be 
reduced to the corresponding amine [48] under hypoxic conditions,?9 
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lA. Research aims 
The indolequinone moiety has been shown to be incorporated in a wide range of bioreductive 
prodrugs, of which MMC [10] is a leading example. Biological reduction of the quinone 
provides the initial impetus for the activation into a cytotoxic species. The unique 
thiazolylindolequinone structure of the natural compound BE 10988 [43] suggested that 
analogues could be synthesised which are specifically activated under a hypoxic environment 
into cytotoxic agents. The nature of the cytotoxic effect being a consequence of either: 
i) DNA alkylation, as a result of activation into a highly electrophilic species; 
ii) inhibition of the topoisomerase IT, based on the reported potent topo IT inhibition of BE 
10988 [43]. 
104.1 Aziridinyl quillones as bioreductive alkylating agents 
Functionality was required on the indolequinone nucleus of BE 10988 [43] which would be 
activated following reduction of the quinone into a species capable of alkylating DNA. The 
attachment of a quinone moiety on the nitrogen of an aziridine ring discourages nucleophilic 
ring opening, as in structure [49], Scheme 13. However, reduction of the quinone facilitates 
protonation to form a aziridinium ion intermediate [50] and hence nucleophilic ring opening to 
form the ring opened amino derivative [51].80 
Nu 
i'NAR' 't.4'hR' ~~)yR' 
R1~R-3 ----o·~R1yR3-----l: .. 1VR3 
o OH OH 
[49] [50] [51] 
Scheme 13 
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Examples of such aziridino quinone componds include the highly functionalised quinone 
MeDZQ [52]SI and the aziridino indolequinones [33] and [34]. The high ring strain energy 
of aziridine provides the driving force for nucleophilic ring opening. Lafleur et al. have 
reported the order of reactivity of aziridinyl quinones towards the cleavage of DNA to be 
un substituted > mono-methyl> bi-methyl > ring open. Protonation of the aziridine moiety was 
required prior to the cleavage of DNA.S2 The C(5) amino functionality on BE 10988 appeared 
to be the ideal site for the incorporation of a range of aziridine moieties. 
The highly strained nature of aziridines results in a difference in chemistry. in regards to other 
cyclic amines. in two key areas: firstly. the basicity is greatly reduced; and secondly. aziridines. 
especially protonated aziridines (aziridinium ions). are prone to nucleophilic ring opening 
reactions.S3 Major factors involved in the nucleophilic ring opening of aziridines are: the nature 
of the attacking nucleophilic species; steric effects of substituents on the aziridine ring; and the 
electron-accepting properties of substituents attached to the nitrogen atom. the greater the 
electron withdrawing ability of the nitrogen substituent the greater the rate of ring opening. 
Skibo et al. have studied the hydrolytic chemistry of the reduced benzimidazole (BI) [54] in 
aqueous buffer. Scheme 14.S4 Reduction of the quinone [53] by palladium catalysed 
hydrogenation in a pH 7.4 buffered solution formed the corresponding hydroquinone [54]. 
All the reactivity was found to centre around the aziridinyl ring. which could trap either a 
proton or a nucleophile. Anaerobic incubation of [54] followed by aerobic workup provided 
the products [55]. [56] and [57] (Nu= OH) in 9.1.37.7 and 26.7% yield respectively. The 
products [55] and [56] were formed by proton trapping of the aziridinyl group and [57] by 
nucleophilic ring opening. in this case water acted as the nucleophile. However. when 600-bp 
calf thymus DNA was incubated with the reduced benzimidazole [54]. a blue BI-DNA adduct 
was obtained upon aerobic workup of the reaction [57] (Nu= DNA). The blue chromophore 
is the amino quinone moiety formed upon nucleophilic trapping by the aziridinyl hydroquinone 
followed by air oxidation to the quinone. Removal of the chromophore was not possible by 
precipitating the DNA or by repeated washing with ethanol. The formation of this adduct 
occurred at the expense of the hydrolysis products which were obtained in low yield: [55]. 
1.9%; [56]. 8%; and [57] (Nu= OH) 5.6% yield. 
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Scheme 14: Reagents and conditions: i) H2. Pd on carbon. pH 7.4 Iris buffer 
Bourah and Skibo have suggested a possible mechanism for the hydrolysis products formed 
from the aziridino moiety following initial reduction of the quinone to a hydroquinone, 
Scheme 1585 The aziridinyl hydroquinone [58] can either undergo proton assisted ring 
opening to afford the iminoquinone species [59]. This can then either undergo a further 
protonation to give the amino quinone [60], or can perform a [3,3] sigmatropic rearangement 
to create the intermediate imino species [61]. Hydrolysis of the imino hydroquinone yields the 
amino quinone [62]. However, protonation of the aziridine forms the aziridinium ion species 
[63] which is labile to nucleophilic ring opening, and so nucleophilic attack produces the 
substituted amino hydroquinone [64], which, after oxidation provides the quinone [65]. 
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Scheme 15 
The mechanism of BI alkylation involves oxygen alkylation of the DNA phosphate backbone, 
Scheme 16.86,87 Trapping of the phosphate oxygen anion by reduced quinone [63] affords 
a phosphotriester [66]. Aerobic workup of the alkylation reaction then provides a blue DNA 
adduct [67]. Hydrolysis of this adduct in base results in cleavage of the DNA at 
phosphotriester linkages. In the absence of oxygen, the hydroquinone form of the adduct [66] 
can facilitate backbone cleavage by internal nucleophilic attack to result in single-strand 
cleavage. The single-strand cleavage sites were found to be exclusive to guanine and adenine 
bases. 
The G and A specifity was explained by complexation of the reduced BI [54] in the major 
groove by hydrogen bonding to G and A bases, resulting in placement of the aziridinyl group 
proximal to the phosphate backbone. Molecular models with the similar hydroquinone BI 
analogue [68] showed that major-groove binding as a result of Hoogsteen-type hydrogen 
bonds could result in phosphate backbone alkylation, Figure 5. The PBI hydroquinone [68] 
contained additional hydrogen bonding functionality in the form of the carbamate group, the 
aziridine, the benzimidazole nitrogen and the hydroquinone. 
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Figure 5: Hoogsten-type hydrogen bonding of the reduced PBI allows phosphate backbone 
alkylation of DNA 
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The aziridinyl quinone E09 [34] has a similar cytotoxicity profile to the benzimidazole-based 
DNA cleaving agents. In addition, both E09 and the BI have the unique property of not 
suppressing bone marrow. Since E09 possesses some structural similarities to the BI agents, 
both classes of antitumour agents have been postulated to have a similar cytotoxicity 
mechanism. 
Aziridino quinones have been shown to be reductively activated to result in a species capable of 
alkylating the phosphate backbone of DNA. Nucleophile-assisted breakdown of the resulting 
phosphotriester DNA results in cleavage of DNA. The addition of a aziridine moiety at the 
C(5) position on the thiazolylindolequinone BE 10988 [43] suggested that the synthesis of a 
bioreductive alkylating agent could accomplished. The aziridino thiazolylindolequinone 
compounds [69] and [70] were therefore selected as synthetic targets. The 
thiazolylindolequinone [69] being the C(5) aziridinyl analogue of BE 10988. The C(5) 
aziridinyl thiazolylindolequinone [70] was selected for two reasons: firstly, to study the 
biological effect produced by changing the position of the thiazole ring: and secondly, the 
indolequinone C(3) activated to form a iminium ion which can alkylate DNA, e.g. MMC [10] 
contains the carbamate CH20CCO)NH2 functionality at the indole C(3) position. Therefore the 
addition of similar functionality at the C(3) position on [70] was hypothesised to result in the 
formation of a electrophilic species following quinone reduction, e.g. RI = CH20H or 
CH20CONH2· 
R 
~ Ay'R HN 
L'N 
0 ~ S 
L'N 
0 R1 
L'N 
-N 
NJ R 'I \ s 
0 0 0 
[69] [70] [71] 
The mechanism of BI cytotoxicity has been shown to involve DNA cleavage as a result of 
binding to the major-groove followed by phosphate backbone alkylation. The major-groove 
binding was thought to be a result of Hoogsteen-type hydrogen bonds, between the drug and 
DNA, Figure 5. The pKa of the thiazole nitrogen is 2.53 and would therefore be expected to 
show poor hydrogen bonding acceptor properties. The C(5) aziridinyl imidazolyl-
indolequinone compound [71] was postulated as a compound more likely to result in hydrogen 
bond formation with DNA. The pKa of imidazole is 7.0 whereas for benzimidazole the pKa is 
5.3. The increased basicity of the azole nitrogen in imidazole over thiazole will greatly enhance 
hydrogen bond acceptor properties. 
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1.4.2. Investigation into the topo 
thiazolylindolequinone natural compound BE 
11 inhibitory 
10988 [43J 
affect of the 
The thiazolylindolequinone natural compound BE 10988 [43] was reported to act as a inhibitor 
of topo n. A major requirement for topo II inhibitors is that they possess DNA intercalation or 
'intercalation like' DNA association properties. Lerman has proposed a model for DNA 
intercalators, in that they are flat heteroaromatic species which insert between two adjacent 
layers of base pairs and are held there by Van der Waals forces. 88 A consequence of DNA 
alkylation is that the DNA helix is partially lengthened and thus somewhat unwound, in 
comparison to the original structure. Upon intercalation the average separation between two 
stacked base pairs increases from 3-4 A. to approximately 7-8 A.. If there is a sidechain present 
in the molecule, it can interact with the phosphates of the DNA backbone. The 
thiazolylindolequinone natural compound BE 10988 [43] contains the aromatic thiazole 
moiety. Although a single thiazole ring would not be expected to result in DNA intercalation, 
bithiazoles are known to result in 'intercalation like' DNA association. The bithiazole [73] is a 
side chain of the chemotherapeutic agent bleomycin A2.89 Stubbe et al. have established 
unambiguously that the mode of binding of Co bleomycin A2 green involves partial 
intercalation of the bithiazole side chain and the binding is with the DNA minor groove.90 ( see 
Chapter 3 for a more detailed dissusion of bleomycin and related products). Elaboration of the 
thiazole moiety on the thiazolylindolequinone [72] to the bithiazole [73] would be expected to 
significantly increase DNA intercalation. 
x 
o 
o 
[72] [73] 
The substituent X attached to the quinone ring in [72] will influence the biological activity in 
several ways: 
i) the reduction potential of the indolequinone moiety is dependent upon substituents attached to 
the quinone. The ease of reduction is associated with the electron donating power of the 
quinone substituent at C(5). Increased electron donation into the quinone moiety consequently 
increases the electropotential of the quinone, therefore augmenting the energy required for 
reduction; 
ii) modification of the C(5) substituent may change the partition coeffIcient of the drug, and 
hence affect the cell penetration of the chemotherapeutic agent; 
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iii) The C(5) can alter the stability, reactivity, and toxicity of the activated drug; 
iv) changes in the steric size and composition of the C(5) substituent may influence the ability 
of the drug candidate to bind (i.e., van der Waals, hydrogen bond) to DNA. 
Therefore, a series of amino and alkoxy derivatives with varying electron donating abilities 
were selected for incorporation on to the C(5) position. 
1.5. Conclusions 
• Although hypoxia can be regarded as being deleterious towards conventional cancer 
therapy, bioreductive prodrug chemotherapy can be utilised as a means of forming hypoxia 
selective cytotoxic species. 
• Bioreductive prodrugs can be considered to comprise of three domains: trigger and effector 
units joined by a linker mechanism. 
• DNA alkylating agents have been shown to be applicable towards bioreductive prodrug 
chemotherapy, with particular reference to indolequinones. 
• DNA topoisomerase II inhibitors have also been shown to be applicable to a bioreductive 
activation process. 
• Aziridino quinone moieties have been shown to act as bioreductive prodrugs. Hence 
bioreductive aziridino thiazolylindolequinone analogues based on the natural compound BE 
10988 [43] have been hypothesised. 
• The incorporation of functionality known to result in 'intercalation like' DNA association 
onto the thiazolylindolequinone nucleus was hypothesised to result in an increase in topo II 
activity. 
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Chapter 2 
The synthesis 
of 
thiazolylindoles. 
2.1. Introduction 
Before embarking upon the synthesis of complicated indoiequinone analogues based on BE 
10988 [43], with the generic structure [74], it was decided to carry out the synthesis of 
'simple' thiazolylindoles loosely based on the structure [75], in order to gain an insight into 
the chemistry of these species. The synthesis of 'simple' thiazolylindole analogues will be 
discussed within this chapter and the synthesis of the more structurally challenging 
indolequinones [74] in chapter 3. 
o [43] 
2.2. The synthesis of thiazoles by the Hantzsch reaction 
The overall strategy for the construction of the thiazole ring was by a Hantzsch thiazole 
reaction.91 The Hantzsch synthesis is the cyclisation of an a-halo or a-hydroxycarbonyl 
compound [76] (X = Cl, Br, I or OH) with a thioamide [77], shown below.92 
JL ______ ~=~2~S~~ 
+ R3 NH2 "" R3 
[76] [77] [78] 
The regiochemistry of the Hantzsch reaction can be explained upon close inspection of the 
reaction mechanism, Scheme 17. Nucleophilic substitution by sulfur, on the halogen of the 
of the a-haloketone, occurs first to give the open chain thioketone [79] which then undergoes 
proton transfer followed by 5-Exo-Trig cyclisation to form the intermediate 4-hydroxy-tl-
thiazoline [80]. Acid catalysed dehydration in protic solvents of the protonated intermediate 
[81] provides the aromatic thiazole species [78]. Thiazole is an electron rich aromatic 
compound which can be considered to apply to the Hiickel (4n + 21t) electron rule and so the 
resonance stabilisation energy of the aromatic system provides the driving force for the 
reaction. 
37 
11 
[78] 
Scheme 17: The mechanism of the Hantzsch reaction 
Retrosynthetic analysis of the generic thiazolylindole [75], Scheme 18, applying the 
Hantzsch reaction for the construction of the thiazole moiety yields the indole thioamide [82] 
(Z= S) and a-haloketone [83] reaction precursors. The indole thioamide [75] can be derived 
by functional group interconversion from a corresponding amide [82] (Z= 0). Unfortunately 
indole substituted amides were not commercially available, therefore, an independent synthesis 
of these reaction precursors was required. 
z 
;. 
[83] 
Scheme 18: Retrosynthesis of the generic thiazolylindole [75] 
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2.3. The synthesis of various thiazoles containing a indole moiety at the 
thiazole e(2) position, by the Hantzsch reaction 
The conventional synthesis of primary amides involves the reaction of an acyl halide with 
ammonia.93 Commercially available indole-3-carboxylic acid [84] was both N- and 0-
methylated by reaction with iodomethane in DMF under a nitrogen atmosphere employing 
potassium hydride to form [85] in 95% yield, Scheme 19. IR spectroscopy of the indole 
derivative [85] showed the characteristic ester carbonyl C=O absorption at 1687 cm-I, the low 
value can be explained by electron delocalisation from the indole nitrogen with the carbonyl. 
Hydrolysis of the methyl ester functionality afforded the indole carboxylic acid compound 
[86] in 81 % yield. Activation of the carboxylic acid functionality to an acyl chloride derivative 
was accomplished by reaction of the indole carboxylic acid [86] with 20 equivalents of thionyl 
chloride in refluxing dichloromethane. in situ Monitoring of the reaction by IR spectroscopy 
showed the appearance of the acyl chloride C=O absorption at 1766 cm- I and the loss of the 
carboxylic acid C=O absorption at 1710 cm- I after 2 h. The excess thionyl chloride and 
dichloromethane were carefully removed by evaporation [CAUTION thionyl chloride is a 
lachrymator], and the crude indole acyl chloride was reacted with liquid ammonia at -78°C to 
form the desired indole amide [87] in 60% yield. 
CONH2 ~ ...... E--_iii __ _ 
vi 
Me 
[87] [86] 
Scheme 19: Reagents and conditions i) KH, DMF, Me!, N2, 95%, ii) KOH, THF, H20, reflux, 16 h, 
SI %, iii) SOCI2, CH2CI2 then NH3, CH2CI2, -7S'C, 60% 
However, upon scale-up, the amination reaction proved capricious and so it was decided to 
synthesise the key indole amide [87] via a more efficient process. Closer inspection of the 
literature revealed a variety of methods for the direct conversion of carboxylic esters into 
primary carboxamides. The most commonly used protocol appeared to be that pioneered by 
Weinreb et al.,94, 95 in which an ester is reacted with trimethylaluminum and ammonium 
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chloride in benzene to form the corresponding primary amide in moderate to good yields, e.g. 
the conversion of ethyl nicotinate [88] to nicotinamide [89] in 32% yield, Scheme 20. 
~CONH2 
~.J N 
[89] 
Scheme 20: Reagents and conditions i) Me3AI, NH4CI, benzene, 60°C, 16h, 32% 
Reaction of the indole ester derivative [85] under the Wienreb protocol formed the desired 1-
methylindole-3-carboxamide [87] in 74% yield, Scheme 21. 
OMe 
Me Me 
[85] [87] 
Scheme 21: Reagents and conditions i) Me3AI, NH4CI, toluene, 60°C, 74% 
Weinreb has suggested the amination reaction proceeds via a methyl chloroaluminum species 
[90], formed from initial reaction of trimethylaluminum and ammonium chloride, Equation 
1, although isolation and characterisation has not been reported.95 The intermediate aluminum 
species [90] is then thought to react with the ester to form the amide. 
Cl 
, 
Benzene 
Equation 1: Weinreb's initial postulation as to the reaction intermediate 
However, Sidler et al. have recently studied the mechanistic implications of the Weinreb 
amination procedure, with particular reference to the reaction between N,N-dimethylamine, 
trimethylaluminum and methyl benzoate.96 Contrary to the original postulation by Weinreb, 
they failed to find any of the so called trivalent aluminum species [90], however, IR, IH NMR 
and 27 Al NMR spectroscopy supported the formation of the tetrahedral complex [91], 
Equation 2. 
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H3C,,_ I 
-----J.~ ;AI,- + CH4(g) 
H3C N(CH3)2 
[91 ] 
Equation 2: The formation of the tetrahedral aluminium species 
Either independent synthesis of the tetravalent complex [91] or in situ formation, followed by 
reaction with methyl benzoate afforded quantitative conversion to N,N-dimethylbenzamide 
[92], Scheme 22. Both in situ 27 AI NMR and IR studies of the reaction showed the 
disappearance of the ester functionality accompanying the formation of the amide. Thus 
supporting a mechanism where the benzamide is formed directly under the reaction. 
o 0 
)l ---- )l Ph OMe Ph N(CH3h [92] 
Scheme 22: Reaction of the tetravalent aluminium complex [91] with methyl benzoate 
Closer inspection of the literature also revealed a method for the direct conversion of indole 
[93] to the corresponding indole-3-carboxamide derivative [95], Scheme 23.97, 98 
Electrophilic substitution of indole with chlorosulfonylisocyanate (CSn forms the intermediate 
N-chlorosulfonyl amide [94], which may be isolated, or cleaved under hydrolytic conditions 
(10% potassium hydroxide, acetone, water) to provide indole-3-carboxamide [95] in 60% 
yield. 
~ ~l 
H 
[93] 
o 
[94] [95] 
Scheme 23: Reagellls and conditions i) CS!, MeCN, O°C to 25°C, ii) KOH(aq), acetone, 60% 
Reaction of the cheap and commercially available l-methylindole [96] with CSI in acetonitrile 
followed by hydrolysis with 10% aqueous potassium hydroxide in acetone formed the desired 
indole amide [87] in 60% yield, Scheme 24. The reaction could be carried out on a large 
scale (i.e. > 5g) with no adverse effects in the reaction yield. 
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Scheme 24: Reagents and conditions i) CSI, MeCN, Doe to 25°C, ii) KOH(aq), acetone, 60% 
The conversion of l-methylindole-3-carboxamide [87] to the corresponding indole thioamide 
derivative [97]. was achieved by reaction with Lawesson's reagent (LR) [99], Scheme 
25.99 LR was originally chosen as the thionating reagent for the conversion of amides to 
thioamides because of its reported superior yields and low tendency towards the formation of 
decomposition products. 100 However, performing the reaction with 0.5 equivalents of LR in 
refluxing toluene occasionally resulted in the formation of considerable amounts of the 
unwanted decomposition product [98]. In some cases the sole product was the decomposition 
product [98]. Performing the thionation reaction in refluxing benzene, rather than toluene, 
resulted in a 60% yield of the desired indole thioamide and a significantly decreased yield of the 
decomposition product, i.e., < 10%. The yield of the decomposition product was found to be 
dependent upon the reaction time and the purity of the LR. The use of freshly recrystallised LR 
dramatically reduced the amount of decomposition product. 
CONH2 ~ vi 
Me 
[87] [97] 
NH2 CN 
+~ VN/ 
Me 
[98] 
Scheme 25: Reagents and conditions i) Lawessan's reagent [99] , either refl~xing benzene or toluene, 60% 
Superficial studies into the formation of the decomposition product [98] suggested that the 
thioamide [97] was not stable under the reaction conditions. The nitrile [98] was found to be 
formed only after the formation of the thioamide, observed by in situ IR and TLC analysis. 
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The thioamide moiety in [97] can be considered to be electron rich, due to conjugation with the 
lone pair of electrons on the indole nitrogen. This is enhanced by the positive inductive effect 
of the methyl group attached to the indole nitrogen. Ayer et al. have shown that reaction of the 
indole amide [95] with LR in refluxing benzene leads to complete formation of the 
decomposition product. 101 
However, reaction of the N-tert-butyloxycarbonyl (Boc) protected indole [100] with 0.5 
equivalents of LR in refluxing benzene was found to form the thioamide [101] in 94% yield, 
without a trace of the decomposition product, Scheme 26. In the case of [101] the lone pair 
of electrons on the indole nitrogen are in conjugation with the Boc protecting group, and so the 
electron density on the thioamide moiety is significantly reduced. These initial observations 
suggest that the electronic environment of the newly formed thioamide moiety significantly 
contributes towards the formation of the nitrile decomposition product. 
CONH2 CSNH2 ~ --.~ Vi Vi 
I But I B t 
o0cr o0cr u 
[100] [101] 
Scheme 26: Reagents alld conditions i) LR, toluene, reflux, 94% 
Due to the undesirable decomposition of the indole thioamide, synthetic efforts were 
concentrated on the conversion of indolyl amides to thioamides, by a reactant other than LR. 
Reaction of the indole amide [97] with phosphorus pentasulfide in refluxing benzene over 2 h, 
unfortunately resulted in the formation of significant amounts of decomposition product. 
Woollins et at. have reported the synthesis of novel aryl thiophosphine sulfide reagents, which 
react in a similar fashion to LR.102, 103 The tert-butyl aryl thiophosphine sulfide [102], 
naphthyl thiophosphine sulfide [103], and ferrocenyl thiophosphine sulfide [104] thionating 
reagents were examined as possible alternatives for LR. The reactions were performed in 
refluxing benzene using 0.5 equivalents of the thionating reagent, Table 1. The tert-butyl aryl 
thiophosphine sulfide [102] was found to be the most efficient, forming the desired indole 
thioamide [97] in 58% yield, however, only a trace of the decomposition product was 
observed. The naphthyl thiophosphine sulfide [103] and the ferrocenyl thiophosphine sulfide 
[104] reagents were found to be less efficient than LR, forming the desired indole thioamide 
in 31 and 26% yield respectively, again the amount of decomposition product formed was 
significantly reduced, even though the reactions were left for 24 h. 
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[87] [97] [98] 
Thionating reagent Time Ch) Yield Yield 
[97]% [98]% 
But 
3 58 Trace -O-~ ?"s,-o-MeO p".e ~ ;; OMe 
- Ss 
[102] But 
24 31 <5 
24 26 <5 
[104] 
Table 1: The reaction of indole-3-carboxamide [87J with various thionating reagents. All 
reactions were carried out in refiuxing benzene with 0.5 equivalents of thionating reagent 
The mechanism of LR is thought to proceed via a betaine type intennediate [106], Scheme 
27.100 Lawesson has suggested the formation of the dipolar species [105] at low 
concentration in solution, based on 31 P NMR spectroscopy, although the species has never 
been fully isolated or characterised. Further evidence for the dipolar species [105] comes 
from experimental evidence, in that the reaction can proceed efficiently using only 0.5 
equivalents of LR. The dipolar species [105] is thought to attack the carbonyl functionality to 
fonn the intennediate betaine species which collapses to give the thionated product [107] and 
the dipolar species [108]. 
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Scheme 27: Proposed mechanism for the reaction of LR with a carbonyl compound 
The attendent formation of the trimer [109], isolated as a white crystalline powder of low 
solubility also lends credibility to the proposed betaine mechanism, Scheme 28.100 
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In order to closely examine the mechanism of LR, Yoshifuji et al. have synthesised the 
sterically challenged thionating reagent 2-4-di-tert-butyl-6-methoxyphenyldithioxophosphorane 
[110] (abbreviated to MOX : methQxy-m-Kylene), which, under an inert atmosphere in non-
polar solvents, exists almost exclusively as the dithiophosphorane [111], Scheme 29. The 
dithiophosphorane [111] was found to readily thionate benzophenone in refluxing benzene, 
thus lending credibility to the proposed dipolar species [105].104 
Bu' ;{U'~!,;u~ }-BU' ~- Ss 
OMe MeO 
[110] 
Scheme 29 
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Further evidence for the proposed proposed species [105] has been provided by Bertrand et 
al. who employed the dithioxophosphorane [105] as a dipolarophile in [2 + 3] cycloaddition 
reactions. Reaction of [105] with the nitrone dipole [112] formed the 
oxathioxaphospholinine [113] product in 79% yield,Scheme 30.105 
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With the key indole thioamide derivative [97] in hand, synthetic efforts were concentrated on 
its application in Hantzsch reactions to form indolythiazoles. Reaction of the indole thioamide 
[97] with commercially available ethyl bromopyruvate in reflxing ethanol formed the 
thiazolylindole with an ethyl ester functionality positioned at the C(4) thiazole position [114] 
in 64% yield, Scheme 31. Elaboration of the thiazole ethyl ester into a primary amide was 
achieved by reaction with a 0.88 solution of ammonium hydroxide and ammonium chloride in 
a Young's sealed tube at 100°C for 24 h to form [115] in 73% yield. 106 
CSNH2 ~i vi 
Me 
[97] 
• 
[114] [115] 
Scheme 31: Reagents and conditions i) ethyl bromopyruvate, ethanol, reflux, 64%. ii) NH40H, NH4Cl, 
100°C. sealed tube, 24h, 73% 
Reaction between the indole thioamide [97] and commercially available chloroacetone in 
refluxing ethanol formed the indolethiazole [116] containing a methyl substituent at the 
thiazole C(4) position in 43% yield, Scheme 32. 
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Scheme 32: Reagents and conditions i) chloroacetone, ethanol, refiux, 3 h, 43% 
2.4. Nucleophilic displacement reactions by an indolyl anion on 2-
bromothiazole 
Ayer et al. have utilised the Hantzsch reaction as a key step in the synthesis of the natural 
product camalexin [117], Scheme 33101 Indole-3-carboxamide [95] was reacted with 
phosphorus pentasulfide in benzene for 3 h to form the corresponding indole-3-
thiocarboxamide in situ which was then reacted with chloroacetaldehyde diethyl acetal in 
refluxing ethanol for 15 h, to form camalexin [117] in 35% yield. 
CONH2 ~ v/ 
H 
[95] 
ii 
Scheme 33: Reagents alld conditions i) P4SIO, benzene 3 h, ii) CICH2CH(OC2HS)z, ethanol, refiux, 15 
h,35% 
Unfortunately the authors found that the above reaction was only sufficient for the preparation 
of small quantities of camalexin. However, the authors found that a nucleophilic substitution 
reaction on 2-bromothiazole by an indolyl anion, formed by reaction of indole [93] with 
methylmagnesium iodide, resulted in the formation of camalexin [117] in a very reasonable 
68% yield, Scheme 34. 
~ ~l 
H 
[93] 
~ ~l 
I 
MgI 
i 
[117] 
Scheme 34: Reagents and conditions i) Et20, methylmagnesium iodide, ii) benzene, 2-bromothiazole, 
refiux, 67 h, 66% 
47 
---------- ---- --
The indolyl anion can be considered to act as as an ambident nucleophile, with the negative 
charge residing mainly on the nitrogen and the ~-carbon, Figure 6.107 
Figure 6 
~ ~i/ • ~ ~N'/ 
The ratio of nitrogen to ~-carbon substitution upon reaction with electrophiles is dependent 
upon: the associated metal of the base used; the polarity of the solvent; and the nature of the 
electrophile. Generally, more ionic sodio- and potassio- derivatives tend to react at nitrogen 
whereas magnesio-derivatives have a greater tendency to react at the ~-position.108 However, 
reaction of indolyl Grignards in polar solvents, such as HMPA, leads to more attack at 
nitrogen, whereas non-polar solvents favours attack at the ~-carbon. Complementarily, more 
reactive electrophiles show a greater tendency to react at nitrogen than less electrophilic species. 
According to electronic theory and MO calculations, the carbon atom of a neutral thiazole ring 
that is most sensitive to nucleophilic attack is the C(2). The reaction of nucleophiles is not 
observed unless strong nucleophiles are employed. However, thiazoles with a leaving group at 
the C(2) position react readily with nucleophiles to give nucleophilic substitution products. 102 
The reaction is facilitated by the thiazole nitrogen which can stabilise the reaction intermediate. 
2-Chlorothiazole is known to be 100 times more reactive than 2-chloropyridine towards 
nucleophilic displacement reactions. 
The methodology utilised by Ayer et al. in the synthesis of camalexin appeared to be ideal for 
the synthesis of thiazolylindoles, in which the thiazole was substituted by a hydrogen at the 
thiazole C(4) position. 101 However, in our hands, only a 30% yield of camalexin [117] was 
achieved, as well as a 10% yield of the acylated camalexin [118] side product, formed by 
quenching the indolyl Grignard with ethyl acetate, Scheme 35. In order to achieve a higher 
preponderance of attack at the ~-carbon on indole, the polar diethyl ether solvent used in the 
initial formation of the indolyl Grignard was removed and replaced with the non-polar solvent 
benzene, prior to the addition of 2-bromothiazole. 
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Scheme 35: Reagents and conditions i) methyl magnesium iodide, 6t20, ii) benzene, 2-bromothiazole, 
reflux, 67 h, 30% and 10% 
N-alkylation of camalexin [117] was accomplished by employment of the Heaney-Ley N-
methylation protocol by reaction with iodomethane in DMSO with potassium hydroxide as the 
base to form the N-methyl derivative [119] in an excellent 80% yield, Scheme 36.109 
.. 
Scheme 36: Reagents and conditions i) KOH, DMSO, Mel, 80% 
Me 
[119] 
The N-acylated camalexin [118] side product was readily converted by basic hydrolysis to 
form camalexin [117] in 83% yield, Scheme 37 . 
.. 
[118] [117] 
Scheme 37: Reagents and conditions i) NaOH, H20, THF, reflux, 83% 
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2.5. The synthesis of various thiazoles containing an indole moiety at the 
thiazole C(4) position, by the Hantzsch reaction 
The Hantzsch reactions disscused so far constructed the thiazole ring by reaction between a 
indole substituted thioamide and a a-haloketone. However, if the a-haloketone moiety was 
attached to the indole derivative, as in [120] (X= Cl or Br), then the resultant thiazole formed 
would contain the indole substituent attached to the thiazole C(4) position [121], Scheme 
38. 
+ 
Scheme 38: Proposed synthetic route towards C-4 indole substituted thiazoles 
The synthesis of the indole a-haloketone precursor 3-(2-bromoacyl)indole [123] was 
acheived by prior formation of the a-chloroketone indole derivative [122] 110 which was then 
converted to the a-bromoketone indole [123] by a Finkelstein reaction in 62 % , Scheme 
39111 
~ ~l 
H 
[93] 
Cl Br 
i 
Scheme 39: Reagents and conditions i) CICH2COCl, pyridine, toluene, 60°C, 80%, ii) NaBr, acetone, 
reflux, 62% 
The synthesis of an thiazolylindole analogue with no functionality at the thiazole C(2) position, 
i.e. for [121] Y=H, required a Hantzsch reaction between the a-haloketone indole derivative 
[123] and thioformamide. Unfortunately thioformamide is not commercially available, 
however, the synthesis is fairly trivial, Scheme 40.1 12 Reaction between formamide [124] 
and phosphorus pentasulfide in refluxing diethyl ether afforded thioformamide [125] in a 
rather poor 24% yield. 
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Scheme 40: Reagents and conditions i) P4S 10, diethylether, reflux, 14 h, 24% 
Reaction of the a-bromoketone indole derivative [123] with thioformamide [125] in 
refluxing ethanol gave a modest 30% yield of the desired thiazolylindole [126], Scheme 41. 
The low yield may be explained due to the poor thermal stability of the thioformamide. The 
thiazolylindole [126] was elaborated to the N-methyl derivative [127] by the Heaney-Ley N-
methylation protocol in 80% yield. 
Scheme 41: Reagents and conditions i) thioformamide, ethanol, reflux, 30%, ii) KOH, DMSO, Mel, 80% 
Reaction between the a-chloroketone indole derivative [122] and thioacetamide in refluxing 
ethanol formed the thiazolylindole [128] in which a methyl group was attached to the thiazole 
C(2) position in a reasonable 43% yield, Scheme 42. N-Alkylation of the indole derivative 
[128] by the Heaney-Ley N-methylation protocol formed the N-methyl thiazolylindole 
derivative [129] in 75% yield. 
Scheme 42: Reagents and conditions i) thioacetamide, ethanol, reflux, 43%, ii) KOH, DMSO, Me!, 75% 
A Hantzsch reaction between the a-bromoketone indole derivative [123] and commercially 
available ethyl thiooxamate in refluxing acetonitrile, I 13 formed the thiazolylindole [130] in 
74% yield. The use of ethanol as the solvent failed to form any of the desired product. In this 
case the thiazole contained an ethyl ester functionality at the thiazole C(2) position, Scheme 
51 
43. Alkylation of the indole nitrogen to the corresponding N-methyl derivative [131] was 
carried out by reaction with iodomethane in DMF at room temperature under a nitrogen 
atmosphere with sodium hydride as the base in 90% yield. 
ii 
Me 
[131 ] 
Scheme 43: Reagents and conditions i) ethyl thiooxamate, acetonitrile, reflux, 74%, ii) NaH, DMF, Mel, 
90% 
The ethyl ester functionalities on [130] and [131] were smoothly converted to the 
corresponding primary amide groups under the standard conditions in 47 and 58% yield 
respectively, Scheme 44. 
N 
R 
R=H [130] 
R=Me [131] 
N 
R 
R=H [132] 
R=Me [133] 
Scheme 44: Reagents and conditions i) NH40H, NH4CI, 100°C, sealed tube, 58% 
2.6. The synthesis of thiazolylindoles, in which the thiazole is attached to the 
indole C(2) position 
It was anticipated that the Hantzsch reaction could be extended towards the synthesis of 
thiazolylindoles in which the thiazole moiety was attached to the indole C(2) position. 
52 
~C02H ~Nr-
H 
[134] 
------~.~  C02Me ~Nr-
ii 
Me 
[135] 
~CSNH2~.~_ii_i __ _ ~Nr- ~ CONH2 ~Nr-
Me 
[137] 
Me 
[136] 
Scheme 45: Reagents and conditions i) DMF, NaH, Mel, 90%, ii) Me3AI, NH4C1, benzene, 60°C, 16h, 
58%, iii) LR, benzene, reflux, 70% 
The cheap and commercially available indole-2-carboxylic acid [134] was elaborated by 
standard chemistry over three steps to the indole thioamide [137], Scheme 45. 
Commercially available indole-2-carboxylic acid was both N- and O-methylated to form [135] 
in 90% yield. IR spectroscopy showed the ester C=O absorption at 1704 cm- I (note the 
absorbance is higher than the C-3 substituted ester [85] because of decreased electron 
delocalisation on the carbonyl). The resulting methyl ester derivative [135] was converted to 
the amide [136] by application of the Weinreb amination protocol in a respectable 58% yield. 
Reaction of the amide [136] with LR in refluxing benzene formed the indole-2-thioamide 
[137] in 70% yield. Again there were problems associated with the decomposition of the 
thioamide to the corresponding nitrile, however, not as pronounced as in the C(3) indole 
thioamide [97], and generally less than 5% of the decomposition product was formed. 
The thiazolylindole, which contained a methyl group at the thiazole C(4) postion, was 
synthesised by reaction of [137] with chloroacetone and sodium bromide in refluxing 
acetonitrile in 71 % yield, Scheme 46. 
~CSNH2 ~N/ 
Me 
[137] 
_~.~ ~s) ~N~-\ 
Me CH 3 
[138] 
Scheme 46: Reagents and conditions i) chloroacetone, NaBr, acetonitrile, reflux, 71% 
A Hantzsch reaction between the indole thioamide derivative [137] and ethyl bromopyruvate 
in refluxing ethanol constructed the thiazole C(4) ethyl ester substituted derivative [139] in 
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48% yield, Scheme 47. Elaboration of the ethyl ester functionality to the primary amide was 
acheived by reaction with liquid ammonia at room temperature in a Young's sealed tube over a 
4 day period to form [140] in 80% yield. 
~cSNH2 ~N~ 
Me 
[137] 
~ ~s) ~N~--Z 
Me R 
i 
• 
R = cO2 Et [139] 
R = cONH2 [140] 
Scheme 47: Reagents and conditions i) ethyl bromopyruvate, ethanol, reflux, 48%, ii) NH3(l), CH2CI2, 
sealed tube, rt, 4 days, 80% 
2,7, Synthesis of the e(2) substituted indolyl benzothiazole [141] 
Hudkins has recently reported the synthesis of aryl substituted benzothiazoles by the reaction 
of an aryl ester with aminothiophenol and trimethylaluminum. 114 It was anticipated that this 
methodology could be applied towards the synthesis of the novel indolyl benzothiazole [141], 
Scheme 48. Reaction of methyl l-methylindole-2-carboxylate [135] with 
trimethylaluminum and 2-aminothiophenol fonned the C(2) substituted indolyl benzothiazolc 
[141] in 57 % yield. It was hypothesised that the benzothiazole moiety would facilitate 
increased interaction of the indole derivative with DNA, this in turn would hopefully lead to 
enhanced antitumour properties. 
'01iu 
[135] [141] 
Scheme 48: Reagents and conditions i) Me3AI, 2-aminothiophenol, toluene, 60°C, 57% 
2.S. Conclusions 
• The Hantzsch thiazole methodology has been shown to be applicable to the synthesis of 
various thiazolylindole compounds. 
• The ester functionality on the thiazole ring can be elaborated into a primary amide. 
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• Nucleophilic substitution of 2-bromothiazole by an indolyl anion has been shown to be 
applicable towards the synthesis of thiazolylindoles. 
• The synthesis of indolyl benzothiazoles has been achieved. 
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Chapter 3 
The synthesis of 
thiazolylindolequinones. 
3.1. The synthesis of BE 10988 [43J 
To date there have been two reported total syntheses of BE 10988 [43]: the first, by Moody 
and Swann, in 1993; 115 and the second, by Shizuri et al., also in 1993. 116 The thiazole ring in 
both syntheses was constructed by a Hantzsch reaction. 
o 
BE 10988 [43] 
The origin of the Moody and Swann synthesis was the readily available indole carboxaldehyde 
[142]. Decarbonylation of [142] by the modified Wilkinson's catalyst «Ph3PhRh(CO)CI) 
and subsequent N-methylation formed the N-methyl indole [143], Scheme 49. Thioamide 
functionality at the indole C(3) position was introduced by reaction with CSI in diethyl ether 
followed by decomposition of the intermediate N-chlorosulfonylamide with tri-n-butyltin 
hydride in the presence of the radical initiator AIBN in refluxing benzene to form a C(3) 
substituted amide derivative. Thionation of the amide by reaction with Lawesson's reagent 
[99] in refluxing benzene formed the corresponding indole thioamide derivative [144]. A 
Hantzsch reaction between the thioamide [144] and ethyl bromopyruvate formed the indolyl 
thiazole [145]. The reaction also resulted in cleavage of the the O-benzyl protecting group, 
presumably by hydrobromic acid. Oxidation with Fremy's salt CCKS03)2NO') in a 0.17M 
sodium phosphate buffered acetone solution formed the indolequinone [146]. Finally 
ammonolysis of the quinone by reaction with liquid ammonia at rt over 4 days in a Young's 
sealed tube formed BE \0988 [43], as a bright red solid. 
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Scheme 49: Reagents and conditions i) (Ph3P}zRh(CO)CI, Ph2P(CH2l3PPh2, mesitylene, reflux, 82%, 
ii) KH, DMF, Me!, 91%, iii) CS!, Et20, 97%, iv) BU3SnH, AIBN, benzene, reflux, 88%, v) LR [991, 
benzene, reflux, 94%, vi) ethyl bromopyruvate, ethanol, reflux, vii) Fremy's salt, acetone, NaH2P04, 65%, 
viii) NH3(1), rt, sealed tube, 4 days, 72% 
The second reported synthesis, Scheme 50, started from commercially available fast blue RR 
[147]. Monomethylation by the use of a addition-reduction protocol followed by alkylation 
with bromoacetaldehyde diethylacetal formed [148], which was subjected to a modified 
Norlander synthesis to form the indole [149]. The C(3) thioamide functionality in [150] was 
introduced by a Friedel-Crafts thioacylation reaction with ethoxycarbonyl isothiocyanate, 
followed by hydrolytic cleavage of the intermediate N-ethoxycarbonyl thioamide. A Hantzsch 
reaction with bromopyruvamide afforded the primary amide substituted thiazole and oxidation 
of the para-dimethoxy aryl moiety with ceric ammonium nitrate (CAN) formed the quinone 
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[151]. Finally the benzamide protecting group on the C(S) amino substituent was removed by 
an addition-elimination reaction in ammonia saturated methanol to form BE 10988 [43]. 
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Scheme 50: Reagents and conditions i) (CH20)}, NaOMe, NaBH4, 72%, ii (EtOhCHCH2Br, K2C03, 
MeOCH2CH20H, 26%, iii) ZnCI2, DMF, 42%, iv) EtC02NCS, toluene, 54%, v) KOH, ethanol, 71%, vi) 
bromopyruvamide, ethanol, 82%, vii) CAN, 78%, viii) NH40H, methanol, 96% 
3.2. The synthesis of indolequinone derivatives with, a thiazole moiety at the 
indole C(2) position 
It was reasoned that the synthetic methodologies employed by Moody and Swann, Scheme 
49, as well as those utilised for the construction of the 'simple' indolyl thiazoles, Chapter 2, 
could be combined to provide the generic thiazolylindolequinones [152] and [153]. The 
readily available functionalised indole [154] appeared to be an attractive precursor for the 
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synthesis of the C(2) thiazole analogue [153] since indole carboxylic esters have previously 
been shown to be readily converted to thioamides (for a detailed account towards the synthesis 
of [154], see Chapter 4). 
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Initial N-methylation of the indole [154] was achieved by a variety of N-alkylation conditions, 
Table 2, Scheme 51. All of the methods attempted formed the desired N-methyl indole 
[155] in yields ranging from 61 to 81 %. 
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Scheme 51: Reagents and conditions i) Table 2, ii) Table 3 
Table 2 
Conditions i 
NaH, DMF, MeI 
KH,DMF, MeI 
KOH, DMSO, MeI 
K2C03, acetone, MeI, reflux 
59 
Yield [155] % 
61 
77 
81 
75 
The construction of a thiazole ring at the C(2) position by the Hantzsch reaction required 
elaboration of the methyl ester functionality to a thioamide moiety. The Weinreb amination 
protocol has been shown to be suitable for the synthesis of simple indolyl amides, however, 
reaction of the methyl ester derivatised indole [155] under the Weinreb amination conditions 
resulted in a poor 38% yield of the amide [156], Table 3. The poor yield possibly could be 
explained by complexation of the proposed tetravalent aluminum intermediate with the oxygen 
substituents on the indole ring. The method was very messy and TLC indicated several side 
products. The most efficient method for the synthesis of [156] was found to be application of 
the Davey ami nation protocol, by reaction with a 0.88 solution of ammonia and ammonium 
chloride in a Young's sealed tube at JOO°C for 2 days, forming the desired amide [156] in a 
reasonable 78% yield. Both reaction with liquid ammonia in a sealed tube at rt. and methanolic 
ammonia solution failed to form any significant amounts of amide product. 
Table 3 
Conditions ii 
Me3Al, NH4Cl, toluene, 
60°C 
NH3(l), sealed tube, rt 
NH40H, NH4Cl, sealed 
tube, JOO°C 
NH40H, MeOH, reflux 
Yield [156] % 
38 
trace 
78 
A major problem associated with the Davey amination reaction was that it proved to be 
experimentally difficult during scale up, i.e., the problem associated with a large reaction 
vessel under pressure at JOO°C for up to two days. Indole acyl chlorides have previously been 
shown to be applicable towards the synthesis of primary amides, Scheme 19. Hydrolysis of 
the indole methyl ester [155] to the indole acid [157] provided a species capable for 
carboxylate activation, Scheme 52. However, activation of the carboxylic acid functionality 
to the corresponding acyl halide proved far from trivial. Conventional methods for the 
formation of acyl halides, e.g. reaction with thionyl chloride or oxalyl chloride, resulted in the 
formation of a complex mixture of products. It was found that reaction of the indole acid 
[157] with acetyl chloride and phosphorus pentachloride followed by subsequent reaction 
with liquid ammonia at -78°C, formed then primary amide [156] in a poor 32 % yield. ll7 
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Scheme 52: Reagents and conditions i) NaOH, THF, H20, 76%, ii) CH3COCI, PCIs, NH3, CH2CI2, 
32% 
Reaction of the primary amide [156] with 0.5 equivalents of LR [99] in refluxing benzene 
proved unreliable and, at best, gave a 64% yield of the desired thioamide [159] as well as 
varying amounts of the nitrile decomposition product [158], Scheme 53. The yield of the 
decomposition product was dependent upon reaction time and the purity of the LR. Generally 
after I h the yield of the nitrile [158] side product rapidly increased and, if the LR used was 
not recrystallised prior to use the sole product formed was the nitrile [158]. The thioamide 
functionality in [159] is electron rich because of electron delocalisation from the C(5) methoxy 
group. As has been shown previously, in chapter 2, electron rich indole thioamides are prone 
to decomposition under the reaction with LR. 
Me 
[156] 
~ 
N 
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Me 
eONH 2 ---.. ~ 
OBn 
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Scheme 53: Reagents and conditions i) LR [99], benzene, reflux, 64% [159] 
OBn 
Due to the undesired formation of the nitrile [158] decomposition product, a method was 
required to recycle the nitrile back to a useful intermediate. The hydrolysis of nitriles to amides 
is a well known synthetic reaction, however, problems can be associated with excess 
hydrolysis of the newly formed amide to the corresponding carboxylic acid. The hydrolysis of 
the indole nitrile [158] by reaction with potassium hydroxide in tert-butanol formed the 
desired amide [156] in 86% yield, Scheme 54. 118 
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Scheme 54: Reagents and conditions i) KOH, (CH3)3COH, reflux, 86% 
The a-bromoketone used in the Hantzcsh reaction dictates the functionality at the thiazole C(4) 
position [160]. By altering the a-bromoketone various C(4) substituted thiazoles can be 
prepared, i.e. the use of bromopyruvic acid (R2 = C02H) will form a carboxylic acid 
substituted thiazole whereas reaction with bromoacetone (R2 = CH3) will form the 
corresponding methyl substituted thiazole. 
A Hantzsch reaction between the indole thioamide [159] and bromopyruvic acid formed the 
carboxylic acid functionalised thiazole [161] in 61 % yield and the corresponding ethyl ester 
functionalised thiazole [162] in 19%, Scheme 55. AUemps to directly form of the thiazole 
ester [162] by reaction with ethyl bromopyruvate resulted in the formation of a complex 
mixture. Standard acid catalysed esterification of the thiazole carboxylic acid derivative [161] 
formed the ethyl ester thiazole [162] in 85% yield. 
The a-benzyl protecting group was originally chosen because of its reported facile removal 
under hydrogenolysis conditions. I 19 However, under conventional hydrogenolysis reactions 
the a-benzyl group on the indole derivative [162] proved rather stubborn to removal. 
Reaction of the benzyl protected indole [162] under a hydrogen atmosphere, at atmospheric 
pressure, with 10 mol% of a palladium on activated carbon catalyst in either ethanol or ethyl 
acetate as the solvent (for up to 4 days) gave poor yields of the desired debenzylated product. 
Performing the hydrogenolysis reactions under three atmospheres of pressure failed to increase 
the yield of the desired product. However, reaction of the indole [162] under a atmospheric 
hydrogen atmosphere in ethanol with 10 mol% of palladium hydroxide (Pearl man's catalyst), 
for 48 h, cleaved the a-benzyl protecting group quantitatively. The resultant debenzylated 
product was found to be somewhat unstable, rapid colourisation occurred only a few hours 
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after isolation, and so complete characterisation proved fruitless. Therefore immediately after 
the removal of the O-benzyl protecting group the phenol derivative was oxidised to the 
indolequinone [163] by reaction with a 0.17 M sodium phosphate buffered aqueous acetone 
solution of the stable free radical species Fremy's salt (potassium nitrodisulfonate 
((KS03)zNO)) in 64% yield. 
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Scheme 55: Reagents and conditions i) bromopyruvic acid, ethanol, reflux, 61 % [1611 and 19% [1621, ii) 
concentrated. H2S04, ethanol, reflux. 85%, iii) H2, ethanol, Pd(OH)2, iv) Fremy's salt «KS03lzNO), 
acetone, NaH2P04(aq), 64% 
The synthesis of the corresponding methyl substituted thiazole [165] is shown, Scheme 56. 
A Hantzsch reaction between the thioamide [159] and bromoacetone in refluxing ethanol 
formed the C(4) methyl substituted thiazole derivative [164] in 69% yield. The O-benzyl 
protecting group was cleaved under conditions analogous for the ester thiazole [162]. Again 
the debenzylation product proved to be somewhat unstable and so the oxidation, carried out 
under the standard conditions with Fremy's salt, was performed immediately after isolation of 
the phenol, to form the quinone [165] as orange solid in 59% yield. 
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Scheme 56: Reagents and conditions i) bromoacetone, ethanol, reflux, 69%, ii) H2, ethanol, Pd(OH)2, iii) 
Fremy's salt, NaH2P04(aq), acetone, 59% 
3.3, Bithiazoles as DNA intercalating agents 
The bleomycins (BLM) are a series of compounds which are currently used in the clinic as 
anticancer agents, mainly for the treatment of head, neck and testicular cancers.89 The 
bleomycins require two cofactors: a metal (particularly iron and cobalt); and oxygen (02) in 
order to induce double-strand cleavage sites in DNA. Bleomycin A2 [166] and B2 [167], 
contain a bithiazole side chain, shown in the box, and it is this side chain that is thought to bind 
with the DNA helix and so bring the active centre of the BLM into close proximity with DNA. 
Povirik et al. initialy reported the unwinding and lengthening of DNA upon binding of BLM, 
this provided the first experimental evidence for the intercalation of BLM with DNA.120 
Stubbe et al. have established unambiguously that the mode of binding of Co BLM A2 green 
involves partial intercalation of the bithiazole side chain.90 2D NMR studies showed that BLM 
binds via partial intercalation of the bithiazole tail, observed by an upfield shift in the I H NMR 
of the bithiazole protons. 
It was hypothesised that the bithiazole moiety could be incorporated into the indolequinone 
compounds. This would provide increased binding of the indolequinone agents to DNA, and 
hopefully increase DNA topoisomerase II inhibitory activity. Synthetic efforts were initially 
concentrated towards the synthesis of the indolequinone bithiazole [168]. With the aim of 
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elaborating the ethyl ester functionality at the thiazole C(4) position to the sulfide containing 
side chain, as in [73]. 
~H2 
N N HO - ' N J.., Jl _ ' N R 
H2N- ~t !~ 0 . °HO: t~)--4s \ 
N : Me H Me 
H H 
o NH ~o HI/) H 0 0 N l.:-o~OH OH ~OH 
OH 0 
OJ-- NH2 
Bleomycin B2 [167]R= 
Bleomycin A2 [166]R= 
o 
Me 
o [168] 
HN~;_CH3 
I 
CH3 
H 
HN~NI(NH2 
NH 
It was anticipated that two successive Hantzsch reactions could be employed for the 
construction of the bithiazole moiety. The ethyl ester functionality at the thiazole C(4) position 
on the indole derivative [162] was initially elaborated into a thioamide, which was then 
subjected to a Hantzsch reaction, Scheme 57. Reaction of the indole derivative [162] under 
the Davey amination conditions formed the thiazole substituted amide [169] in 76% yield. 
The primary amide functionality was poorly converted to the corresponding thioamide [170] 
by reaction with 0.5 equivalents of LR in refluxing benzene, however, reaction with 0.5 
equivalents of LR under an inert atmosphere in THF at rt formed the desired thioamide in 55% 
yield. The bithiazole [171] was constructed in two steps in 60% yield from the thioamide 
[170]: first, by reaction of the thioamide with bromopyruvic acid in refluxing ethanol followed 
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by acid catalysed esterification. However, deprotection of the O-benzylated indole derivative 
[171] under a hydrogen atmosphere, either at atmospheric pressure or three atmospheres, in 
ethanol with 10 mol% Pearl man's catalyst failed to form cleaved product [172]. Holmes et al. 
recently suggested the use of the Lewis acid complex boron trichloride dimethylsulfide as a 
selective reagent for the cleavage of O-benzyl ethers. 12l Unfortunately reaction of the 
bisthiazole [171] with boron trichloride dimethyl sulfide in dichloromethane at Qoe resulted in 
complete decomposition of starting material and therefore, work on this compound was 
curtailed. 
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Me 
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Scheme 57: Reagellls and conditions i) NH40H, NH4Cl, 100°C, sealed tube, 2 days, 76%, ii) LR [991, 
THF, rt, 55%, iii) bromopyruvic acid, ethanol, reflux, iv) ethanol, H2S04, reflux, 60% 
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3.4. Studies towards the synthesis of [175J 
It was envisaged that the nucleophlic substitution reaction previously discussed in Scheme 34 
could be applied towards the construction of the more complicated thiazolylindole [175]. In 
this case the indolyl anion would be derived from the highly substituted indole [154]. 
Reduction of the methyl ester side chain on the indole [154] using lithium aluminium hydride 
in refluxing THF formed the alcohol [173] in 93% yield. Scheme 58. Oxidation to the 
aldehyde [142] was achieved by reaction with manganese(IV)oxide in refluxing 
dichloromethane in 50% yield. Manganese(IV)oxide is well known as a oxidising agent for 
benzylic alcohols. In the case of the indole alcohol [173] the low yield can probably be 
explained by the electron rich nature of the indole. Attempts to directly form the aldehyde 
[142] from the indole ester [154] by reduction with DmAL-H resulted in complete reduction 
to the alcohol [173]. The indole carboxaldehyde was decarbonylated by reaction with the 
modified Wilkinson's catalyst (Ph3PhRh(CO)Cl in 84% yield. 122 The ligand 
bis(diphenylphosphino)propane is thought to exchange in situ with the triphenylphosphine 
ligands on the catalyst to form a more active decarbonylating reagent. 
OBn 
Me MeO OH 
C02Me • 
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[174] [142] 
Scheme 58: Reagents and conditions i) LiA1H4, THF, rellux, 93%, ii) Mn02, CH2CI2, 50%, iii) 
(Ph3PhRh(CO)CI, Ph2P(CH2hPPh2, mesitylene, rellux, 84% 
Unfortunately attempts to form the C(3) indole thiazole [175] resulted in failure, Scheme 59. 
Reaction of the indole [174] with commercially available methylmagnesium iodide in diethyl 
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ether to form the indolyl anion and subsequent removal of the solvent followed by reaction 
with a benzene solution of 2-bromothiazole at reflux for 72 h resulted in a complex mixture. 
Decreasing the reaction time and performing the coupling reaction at rt failed to form any of the 
desired product. 
OBn 
Me Me 
X .. 
Scheme 59: Reagents and conditions i) methyl magnesium bromide, diethyl ether, ii) 2-bromothiazole 
benzene or toluene 
3.5 Methoxyquinone exchange reactions on various thiazolylindolequinones 
The C(7) methoxy group on mitomycin A [176] has been shown to undergo a variety of 
nucleophilic substitution reactions, especially with alkoxides l23 and amines l24 including 
aziridines. 125 The reaction with any nucleophile can be envisaged as a three step addition-
elimination reaction. 126 Initially a nucleophile adds at the C(7) end of the conjugated carbonyl 
system (Michael type addition) affording the intermediate [177], Scheme 60. A proton is 
then transfered to the C(7) methoxy group generating the intermediate [178], and methanol is 
eliminated to afford the desired C(7) substituted mitomycin A derivative [179]. 
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Scheme 60: Reaction of MMA with a nucleophile 
It was envisaged that the thiazoleindolequinone compounds [163] and [165] could be 
subjected to C(5) nucleophilic exchange reactions with a range of nitrogen nucleophiles to form 
the corresponding 5-(substituted-amino) indolequinone compounds. 
The substituent attached to the C(5) position on the quinone ring will influence the biological 
activity in several ways: 
i) the reduction potential of the indolequinone moiety is dependent upon substituents attached to 
the quinone. The ease of reduction is associated with the electron donating power of the 
quinone substituent at C(5). Increased electron donation into the quinone moiety consequently 
increases the electropotential of the quinone, therefore augmenting the energy required for 
reduction; 
ii) modification of the C(5) substituent may change the partition coefficient of the drug, and 
hence affect the cell penetration of the chemotherapeutic agent; 
iii) The C(5) substituent can alter the stability, reactivity, and toxicity of the activated drug; 
iv) changes in the steric size and composition of the C(5) substituent may influence the ability 
of the drug candidate to bind (i.e., van der Waals, hydrogen bond) to DNA. 
v) the introduction of an aziridinyl substituent at the C(5) position would result in DNA 
cleavage, with the order of reactivity towards the cleavage of DNA being, unsubstituted > 
mono-methyl> bi-methyl > ring open. 
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The ester substituted thiazole [163] was treated with an excess of a variety of primary and 
secondary amines, ranging from acyclic amines such as cyclopropylamine, to cyclic secondary 
amines such as aziridine and piperidine, Table 4. All the reactions were carried out in 
methanol at rt and the products were purified by column chromatography on silica gel followed 
by size exclusion chromatography on Sephadex® LH20 gel. From Table 4 it can be seen that 
the desired 5-(substituted-amino) derivatives of the indolequinone [163] were formed when 
the amines: aziridine, 2-methylaziridine, pyrrolidine, piperidine and cyclopropylamine were 
used, in yields ranging from 37-81 %. Attempts to form the desired eis-dimethyl aziridine, 
tetramethyl aziridine and azetidine derivatives resulted in failure, and in the case of reaction 
with tetramethyl aziridine, complete decomposition of the SM resulted. As can be seen all the 
aziridine containing products were red solids and the pyrrolidine, piperidine and 
cyclopropylamine derivatives were purple solids. 
All the amines were commercially available except aziridine, which was prepared according to 
the literature procedure of Alien et al. in which 2-aminoethanesulfonic acid is cyclised to 
aziridine by reaction with 40% sodium hydroxide. 127 eis-dimethyl aziridine and tetramethyl 
aziridine were kindly supplied by the MRC Unit, Didcot. Extreme care was taken at all times 
when handling the aziridines, as these compounds are extremely toxic, and are potent 
alkylating agents of DNA. All the reactions were carried out in an efficient fume cupboard and 
contaminated glassware was washed in dilute acid. Also because of the sensitivity of aziridines 
towards acidic media, the excess aziridines were removed by evaporation, carried out under 
strict safety precautions. In the case of pyrrolidine, piperidine and cyclopropylamine reactions 
the excess amine was removed by an acidic workup. 
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0 0 
Me ~~RH' methanol R S 
.. ~~ N C02Et N C02Et [163] 0 0 
R Time Yield Colour Product 
(h) % No. 
[:::N 24 42 Red [180] 
\N 
24 37 Red [181] 
-=-"" [:::N 24 
~ 
jN 24 
" [j 24 
eN 12 81 Purple [182] 
eN 
12 60 Purple [183] 
[>---NH 12 80 Purple [184] 
Table 4 
It has previously been shown, Scheme 49, that the C(5)-methoxy substituent on the BE 
10988 precursor [146] can be exchanged by an amino group. It was anticipated that this 
methodology could be extended towards the synthesis of the BE 10988 analogue [185], in 
which the thiazole is attached to the C(2) position of the indolequinone, Scheme 61. 
Unfortunately, reaction of the quinone [163] with liquid ammonia at room temperature in a 
Young's sealed tube resulted in the formation of a complex mixture of products. Alternative 
procedures, e.g. reaction of the indolequinone with a 0.88 solution of ammonium hydroxide; 
reaction with a 0.88 solution of ammonium hydroxide and ammonium chloride at 100°C in a 
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sealed tube; and reaction with ammonium chloride in refluxing methanol, all failed to form any 
of the desired indolequinone [185]. 
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Scheme 61 
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N CONH2 
0 
[185] 
It was also possible to exchange the C(5)-methoxy group of the indolequinone derivative 
[165] with a variety of primary and secondary amine nucleophiles, in yields ranging from 27 
to 85%, Table 5. Reaction of [165] with tetramethyl aziridine resulted in complete 
decomposition of the SM. However, contrary to the ester substituted thiazole derivative 
[163], reaction of the indolequinone [165] with cis-dimethylaziridine and azetidine formed 
the desired 5-(substituted-cis-dimethylaziridino) derivative [188] and 5-(substituted-azetidino) 
product [189] in 27% and 43% yields respectively. The ring strain in azetidine is less than 
that in the three membered aziridine series, and as a result azetidines show few of the 
exceptional properties associated with aziridines, however, ring cleavage reactions occur with 
greater ease than in the larger cyclic amines. 128 It was envisaged that the azetidine substituent 
would be activated in a manner similar to the aziridine series, although because of the decrease 
in ring strain the formation of drug-DNA alkylation sites would not be as pronounced as for the 
aziridino derivatives. The colour of the indolequinone derivatives was dependent upon the 
substituent at the C(5) position i.e., the methoxy derivative [165] was orange, the aziridino 
derivatives were all red and the amino derivatives were purple. 
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0 0 
Me Sl RH, methanol R Sl ~ ~ ~ . 
N CH3 N N CH3 
[16510 Me 0 
R Time Yield Colour Product 
(h) % No. 
[::N 24 85 red [186] 
\N 
48 40 red [187] 
-:. . ~. 
[::N 48 27 red [188] 
.{ 
,. 
)2N 24 
" 
\ C1 12 43 purple [189] 
eN 
12 63 purple [190] 
eN 
12 73 purple [191] 
f\. 12 67 purple [192] 
0'---lN 
[>---NH 12 57 purple [193] 
Table 5 
The thiazolylindolequinones [146], [196] and [199] have previously been synthesised 
within these laboratories. 129 It was envisaged that C(S)-methoxy quinone exchange reactions 
could be utilised for the formation of various C(S)-aziridino and 2-methylaziridino analogues. 
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Table 6 
Time 
(h) 
24 
48 
RH, methanol 
Yield 
% 
95 
84 
R 
.. 
o 
Product 
colour 
red 
red 
Product 
No. 
[194] 
[195] 
The thiazolylindolequinones [146], [196] and [199] were reacted with an exess of aziridine 
in methanol at rt over 24 h to form the desired 5-(substituted-aziridine) derivatives [194], 
[197] and [200] in 95, 92 and 87% yields respectively, Tables 6,7 and 8. Likewise 
reaction with an excess of 2-methylaziridine in methanol at rt over a 48 h period formed the 5-
(substituted-methylaziridine) derivatives [195], [198] and [201] in 84,72 and 78% yields 
respectively. 
o 
Me 
[196] 0 
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Table 7 
Time 
(h) 
24 
48 
RH, methanol 
Yield 
% 
92 
72 
74 
R 
.. 
Product 
colour 
red 
red 
Product 
No. 
[197] 
[198] 
H3C H3C ~S N~S N 
0 
Me R 
RH, methanol 
~ 
[199] 
0 0 
R Time Yield Product Product 
(h) % colour No. 
[::N 24 87 red [200] 
\N 48 78 red [201] 
Table 8 
3.6. Physical properties of C(S) substituted thiazoylindolequinone compounds 
One of the striking properties of the C(5) substituted thiazoylindolequinone compounds is their 
colour, for example, orange for the 5-methoxy derivatives, purple for the 5-(substituted-amino) 
analogues and red for the C(5) aziridino derivatives. These physical properties can be 
rationalised as follows. Both the oxygen of the 5-methoxy indolequinones (X= OMe) and the 
nitrogen of the 5-(substituted-amino) derivatives (X= NR I R 2) can rehybridise from sp3 [202] 
to sp2 [203], planar geometry, Figure 7. Since the lone pair of electrons on nitrogen is not 
so tightly bound, this leads to more extensive delocalisation of the chromophore, and a shift to 
a longer wavelength (red shift). 
Sp2 Hybridised (planar) [203] 
Figure 7 
[202] 
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Sp2 Hybridised (planar) [204] 
However, in the case of the aziridine derivative it is not favourable for the aziridine nitrogen 
atom to rehybridise from sp3 to sp2, planar geometry, as this would increase the strain in the 
three-membered ring [204]. Hence, in the aziridino thiazoylindolequinone analogues, there is 
no extensive delocalisation of the chromophore, and a shift to a shorter wavelength compared 
with other amino derivatives is observed. Thus, these compounds appear red in colour. 
A consequence of extensive delocalisation also results in an increase in quinone 
electropotential. This is reflected in the ap values (aziridine is -0.25,130 methoxy = -0.28 131), 
whereas other amine substituents are much more electron releasing (e.g., pyrrolidinyl = 
_0.77 130), and as a result amino quinones are more difficult to reduce. 
The various substituents attached to the C(5) position on the thiazoylindolequinones radically 
effect the NMR spectrum of the quinone moiety, Figure 8. The electron distribution within 
the enone portion is displaced by a series of inductive effects, which operate within the 0'-
framework (and fall off with distance) and conjugative effects, which operate in the 1t-system 
(and alternate along the conjugated chain). 
X =1t-donor, 
a-acceptor 
Figure 8 
x) 0) 
¥ 
H 
+ _ electron density at the 
~x 0 ~ yposition is lowered, hence ~.o----_. # deshielding H electron density at the 
"'-/ ~ position is raised, hence 
shielding 
Thus, were X= a methoxy or amino (not aziridino) substituent the 1t-donor, a-acceptor effect is 
enhanced, such that the nuclei at the ~-position are shielded, causing an upfield shift in the 
spectrum and the carbony I carbon at the y-position is deshielded, causing a downfield shift. As 
previously mentioned, the lone pair of electrons on the nitrogen of aziridino substituents act 
less efficiently than other amines with conjugated substituents, and so the 1t-donor property is 
lowered, such that the shielding and deshielding effects at the ~- and y-positions are reduced. 
The liH and lie values for the ~-hydrogen and y-carbonyl carbon resonances for a series of 
C(5) substituted thiazoylindolequinones are shown, Table 9. Consequently the more 1t-
donating cyclopropylamino substituted derivative [193] shows an upfield shift in the I H 
NMR spectrum at the H6 ~-position and a downfield shift in the 13e NMR of the C7 y-
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carbonyl position in comparison with the poor It-donating aziridino substituted derivative 
[186]. 
R /lHPpm /leppm colour No. 
[::N 5.88 179.43 red [186] 
MeO 5.75 179.21 orange [165] 
eN 
5.59 180.29 purple [191] 
[>-NH 5.56 180.31 purple [193] 
Table 9 
3.7. Conclusions 
• The Hantzsch thiazole reaction can be applied towards the synthesis of the structurally 
challenging indolequinones [163] and [165]. 
• The Hantzsch thiazole reaction can be applied towards the synthesis of a indole substituted 
bithiazole 
• Application of a indolyl anion nucleophilic substitution reaction on 2-bromothiazole, failed 
in the case of the highly substituted indole [174]. 
• C(5) methoxy quinone exchange reactions were found to proceed readily with a wide range 
of nitrogen nucleophiles on various thiazolylindolequinone compounds. 
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Chapter 4 
The synthesis of highly 
substituted indoles. 
4.1. Introduction 
The indole methyl ester [154] is not only a key intermediate in the synthesis of BE 10988 
[43] and its analogues I 15,129, Chapter 3, but also the useful anticancer compound E09 
[34],140 and the cyclopropamitosenes [32, 33].50-52, 132 
OBn 
Me 
[154] 
, 
N 
H 
The methyl ester functionality at the C(2) position on the indole [154] can be readily 
transformed into useful functionality, e.g. either to a primary amide [156], Scheme 51; an 
aldehyde [142], Scheme 58; or a hydrogen [143], Scheme 58. 
4.2. The synthesis of methyl 4-benzyloxy-5-methoxyindole-2-carboxylate 
[154] via a vinyl nitrene cyclisation 
The Moody-Rees vinyl azide cyclisation was employed for the synthesis of the indole [154] as 
this allowed the introduction of carboxylate functionality at the indole C(2) position.1 33 The 
synthesis of the indole [154] started from the cheap and readily available arrha-vanillin [206] 
which was O-benzylated by reaction with benzyl chloride in refluxing ethanol using potassium 
hydroxide as the base, in 74% yield, Scheme 62. The benzyl protecting group was originally 
chosen due to its facile removal under hydrogenolysis and its relative stablility to both acidic 
and basic media. I 19 The O-benzylated aldehyde [207] was then condensed with methyl 
azidoacetate [205] using sodium methoxide as the base in methanol, to form the vinyl azide 
[208] in 82% yield. The resulting vinyl azide was thermolysed in refluxing xylene to afford 
the desired indole [154] in 66% yield. 
78 
OH OBn 
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OBn 
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[208] 
Scheme 62: Reagents and conditions i) BnCl, KOH, ethanol, reflux, 74%, ii) methylazidoacetate [205], 
methanol, MeONa, _15°C, 82%, iii) xylene, reflux, 66% 
The geometry of the vinyl azide [208] is of no significance in the final outcome of the 
thermolysis reaction. The mechanism of the indole forming reaction, Scheme 63, is 
considered to proceed via the 2H-azirine [209] intermediate. Hemetsberger et al. have shown 
in the thermolysis of a series of azidocinnamates, the 2H-azirine intermediate accumulates at 
80°C (shown by IR and IH NMR spectroscopy) and is converted upon further heating at 110°C 
to the corresponding indole. 134 The 2H-azirine is in equilibrium with the vinyl nitrene [210], 
and molecular orbital (MO) studies support the assumption that the C-N bond breaking requires 
less energy than C-C bond breaking, with no energy barrier for the conversion of nitrene back 
to the 2H-azirine. 135 The vinyl nitrene [210] then undergoes a 61t electrocyclisation to form 
[211] which, after a [1,5] H shift, forms the indole [154]. 
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Scheme 63: Mechanism for the formation of indoles via a vinyl nitrene cyclisation 
However, there are three major problems associated with the synthesis of the indole [154] via 
the thermolysis of the vinyl azide [208]: firstly, the occurrence of unwanted side products; 
secondly, the need for high dilution during the thermolysis reaction; and thirdly, the use of 
dangerous reactants, namely the use of large amounts of sodium azide required for the 
synthesis of methyl azidoacetate [205]. 
Analysis of the reaction mixture has shown the formation of the benzylic nitrile [214], formed 
as a by product from the vinyl nitrene intermediate [210], Scheme 64. In some cases up to 
15% of the unwanted nitrile [214] has been observed.132 Resonance of the intermediate vinyl 
nitrene [210] provided the charged compound [212], which can be stabilised by the adjacent 
carbonyl group to form the intermediate [213], which can collapse to form the nitrile side 
product [214]. 
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Scheme 64: Mechanism for the formation of the benzylic nitrile side product 
Perhaps the biggest problem associated with the thermolysis of the vinyl azide [210] has been 
the need for high dilution, it was found that the yield of the indole [154] decreased as the 
concentration of the vinyl azide increased. Optimised conditions for the reaction were found, 
in which the vinyl azide was;:: 0.023 M. However this proved to be experimentally difficult, 
in that large quantities of xylene were required in order to produce 10-ISg of the indole [154]. 
Because of the importance of the indole [154] an alternative synthesis was required. The main 
criteria for the surrogate synthesis was to construct the indole [154] on a large scale without 
the need for chromatography and the use of dangerous reagents. 
4.3. The synthesis of indole-2-carboxylates 
The synthesis of an indole moiety substituted at the C-2 position with a formyl or carboxylate 
functionality is far from trivial. The natural site for electrophilic substitution reaction on indole 
is at the C(3) position. Whereas Vilsmeier formylation proceeds with ease at the activated C(3) 
position, 136 Vilsmeier formylation at C(2), via a blocked C(3) indole does nOl. 137 It has been 
shown that certain protected indoles (namely N-methyl, N-benzenesulfonyl, and N-2-
(trimethylsilyl)methoxymethyl) 138 can be selectively lithiated at the C(2) position and 
subsequentally reacted with a range of electrophiles, however, the formation of the 
corresponding C(2) formyl derivatives have proved elusive. 138 The scarcity of methodology 
for the introduction of carboxylate functionality at the C(2) position on indole meant that a 
synthesis incorporating this functionality was required. 
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Black et al. have shown that the Japp-Klingemann reaction can be used as a entry to ester 
substituted hydrazones [216], Scheme 65. 139 The hydrazone was formed by conversion of 
the aniline [215] to the diazonium salt by reaction with sodium nitrite and hydrochloric acid 
and a Japp-Klingemann reaction with ethyl pyruvate formed the hydrazone [216], which was 
then subjected to a Fischer indole reaction in polyphosphoric acid (PP A) to form the 
corresponding C(2) ester substituted indole [217]. 
~ CH3 
""" 
A 
NH2 N-N C02Et 
H iD .. .. 
~ N i ~ N ~ N I I I 
""" """ """ [215] [216] [217] 
Scheme 65: Reagents and conditions i) NaN02, HC!, ii) ethylpyruvate, iii) PPA 
Kasai et at. have recently shown that a Nenitzescu reaction on quinone [218] in acetic acid at 
50°C with the highly substituted amine [219], prepared from commercially available 4-
methoxyacetoacetate and methylamine, formed the indole [220] in reasonable yield, Scheme 
66. 140 Oxidation of the C(2) side chain with DDQ resulted in the formation of the formyl 
functionality. The indole derivative was subsequently converted into the anticancer agent E09 
[34]. 
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Scheme 66: Reagents and conditions i) ethyl acetate, acetic acid, 50°C 
OH 
Mali et at. have shown that a Cadogan-Sundberg reaction can be applied towards the synthesis 
of indole-2-carboxylates, Scheme 67. 141 The cinnamate derivative [222] was formed by a 
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Wittig reaction between ortho-nitrobenzaldehyde [221] and carbomethoxymethylene 
triphenylphosphorane in refluxing benzene and was subsequently reacted with three 
equivalents of refluxing triethyl phosphite to form the indole-2-carboxylate [223] in 
reasonable yield. 
Scheme 67: Reagents and conditions i) (C6HShP=CHC02Et, benzene, reflux, ii) (EtOhP, l70°C 
4.4. Synthesis of methyl 4-benzyloxy-5-methoxyindole-2-carboxylate [154J, 
via a Cadogan-Sundberg reaction 
Out of the methods discussed the Cadogan-Sundberg methodology appeared to be most 
applicable towards the synthesis of the important indole [154]. Reid and Schiller have 
reported that nitration of benzenesulfonyl protected ortho-vanillin derivative [224] with 
fuming nitric acid results in nitration at the C-6 position, Scheme 68. 142 The functionality on 
[225] suggested that elaboration to the indole [154] could be achieved, via the Cadogan-
Sundberg methodology. ortho-Vanillin was shaken with a 15% solution of sodium hydroxide 
and benzenesulfonyl chloride to form the benzenesulfonyl protected ortho-vanillin [224] in 
89% yield. The reaction could be performed on a large scale (>20g) and the product [224] 
was recrystallised to analytical purity. Reaction of the benzenesulfonyl ortho-vanillin [224] 
with fuming nitric acid, maintaining the temperature between 5-15°C, formed the desired nitro 
compound [225] in 61 % yield, again the product was recrystallised from methanol. 1 H NMR 
spectroscopy of the nitro compound [225] revealed the H4 and H5 resonances as doublets at 
liH 7.09 and 7.56 ppm respectively, with J values of 6.7 Hz. 
OH OS02Ph OS02Ph 
Me~CHO Me0tiCHO i Me~CHO 
I -------' .. ~ I ------ I 
::::,.. ::::,.. ::::,.. N0
2 
[206] [224] [225] 
Scheme 68: Reagents and conditions i) benzenesulfonyl chloride, 15%, shaken not stirred, NaOH, 89%, 
ii) fuming HN03, 61 % 
It was expected that the O-benzyl derivative [207] would be nitrated in a similar fashion to 
form [224]. However, attempted nitration of the O-benzyl aldehyde [207] with fuming nitric 
acid, maintaining the temperature between S-ISoC, failed to form any of the desired nitrated 
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compound [227], Scheme 69. The only product that was separated and characterised from 
the reaction mixture was the 4-nitrobenzyl alcohol [226] in 60% yield, presumably formed by 
nitration of the O-benzyl protecting group and cleavage under the extreme acidic conditions. 
Attempts to nitrate the O-benzyl aldehyde under more facile conditions, e.g. by re~ction with 
trifluoromethanesulfonic acid and nitric acid in dichloromethane as the solvent at -60°C 
resulted in a complex mixture of products. 143 
OBn OBn 
~N02 MeO&CHO Me~CHO I ........ --- I _-'V~ __ .. I HO :::::,... :::::,... /\ :::::,... N0
2 
[226] [207] [227] 
Scheme 69: Reagents and conditions i) fuming HN03, 5-15°C, 60% 
As an alternative synthesis towards the O-benzylated nitro compound [227] it was envisaged 
that the O-benzenesulfonyl protecting group on [225] could be cleaved and subsequently 
replaced with the O-benzyl functionality. However, basic hydrolysis of [225] with a 15% 
solution of potassium hydroxide in refluxing ethanol resulted in the formation of the 
decarbonylated phenol [229] in 90% yield, rather than the expected phenol [228], a 
mechanism for which has so far proved elusive, Scheme 70. O-Benzylation of the phenol 
[229] under standard conditions formed the protected phenol [230] in 96% yield. 
OS02Ph OH OBn Me~CH_O _____ M~:~ ______ M~e~ U
N02 
~ U
N02 
~ U
N02 
[225] ~ [229] [230] 
.. (~ OH MeO~CHO 
U N02 
[228] 
Scheme 70: Reagents and conditions i) 15% KOH, MeOH, 90%, ii) KOH, BnBr. THF, 96% 
Elaboration of the nitro compound [225] by a Wadsworth-Emmons olefination, by reaction 
with methyl diethyl phosphonoacetate or triethyl phosphonoacetate in THF at rt with sodium 
hydride as the base formed the methyl and ethyl cinnamate derivatives [231] and [232] in 85 
and 51 % yield respectively, Scheme 71. The geometry of the olefin formed was 
predominately trans, identified by a coupling constant of 16 Hz between the olefinic protons in 
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I H NMR analysis. A Cadogan-Sundberg reaction of the methyl cinnamate derivative [231] 
with three equivalents of triethyl phosphite at 170°C formed the C(2) methyl ester indole [233] 
in a respectable 66% yield. The corresponding C(2) ethyl ester functionalised indole [234] 
was formed in 79% yield under the same conditions. 
OS02Ph OS02Ph 0 OS02Ph M'~CHO Me P'I ::::::,.. Me OR 
• i C02R 
:::::,... N02 
:::::,... 
N02 N H 
[225] R= Me [231] R= Me [233] 
R= Et [232] R= Et [234] 
Scheme 71: Reagents and conditions i) methyl diethylphosphonoacetate, NaH, THF, rt, 85% [231] or 
triethyl phosphonoacetate, NaH, THF, 51 %, [232) iii) (EtO))P, l70°C, 66% [233) and 79% [234] 
However, upon scale-up, using three equivalents of sodium hydride and methyl diethyl 
phosphonoacetate, it was rather fortuitously found that the resulting cinnamate derivative was 
the deprotected phenol [235] formed in 58% yield, Scheme 72. 1 H NMR revealed the 
phenolic OH resonance as a singlet at OH 6.38 ppm, which disappeared after a D20 shake. 
The phenol [235] was subsequentally protected as the O-benzylcinnamate derivative [236] in 
68% yield by reaction with benzyl bromide in refluxing THF with potassium carbonate as the 
base. A Cadogan-Sundberg reaction of the cinnamate derivative [236] with three equivalents 
of triethyl phosphite at 170°C formed the desired indole [154] in 54% yield. 
Me 
OBn 
Me 
OH 
N02 [235] 
OBn 
N02 
[236] 
o 
OMe 
o 
OMe 
Scheme 72: Reagents and conditions i) methyl diethylphosphonoacelale, NaH, THF, rI, 58%, ii) BnBr, 
K2C03, THF, reflux, iii) (EIO)3P, l70°C, 54% 
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With the knowledge of the fortuitous in situ O-benzenesulfonyl deprotection it was reasoned 
that the corresponding O-methanesulfonyl protected cinnamate derivative would also act as a 
precursor to the indole [154]. artha-Vanillin was reacted with methanesulfonyl chloride in 
dichloromethane with triethylamine as base to form the O-methanesulfonyl protected vanillin 
derivative [237] in an excellent 95% yield. Again the product was easily purified by 
recrystallisation. Nitration of [237] under the standard conditions formed the nitro derivative 
[238] in a tolerable 50% yield, Scheme 73. 
OH OS02Me OS02Me 
Me~CHO Me0'6CHO MeoDcHO 
I ------ I -----~ I ::::,.,. ::::,.,. "-
...... " N02 
[206] [237] [238] 
Scheme 73: Reagents and conditions i) CH3S02Cl, CH2CI2, triethylamine, DOC, 95%, ii) fuming HN03, 
5-l5°C, 50% 
Wadsworth-Emmons olefination of the aldehyde [238] under the standard conditions formed 
the phenolic cinnamate [235] in 73% yield, Scheme 74. 
OS02Me Me~CHO 
V N02 
[238] 
Me 
~ 
OH 
~I ~ 
::::,.,. N02 [235] 
Scheme 74: Reagents and conditions i) methyl diethylphosphonoacetate, NaH, THF, 73% 
0 
OMe 
4.5. Alternative methodologies towards the synthesis of indole-2-carboxylates 
Retrosynthetic analysis of the two methodologies utilized for the synthesis of the indole [154] 
are shown in Figure 9. Both the Cadogan-Sundberg reaction and the vinyl azide 
decomposition reaction form the indole ring via initial formation of a carbon-nitrogen bond. 
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Figure 9: Retrosyntheis of the indole [154J via the Cadogan-Sundberg reaction and vinyl 
nitrene cyclisation reactions 
It was proposed that a indole-2-carboxylate derivative could be synthesised by an 
intramolecular Wadsworth-Emmons olefination to form the indole C(2) / C(3) bond, Figure 
10, in this case between the aldehyde and the nitrogen substituted phosphonate [239]. 
Couture et at. have recently applied an intramolecular Wittig reaction towards the syntheis of 
C(3) substituted indoles144 
OBn 
Meo'Cc~ I 'j-C02Me ~ N 
OBn 
Me~CHO 
===:;> UN/jPO(OEth 
[239]H C02Me [154]H 
Figure 10: Retrosynthesis of a indole 2-carboxamide via a intramolecular Wadsworth-
Emmons reaction 
It has been shown within our research group at Loughborough, that anilines can be converted 
to N-phosphonoacetates [241], Scheme 75, by rhodium(II) acetate catalysed decomposition 
of triethyl diazophosphonoacetate [240] and anilines. 145 
Et02Cy PO(OEt)2 
N2 
[240] 
H 
_____ ----l .. ~Et02C"fPO(OEth 
NHR 
[241] 
Scheme 75: Reagents and conditions i) Rh2(OAc)4, toluene, RNH2, reflux 
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Triethyl diazophosphonoacetate [240] was prepared by the method described by Lee and 
Yuk,146 in which para-toluenesulfonyl azide was added to a solution of triethyl 
ph os ph ono acetate [242] and cesium carbonate in THF to form the diazocompound in 74% 
yield, Scheme 76. 
[242] 
_____ --l .... Et02Cy PO(OEth 
N2 
[240] 
Scheme 76: Reagents and conditions i) CSC03, THF, para-toluene-sulfonylazide, 74% 
It was envisaged that the triethyldiazophosphonoacetate [240] could be used as the source of 
the phosphonoacetate functionality in [239]. A model reaction was originally carried out on 
ortho-nitrobenzaldehyde [221] to assess the fesability of this methodology. Boothroyd and 
Kerr have shown that aryl nitro compounds can be reduced in excellent yield by reaction with 
N,N-dimethylhydrazine and ferric chloride in refluxing methanol, this reaction has the 
advantage that carbonyl functionality is tolerated due to in situ protection as the hydrazone. 147 
ortho-Nitrobenzaldehyde [221] was reduced to the aniline derivative [243] in 50% yield by 
reaction with N,N-dimethylhydrazone and ferric chloride in refluxing methanol, Scheme 77. 
Rhodium(II) acetate catalysed decomposition of diazophosphonate [240] in the presence of the 
aniline [243] resulted in the formation of the N-phosphonoacetate [244] in 47% yield. It was 
anticipated that a intramolecular Wadsworth-Emmons olefination onto the hydrazone would 
result in the formation of the indole. However, reaction of the N-phosphonoacetate [244] 
with a variety of bases, e.g. sodium hydride, potassium hydride or LDA in either THF or DMF 
failed to form any of the desired indole [245]. Due to time constraints it was not possible to 
attempt to deprotect the hydrazone [244] to form the corresponding aldehyde [246] and then 
attempt the intramolecular Wadsworth-Emmons olefination. 
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Scheme 77: Reagents and conditions i) FeCI3.6H20, methanol, N,N-dimethylhydrazine, 50%, ii) [243], 
Rh2(OAc)4, toluene, reflux, 47% 
4,6. The synthesis of indoles by reductive cyclisation of ortho, f3-
dinitrosyrenes 
Showalter and Pohlman have reported the synthesis of 4,7-dimethoxyindole [248] by a 
reductive cyclisation from the ortho,~-dinitrostyrene compound [247], by reduction with iron 
powder in refluxing acetic acid, Scheme 78. 148 
OMe 
OMe 
[247] 
Scheme 78: Reagents and conditions i) CH3C02H, Fe, reflux 
It was contemplated that the reductive cyclisation methodology could be applied towards the 
synthesis of the indole [167], which has been used in the synthesis of BE 10988, Scheme 
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49, and mitomycin analogues. A Knoevenagel reaction between the aldehyde [225] and 
nitromethane in refluxing acetic acid with ammonium acetate formed the ortho,~-nitrostyrene 
[249] in a mediocre 47% yield, Scheme 79. Various alternative conditions for the formation 
of ortho,~-nitrostyrenes resulted in either poor yields of [249] or in the formation of a 
complex mixture of products. 
Reduction of the ortho,~-nitrostyrene [249] with iron powder in refluxing ethanol and acetic 
acid gave a poor 20% yield of the desired indole [250]. Burchardt and Sinhabaubu have 
reported, similar poor yields for the reductive cyclisation of alkoxy-ortho,~-nitrostyrenes to 
alkoxyindoles. However, they showed that the yields were greatly increased by the addition of 
silica gel and performing the reaction in a nonpolar solvent. 149 They reasoned that the poor 
yield in the iron I acetic acid reductive cyclisation was due to intermolecular reactions involving 
basic (neutral or negatively charged) intermediates and the starting material, to form dimeric 
and or intractable polymeric by-products. As silica gel binds polar materials strongly it was 
hypothesised that it would be possible to maintain the relatively nonpolar but reactive starting 
material in the solvent phase and the polar intermediates on the silica gel surface, thereby 
minimising interactions between the polar and the non polar species and also between the polar 
intermediates themselves. Harley-Mason has observed up to 14% of a highly insoluble dimeric 
indole, whilst using iron in acetic for the reductive cyclisation of various ortho,~-nitrostyrenes 
to indoles. 1 50 Reductive cyclisation of the ortho,~-nitrostyrene [249] with iron, acetic acid 
and silica gel in refluxing toluene resulted in the formation of the indole [250] in a much 
improved 85% yield. 
OS02Ph OS02Ph OS02Ph Me~HO Me ::::".. N02 Me ~ 
• 
::::,... N02 N02 
ii oriii N 
H [225] [249] [250] 
Scheme 79: Reagents and conditions i) CH3N02. toluene. CH3C02H. CH3C02NH4. reflux. 47%. ii) 
CH3C02H. Fe. EtOH. 20% or iii) CH3C02H. toluene. Fe. Si02. 85% 
The poor formation of the ortho,~-nitrostyrene [249]. by various Knoevenagel reactions. 
prompted the search for an alternative procedure. The Henry reaction is a versatile procedure 
for the formation of a-hydroxynitro alkanes. 15 I Dehydration of the a-hydroxynitro alkane 
will provide the required nitroalkene functionality. Kamba and Yasuda have shown that 
potassium fluoride can be used to promote the Henry reaction towards unreactive 
aldehydes. 152 The use of 5 mol% potassium fluoride in isopropanol at rt were found to be the 
optimum conditions. Reaction of the aldehyde [225] under the Kamba and Yasuda conditions 
at rt for 24 h resulted in the formation of the nitroalcohol [251] in 71 % yield, Scheme 80. 
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Dehydration of the nitroalcohol [251] employing the Melton and McMurry protocol,I53 by 
reaction with methanesulfonyl chloride and triethylamine in dichloromethane at rt formed the 
artha,~-nitrostyrene [249] in 59% yield. 
OS02Ph OS02Ph OS02Ph 
M'~CHO.M' ~I N02 Me ~I :::::::,.. N02 I 1 • • ~ N02 ~ N02 ~ N02 [225] [251] [249] 
Scheme 80: Reagents and conditions i) KH, (CH3)2CH20H, CH3N02, 71 % ii) CH3S02CI, CH2CI2, 
(CH3)3N, 59% 
4.7. The serendipitous synthesis af a cyclic sulfonate 
Attempted synthesis of the O-methanesulfonyl protected artha-vanillin [237] by employment 
of the standard conditions for the synthesis of the benzenesulfonyl artha-vanillin [224], i.e. 
shaking with a 15% solution of sodium hydroxide and methanesulfonyl chloride, resulted in 
the formation of the cyclic sulfonate [252] in 34% yield, Scheme 81, rather than the desired 
O-methanesulfonyl protected compound [237]. 
0" ,9 
OS02Me OH O/S Me~CHO Me~CHO Me ~I OH I .. X ~I .. ~ ~ 
[237] [206] [252] 
Scheme 81: Reagents and conditions i) 15% NaOH, rnethanesulfonylchloride, shaken not stirred, 34% 
The cyclic sulfonate [252] was initially identified by IH NMR spectroscopy. The protons 
Ha, Hb and Hx formed a classic ABX system with the following coupling constants: Jab 8.6, 
J AX 5.0 Hz; J BA 8.5, J BX 1.2 Hz and J XA 5.0, J XB 1.2 Hz. 
Me 
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A similar reaction has been reported by Reich et al. during attempted O-methanesulfonyl 
protection of the hydroxyl groups on Citreamicin ,,[253]. Reaction with methanesulfonyl 
chloride and triethylamine resulted in the formation of the 7-membered cyclic sulfonate [254], 
Scheme 82. 154 
pH 
~CH3 
ONO 
H3C'" 
o 
[253] 
Scheme 82: Reagents and conditions i) CH3S02CI, (CH3)3N 
o 
[254] 
They proposed that reaction of methanesulfonyl chloride and triethylamine initially formed 
sulfene [256]. Nucleophilic attack on sulfene by the phenoxy anion [255] formed the 
intermediate carbanion [257], Scheme 83. The nature of the polycyclic ring system allowed 
the positioning of the carbanionic species within bonding distance of the quinone carbonyl 
carbon and facilitated the formation of the seven membered cyclic sulfonate [258]. 
} 
[255]0 [257P 
J ~ 0-8,,0 
""" \ I fOH 
: I I} [258] 
o 
Scheme 83: Proposed mechanism for the formation of the cyclic sulfonate [258J 
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A related two-step sequence in carbohydrate chemistry has also been described by de las Heras 
et at. who found that mesylation of furanose cyanohydrins with methanesulfonyl chloride and 
pyridine, yielded a-(mesyloxy) nitriles [259].155 Treatment with the base, DBU in 
acetonitrile, produced a spiro 4-amino-l,2-oxathiole 2,2-dioxide [260] formed via 
nucleophilic attack of a carbanionic OS02CH2- species on the nitrile, Scheme 84. 
ot 
[260] 
Scheme 84: Reagents and conditions i) DBU. acetonitrile 
4.8 Conclusions 
• The Moody-Rees vinyl azide cyclisation can be applied towards the indole [154]. 
however, problems associated with scale up prompted the requirement for a more efficient 
synthesis. 
• The Cadogan-Sundberg indole synthesis can be applied towards the synthesis of methyl 4-
benzyloxy-S-methoxyindole-2-carboxylate [154]. 
• Reductive cyclisation of ortho,~-dinitrosyrenes can be applied towards the synthesis of 
highly substituted indoles. 
• The serendipitous synthesis of cyclic sulfonates has been acknowledged. 
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Chapter 5 
Studies towards the synthesis 
of the nortopsentins. 
5.1. Introduction 
The indolequinone [71] has been suggested as a possible synthetic target, Chapter 1. As in 
the indolequinone thiazole series of compounds, model studies were required in order to gain 
an insight into the synthetic methodology required towards the synthesis of the novel 
imidazolylindole structure. Therefore before embarking upon the synthesis of [71] it was 
decided to synthesise a series of simple imidazolylindoles, based on the generic structure 
[261]. 
o 
[71] 
~R 
HN I 
---N 
[261] 
5.2. The synthesis of 2-4(5)-disubstituted imidazoles 
The reaction between a suitable u-haloketone [76] and an amidine [262] has been shown by 
Brederek et al. to result in the formation of 2-4(S)-disubstituted imidazoles [263], Scheme 
85. 156 
Scheme 85: The synthesis if imidazole via the Brederek amidine cyclisation 
The mechanism for the Brederek imidazole reaction is shown below, Scheme 86. In the case 
where the amidine [262] is formamidine (i.e. R=H) the nature of the u-halocarbonyl 
compound [76] has a major effect on the outcome of the reaction. 157 u-Haloketones in which 
the substituents RI and R2 are aliphatic give almost exclusive formation of the imidazole 
[263], however, if the u-haloketone bears aromatic substituents then the major product from 
the reaction is the oxazole [265]. It is thought that the aromatic substituents favour the 
formation of the enol [264]. Fortunately amidines more complex than formamidine give 
imidazoles exclusively, this is thought to be a consequence of steric hindrance to the reaction of 
the enolic oxygen with the amidine carbon atom in the enol intermediate. 
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Scheme 86: The proposed mechanism for the Brederek amidine cyclisation 
It must be noted that NH imidazoles bearing a substituent at either the C(4) [266] or the C(5) 
[267] position exist as a pair of tautomers, Figure 11, this is because of rapid proton 
exchange between the sp2 NH and the sp C=N nitrogen atoms. 156 
Figure 11 
In neutral or organic solvents this proton exchange can be explained as an intermolecular 
process involving two or more imidazole molecules, Figure 12. In protic solvents, such as 
water, the solvent itself is involved. Thus this protropy makes the C(4) and C(5) positions of 
NH imidazoles magnetically and chemically equivalent. 
Fig 12 
It was contemplated that the Brederek ami dine cyclisation could be applied towards the 
synthesis of the required model imidazolylindole [261] and hence extended towards the 
synthesis of the more structurally challenging indolequinone imidazole [71]. 
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A general route for the synthesis of amidines involves functional group interconversion of a 
thioimidate [268], which can be formed by alkylation of a corresponding thioamide [269], 
Scheme 87. 158 This methodology appeared attractive because of our previous familiarity in 
the synthesis of indolyl thioamides (see Chapter 2 and Chapter 3). 
Scheme 87 
5.3. The Nortopsentins 
SMe 
===»R1~NH 
[268] 
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[269] 
The nortopsentins A [270], B [271] and C [272] have recently been isolated from the deep 
sea sponge Spongosorites ruetzler by Sun et aI., and were found to possess cytotoxic and 
antifungal properties. 159,160 Nortopsentin 0 [273] was formed by catalytic hydrogenation of 
either nortopsentin A, Band C at atmospheric pressure and rt. The imidazole bis[indole] 
skeleton of the natural compounds suggested that the model studies towards the desired 
imidazolylindole [261] could be extended to the synthesis of these complex multiheterocyclic 
natural products. 
Nortopsentin A [270] 
Nortopsentin B [271] 
Nortopsentin C [272] 
273 
R1=Br R2=Br 
R1=Br R2=H 
R1=H 
Retrosynthetic analysis of the general nortopsentin skeleton [274], employing the Brederek 
reaction as the strategem for imidazole formation, revealed the indolyl amidine fragment [275] 
(R 1= H or Br), which in turn can be derived from the corresponding indolyl thioamide [277] 
(again RI = H or Br) and the indolyl a-bromoketone [276] (R2= H or Br), Scheme 88. The 
synthesis of indole containing compounds with similar functionality has been previously been 
described in Chapter 2. It was predicted that the bromine atom at the C(6) position on the 
naturally occurring nortopsentins would not dramatically alter the chemistry of the indoles with 
regards to the formation of the intermediates [275] (R I = Br) and [276] (R 2 = Br). 
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Scheme 88: Retrosynthesis of the nortopsentins 
Ohta et al. have recently reported the total synthesis of nortopsentin D [273] by the use of 
successive palladium mediated Suzuki cross-coupling reactions, Scheme 89. 161 The 
(trimethylsilyl)ethoxymethyl (SEM) protected tribromoimidazole [278] was found to undergo 
a palladium catalysed cross-coupling rection with the tert-butydimethylsilyl protected indole-3-
boronic acid [279] to form the indole-3-imidazole [280], Repetition of the cross-coupling 
reaction resulted in the formation of the imidazole bis[indole] [281]. Subsequent removal of 
the imidazole bromine and the indole and imidazole protecting groups formed nortopsentin D 
[273]. 
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Scheme 89: Reagents and conditions i) [279], Pd(PPh3)4. Na2C03. 70%. ii) nBuLi. iii) H20. iv) 
[CH3(CH2l314NF. 67% (from [281]) 
5.4. Synthetic routes to indole-3-amidilles 
Papadopoulos has shown that a Friedel-Crafts thioacylation reaction can be applied towards the 
synthesis of aromatic thioamides, by reaction of ethoxycarbonyl isothiocyanate with a 
nucleophilic aromatic compound and anhydrous aluminium chloride. 162 The product is a N-
ethoxycarbonyl thioamide which is readily hydrolysed to a thioamide. Indole is known to 
undergo electrophilic substitution at the C(3) position and so this appeared an attractive 
synthetic route towards indole thioamides. This methodology was utilised by Shizuri et at. to 
form the indole C(3) thioamide in the synthesis of BE 10988, Scheme 50I 16 
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However, reaction of indole [93] with ethoxycarbonyl isothiocyanate in refluxing toluene and 
anhydrous aluminium chloride, followed by subsequent basic hydroysis failed to form any of 
the desired thioamide [277], Scheme 90. Altering the Lewis acid, reaction solvent and 
reaction conditions failed to form any product by this method. 
Scheme 90 
~ ~l 
H 
[93] 
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Owing to the failure to form [277] by a direct route, synthetic efforts were concentrated on the 
synthesis via a thionation reaction of the corresponding indole-3-carboxamide [95]. The 
indole amide [95] was synthesised according to the method of Mehta, in 61 % yield, Scheme 
91.97 
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Scheme 91: Reagents and conditions i) CS!, CH3CN, DOC, ii) KOH. acetone. H20. 61 % 
However. reaction of the amide [95] with 0.5 equivalents of LR in either refluxing toluene or 
benzene failed to form any of the desired thioamide [277]. Scheme 92, and contrary to the 
findings of Ayer et al. reaction of the indole [95] with phosphorus pentasulfide in refluxing 
benzene resulted in a complex mixture of products. 101 
o 
x 
[95] 
Scheme 92 
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It has previously been shown, Scheme 26, that N-Boc-protected indole-3-amide [100] was 
readily converted by reaction with LR to the corresponding thioamide [101] in 94% yield 
without forming any decomposition products. The tert-butyoxycarbonyl (Boc) protecting 
group has found widespread use in indole chemistry and can be cleaved either under mild acidic 
conditions or by reaction with sodium methoxide. 163 
The Boc protecting group was introduced by reaction of indole [93] with di-tert-butyl 
dicarbonate and a catalytic amount of dimethylaminopyridine (DMAP), used as a 
hypernucleophilic acylation catalyst, in acetonitrile at rt to form [282] in 96% yield, Scheme 
93. The N-Boc protecting group stabilises indole as a result of conjugation with the lone pair 
of electrons on the indole nitrogen, thus reducing the nucleophilicity at the indole C(3) position. 
Upon initial inspection, the use of such a protecting group would be expected to significantly 
reduce the yield of electrophilic substitution product. However, reaction of the protected indole 
[282] with CSI and subsequent basic hydrolysis formed the indole-3-carboxamide [100] in 
64% yield. Thionation of the indole-3-carboxamide [100] to the thioamide [101] was 
achieved by reaction with 0.5 equivalents of LR in refluxing benzene in excellent 94% yield. 
Alkylation of the thioamide [101] by reaction with iodomethane in dichloromethane at rt for 
24h formed the required thioimidate [283] in a respectable 74% yield. The labile methylthiol 
functionality in thioimidates activates them towards nucleophilic attack at the imine carbon. 
Ammoniolysis by reaction with ammonium chloride in refluxing methanol resulted in the 
formation of the amidine [284], as the hydrochloride salt, in 62% yield. Methanethiol is 
liberated and so extreme care was taken. A potassium permanganate trap was attached to the 
reaction vessel, in order to oxidise the anticipated smelly methanethiol to methanesulfonic acid. 
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Scheme 93: Reagents and conditions i) O[C02C(CH3)3J2, DMAP, CH3CN, 96%, ii) CS!, CH3CN, O°C, 
iii) KOH, acetone, H20, 94%, iv) LR [99], benzene, reflux, 94%, v) CH3!, CH2CI2, 74%, vi) NH4C1, 
CH30H, reflux, 62% 
The indolyl amidine reaction precursor for the synthesis of nortopsentin A [270] and B [271] 
required a bromine atom at the indole C(6) position. Unfortunately 6-bromoindole is not 
commercially available and so an independent synthesis was required. Out of the many 
reported methodologies for the synthesis of 6-bromoindole, employment of a modified 
Leimgruber-Batcho reaction appeared the most promising. 164 4-Amino-2-nitrotoluene [285] 
was converted to 4-bromo-2-nitrotoluene [286] via a Sandmeyer reaction, Scheme 94. 165 
The intermediate diazo compound was formed by reaction of the aniline [285] with 48% 
hydrobromic acid in refluxing water followed by addition of aqueous sodium nitrite, 
maintaining the temperature betweeen O-soC, and the resultant diazo intermediate was then 
reacted with cuprous bromide (copper(I)bromide). Steam distillation of the crude reaction 
mixture afforded the desired product [286] in 88% yield. The aryl bromo derivative [286] 
was subjected to a modified Leimgruber-Batcho indole synthesis by initial reaction with 
pyrrolidine and DMF-dimethylacetal in refluxing DMF to form a intermediate p-dialkylamino-
2-nitrostyrene, this was then reacted under reductive conditions with 80% acetic acid and zinc 
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dust to form 6-bromoindole [287] in 54% yield. The desired indole amidine derivative [292] 
was formed under analogous conditions for the synthesis of [284]. 
qNO' i,ii qNO' ~I .. ~I 
[285] NH2 Br [286] 
j ;;;, • 
D) v D) ... 
B ~ N Br ~ N r I [288] C02tBu [287] H ! 'i~i 
NH2 NH2 
viii 
.. 
Br Br ~ 
I t 
[289] [290] CO2 Bu 
ix 
SCH 3 
x 
... 
Br Br 
[292] 
Scheme 94: Reagents and conditions i) 48% HBr, H20, NaN02, ii) CuBr, iii) pyrrolidine, 
(CH3)2NCH(OC2H5)2, DMF, reflux, 88%, iv) Zn, CH3C02H, H20, 8DoC, 54%, v) O[C02C(CH3)3]2, 
DMAP, CH3CN, 77%, vi) CSl, CH3CN, DOC, vii) KOH, acetone, H20, 64%, viii) LR [99], benzene, reflux, 
49%, ix) CH3l, CH2CI2, 91 % crude, x) NH4C1, CH30H, reflux, 45% 
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5.5. The synthesis of a-bromacetyl indoles 
The synthesis of 3-(2-bromoacyl)indole [123] has been discussed in chapter 2. Scheme 
39. It was originally anticipated that application of the methodology utilized in the synthesis of 
[123] could be extended towards the construction of the desired 6-bromo derivative [293]. 
:::::,... 
[123] 
Br Br 
Br 
However, reaction of 6-bromoindole [287] with chloroacetyl chloride (in this case to form the 
a-chloroketone derivative cf [122]) and pyridine in toluene at 60°C resulted in a complex 
mixture of products, Scheme 95. J to Attempted Vilsmeier acetylation 166 also resulted in the 
formation of a complex mixture of products. 
Br 
Br 
~ BA)l-l 
r [287]H 
x · 
Scheme 95: Attempted direct formation of the a-bromoketone {304] 
The acid catalysed a-bromination of ketones has been well documented in the chemical 
literature for the construction of a-bromo ketones. J 67 Because of the precious nature of 6-
bromoindole, model studies were attempted on the commercially available 3-acetylindole 
[294], Scheme 96. Acid catalysed bromination of 3-acetylindole [294] by reaction with 
bromine in acetic acid failed to form any of the desired a-bromo ketone [123]. Kosower and 
Wu have suggested the use of copper(ll)bromide in a I: I mixture of chloroform and ethyl 
acetate as an alternative procedure for the preparation of a-bromination of ketones. 168 
Reaction of [294] under these conditions failed to form any of the desired compound [123]. 
It was decided to protect the 3-acetylindole [294] as the the N-Boc derivative [295] and then 
attempt the bromination reaction. N-Boc protection of 3-acetylindole [294] under the standard 
conditions formed the N-Boc protected indole [295] in 82% yield. Bromination of [306] by 
reaction with copper(ll)bromide in a I: 1 mixture of refluxing chloroform and ethyl acetate over 
4 h formed the desired bromoacetyl indole [296] in 45% yield. N-Boc protection of the 
previously synthesised bromo derivative [123], by reaction with di-tert-butyl dicarbonate and 
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a catalytic amount of DMAP in acetonitrile, independently formed the desired bromo compound 
[296] in 92% yield. 
.. 
[123] 
Scheme 96: Reagents and conditions i) O[C02C(CH3)3]2, DMAP, 82% [295] and 92% [296] ii) CuB'2, 
CH3CI, ethyl acetate, reflux, 45% 
The corresponding 6-bromo indole derivative [299] was formed via an initial Vilsmeier 
acetylation on 6-bromoindole [287], by reaction with N,N-diethylacetamide and phosphorus 
oxychloride in chloroform to form, after basic work-up, the acetyl indole derivative [297] in a 
poor 8% yield, Scheme 97. 166 The acetyl derivative [297] appeared to be unstable and so 
standard N-Boc protection was immediately carried out to provide the N-Boc protected 
derivative [298] in 40% yield. Bromination of the acetyl derivative [298] by reaction with 
copper(II)bromide in a I: 1 mixture of refluxing chloroform and ethyl acetate over 4 h formed 
the desired bromo compound [299] in a poor 45% yield. 
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Br Br 
Scheme 97: Reagents and conditions i) CH3CON(CH3)2, POCI3, CH3Cl, reflux, ii) 40% KOH, iii) 
O[C02C(CH3)312, DMAP, 40%, iv) CuBrz, CH3Cl, ethyl acetate, reflux, 45% 
5,6, Synthesis of BOC protected nortopsentins 
A Brederek imidazole reaction between the indolyl ami dine [284] and the o:-bromoketone 
[123] with potassium carbonate in refluxing acetonitrile resulted in the formation of the N-Boc 
imidazole bis[indole] derivative [300] in a reasonable 41 % yield, Scheme 98. The imidazole 
bis[indole] [300] is N-Boc protected nortopsentin D [273]. 
CIH,HN 
NH2 
N 
I 
CO tBu [284] 2 
_ HN ~ QrN 
N 
I 
C02tBu 
[300] 
Scheme 98: Reagents and conditions i) K2C03, CH3CN, reflux, 41% 
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Reaction of the 6-bromoindolyl amidine derivative [292] in a Brederek imidazole reaction with 
the (X-bromoketone [123] and potassium carbonate in refluxing acetonitrile produced in a 
modest 34% yield N-Boc protected imidazole bis[indolel [302], Scheme 99. The imidazole 
bis[indole] [301] is N-Boc protected nortopsentin B [271]. 
N 
I 
CO tBu [292] 2 Br 
Br 
Scheme 99: Reagents and conditions i) K2C03, CH3CN, reflux, 34% 
However, attemps to form the N-Boc nortopsentin C derivative [302], Scheme 100, by a 
Brederek imidazole reaction between the indolyl amidine [284] and the 6-bromoindole (X-
bromo ketone [299], and to form the N-Boc protected nortopsentin A derivative [303], 
Scheme 101, by reaction of the 6-bromoindolyl amidine derivative [292] and the (X-
bromo ketone indole derivative [299] both failed to form any identifiable products. TLC 
indicated the formation of three products and efforts to identify the desired nortopsentin 
products [302] and [303] proved fruitless. 
Br 
C1H.HN 
N 
I 
CO tBu [284] 2 
N 
I 
C02 tBu [299] 
Scheme 100 
x · Br 
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CO tBu X Br ~ Br [292] 2 .. N 
Br N 
I 
C02tBu 
[303] 
N 
I 
C02 tBu 
Br 
[299] 
Scheme 101 
With the N-Boc protected nortopsentin Band D derivatives [300] and [301] in hand, 
synthetic efforts were concentrated on cleavage of the N-Boc protecting groups to reveal the 
natural compounds, Scheme 102. However, attempted deprotection, of both [300] and 
[301], either by reaction with trifluoroacetic acid or by reaction with sodium methoxide in 
THF failed to form any of the coveted natural products [273] or [271].163 Under both 
deprotection methodologies a bright blue solution was formed. I H NMR analysis of the crude 
reaction mixture provided no evidence for the formation of the natural products. 
X 
N 
I 
C02tBu 
X = H [300] 
X = Br [301] 
x 
X = H [273] Nortopsentin D 
X = Br [271] Nortopsentin B 
Scheme 102: Attempted Boc deprotection of the imidazole bis{indoleJ compounds [311J 
and [312J 
Because of the problems associated with the Brederek imidazole reaction towards the synthesis 
of the nortopsentins, the synthesis of the imidazolylindole [261] and the required 
indolequinone imidazole [71] was discontinued. 
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5.7. Conclusions 
• Literature precedence has shown that the cyclisation of an amidine with a a-haloketone may 
be applied to the synthesis of the the naturally occuring nortopsentins. 
• The N-Boc protected indole-3-amidines [284] and [292], derived from indole [93] and 
6-bromoindole [287] respectively, can be synthesised. 
• The 3-(2-bromoacetyl)indoles [123] and [299] can be synthesied, from indole [93] and 
6-bromoindole [287] respectively, however, in the case of [299] in great difficulty. 
• The Brederek imidazole reaction has been shown to be applicable towards the synthesis of 
the imidazole bis[indole] compounds [300] and [301]. Unfortunately, deprotetion of the 
indole N-Boc protecting groups, to provide the nortopsentins D [273] and B [271], 
failed. 
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Chapter 6 
Biological results. 
6.1. Introduction 
The synthesis of a series of the so called "simple" thiazolylindoles has been discussed in 
chapter 2. Employment of the Hantzsch reaction allowed the construction of a variety of 
functionalised thiazole derivatives. Such functionality included methyl [116], ethyl ester 
[114] and primary carboxamide [115] moieties. A series of thiazolylindole compounds were 
also synthesised in which structural diversification was centred on the indole nitrogen, e.g. 
the N-H [117] ,N-methyl [119] and N-acetyl [118] camalexin derivatives. The position of 
the thiazole ring, relative to the indole moiety, was also varied. A class of compounds were 
synthesised in which the thiazole derivative was attached to the indole C(3) position, e.g. 
[116] and [129] in conjunction with a sequence of analogues were the thiazole ring was 
attached to the indole C(2) position, e.g. [138]. The synthesis of the miscellaneous 
benzothiazolylindole [141] was also discussed. The compound [141] was synthesised on the 
hypothesis that the benzothiazole moiety would enhance binding of the drug to DNA, 
possibly by intercalation, thus extending the mechanism of action of these compounds. 
The synthesis of a range of thiazolylindolequione analogues, structurally related to the 
natural compound BE 10988 [43], has been discussed in chapter 3. Again a set of 
structurally diverse compounds was synthesised. A major proportion of the synthetic effort 
was concentrated upon the synthesis of the ethyl ester substituted thiazole [163] and the 
methyl substituted thiazole [165]. Both [163] and [165] contain a thiazole moiety attached to 
the indolequinone C(2) position. C(S)-Methoxy quinone exchange reactions with a variety of 
nitrogen nucleophiles, ranging from aziridine to morpholine, allowed the construction of 
various C(S) amino substituted thiazolylindolequinones. C(S)-Methoxy quinone exchange 
reactions, with aziridine and 2-methylaziridine as the nucleophile, were also shown to take 
place readily on the previously synthesised BE 10988 analogues [146], [196] and [199]. 
6.2. Inhibition of DNA topoisomerase 11 
The structurally "simple" thiazolylindole, the miscellaneous benzothiazolylindole [141] and 
the thiazolylindolequinone analogues were initially assessed for their ability to inhibit the 
action of the nuclease topoisomerase H. To evaluate this, the compounds were tested for in 
vitro activity against a human breast cancer cell line (SKBr3).169 The SKBr3 cell line over 
expresses the topo Ha gene and is recognised to be extremely sensitive to known topo H 
inhibitors, such as m-AMSA [37] and mitoxantrone [304]. It is thought that the 
topoisomerase II agents stabilise the so called cleavable complex, resulting in DNA double-
strand cleavage. in vitro Values of ICSO for each compound are given and comparison is 
made with the toxicity of the known topo H inhibitor mitoxantrone [304] and the 
thiazolylindolequinone natural product BE 10988 [43]. The ICSO value indicates the 
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concentration of drug required to inhibit survival by 50% following exposure to SKBr3 cells 
incubated for 4 days at 37°C. 
6.2.1. in vitro Activities (ICSO / f.1M) of the "simple" thiazolylindole and the 
benzothiazolylindole compounds against SKBr3 cell lines 
The in vitro activities for the thiazolylindole compounds [114] - [117] , i.e. analogues with a 
variety of functionality on the indole nitrogen (R t) and the thiazole (R2), are shown, Table 
10. The activities for the natural compound BE 10988 [43] and mitoxantrone [304] are also 
shown. Surprisingly the camalexin analogues [117], [118] and [119] were more potent than 
the natural product BE 10988 [43]. The most active compound [117] was 3.2 times more 
active than [43]. The most active analogue [117] showed approximately 12 fold activity over 
the least effective agent [115]. The activities for the N-methyl analogues (R 1 = CH3) were 
found to be dependent upon the thiazole functionality (R 2). The order of activity being R2 = 
H [117], (IC50 = 2.7) > methyl [116] (lC50 = 6.3) > ethyl ester [114] (IC50 = 19.6) > 
primary carboxamide [115] (ICSO = 32.0). 
SA:y-R2 OH 0 
-N 
OH 0 NH(CH2bNH(CH2)20H 
Mitoxantrone [304] 
Compound RI RZ ICSO(IlM) / SKBr3 
No. 
[117] H H 2.7 
[119] CH3 H 3.8 
[118] Ac H 3.6 
[116] CH3 CH3 6.3 
[114] CH3 C02Et 19.6 
[115] CH3 CONH2 32.0 
[43] 8.7 
BE 10988 
[304] 0.016 
Mitoxant-
rone 
Table 10 
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Mitoxantrone [304] was found to be approximately SSO times more active than the 
supposedly potent topo n agent [43]. The significant reduction in activity of [43] compared 
with the recognised topo 11 inhibitor [304] suggested that inhibition of topo 11 was not a 
consequence of the cytotoxicity of [43], for a more detailed account into the spurious topo 11 
inhibitory effect of [43] , see section 6.2.3. 
The in vitro activities of isomeric thiazolylindole derivatives, against the SKBr3 cell line are 
shown in Table 11. Compound [128] was found to be the most active (lCSO = 4.9) and it 
displayed an approximate two fold increase in activity over [43]. The compound [129] (ICso 
= 9.S) was approximately equipotent in activity with [43]. The range in activity over the 
thiazolylindoles was seven fold. Both sequences of compounds in which the substituent 
attatched to the indole nitrogen (R I) remained constant were shown to be dependent upon the 
nature of the thiazole functionality R2. The order for both the N-H and N-methyl derivatives 
was: CH3 > H > CONH2 > C02Et. 
Compound Rl R2 lC SO(/J.M) I SKBr3 
No. 
[126] H H 18.0 
[127] CH3 H 12.0 
[128] H CH3 4.9 
[129] CH3 CH3 9.5 
[130] H C02Et 3S.S 
[131] CH3 C02Et 3S.S 
[132] H CONH2 32.3 
[133] CH3 CONH2 30.0 
Table 11 
The in vitro activities for the indole C(2) thiazole analogues [138] - [140], designated 
structure A, and the benzothiazolylindole [141], structure B, are shown, Table 12. All the 
I11 
thiazolylindole compounds were found to possess poor activity, the order of activity being, 
RI = CH3 [138] > C02Et [139] > CONH2. However, the benzothiazolylindole [141] 
displayed a dramatic increase in activity (IC50 = 2.6), such that it was the most active 
"simplified" compound synthesised so far. The compound [141] showed approximately three 
times more activity than the natural product BE 10988 [43] and was 15 times more potent 
than the least active compound [140]. 
~~  N N Rl ~D I ~ ~ \ #  N N 
A Me B Me 
Compound Structure RI ICSO(J.IM) / SKBr3 No. 
[138] A CH3 20.0 
[139] A C02Et 30.0 
[140] A CONH2 40.06 
[141] B 2.6 
Table 12 
From the results obtained so far the following generalisations can be made: indolylthiazole 
moieties bearing either an ethyl ester or primary carboxamide functionality on the thiazole 
show much lower activities towards the SKBr3 cell lines than methyl or nonfunctionalised 
thiazoles. The natural product [43] contains a primary carboxamide group attached to the 
C( 4) position on the thiazole, from these preliminary results it can be postulated that 
substitution of the primary amide for a methyl or hydrogen would substantially increase the 
activity. Also attachment of the thiazole at the indole C(2) position reduced the activity 
against the SKBr3 cell line. 
6.2.2. in vitro Activities (IC50 / JIM) of the thiazolylindolequinone compounds against 
SKBr3, A 549 and PV9 cell lines 
The thiazolylindolequinone analogues were screened for in vitro topo H inhibitory activity 
against the human breast cancer SKBr3, the human lung carcinoma A549 and PV9 cell lines. 
The A459 cell line also shows amplification of the topo Hu gene and has been shown to be 
hypersensitive towards recognised topo Il inhibitors, such as mitoxantrone [304] and 
etoposide [44]. Whereas the PV9 cells were selected as a stably resistant population. 
Following long term etoposide [44] exposure the PV9 cell lines are found to become drug 
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resistant. This cell line exhibits significant cross-resistance to etoposide [44], adriamycin 
[39], m-AMSA [37], mitoxantrone [304] and all agents thought to act through topoisomerase. 
Therefore topoisomerase inhibitors are expected show increased activities in the SKBr3 and 
A4S9 cell lines and poor activities in the PV9 cell line. The in vitro activities, reported as 
ICSO values, for the thiazolylindolequinone analogues against these cell lines are shown, 
Table 13. The compounds tested were derived from the indolequinones [163] (R2 = C02Et) 
and [165] (R 2 = CH3), see structure below. The functionality at the indolequinone C(S) 
position (R I) ranged from a simple methoxy group to acyclic amines (such as cyclopropyl 
amine) and three, four, five and six-membered cyclic amines. 
o 
o 
The most striking observation in this series of compounds is the high activities of the 
aziridino derivatives [180] and [186], both of which were significantly more active than BE 
10988 in the SKBr3 cell line. In the case of [186] a 40 fold increase in activity was noted. 
However, for [186] high activities were observed in all the cell lines. The similar activity in 
the PV9 cell line to the SKBr3 and AS49 indicated that the mechanism of cytotoxicity was 
probably not a result of topoisomerase II initiated cleavage of DNA. The order of reactivity 
for the aziridino compounds was: unsubstituted > mono-methyl > bi-methyl, which 
corresponds to the studies of Lafleur et al. Both the methoxy derivatives [163] and [165] 
showed approximately two fold increase in activity over BE 10988. The remaining amino 
derivatives were all significantly less active than the aziridino compounds. Generally all the 
derivatives were found to be more active than the simple C(2) indolethiazole compounds 
(Table 12), with the exception of the azetidinyl [189] and the cyclopropylamine [193] 
derivatives. Likewise the methyl thiazole compounds were more active than the ethyl ester 
thiazole compounds (a similar trend was observed in the simple C(2) indolethiazole 
compounds, Table 12). 
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Compound 
No. RI R2 ICSO{J1M) 
SKBr3 AS49 PV9 
[163] OCH3 C02Et 3.9 
[165] OCH3 CH3 3.2 
[180] [>- C02Et 0.42 
[186] ~N- CH3 0.2 0.7 0.5 
[181] Me~ N- C02Et 4.2 
[187] Me~N_ CH3 7.0 25.7 27.1 
Me//, 
[188] l~N- CH3 8.9 19.0 19.7 
Me\'"'' 
[189] ~N- CH3 30.1 26.1 36.3 
[182] CN- C02Et 11.3 13.9 24.3 
[190] CN- CH3 8.5 14.6 7.5 
[183] 0- C0 2Et 21.5 20.1 31.4 
[191] CN- CH3 12.4 23.2 21.3 
[184] [>---~, C02Et 10.1 22.6 38.0 
[193] [>---~, CH3 22.3 38.1 37.5 
Table 13 
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The in vitro activities of the aziridino [194], [197] and the 2-methylaziridino [195], [198] 
thiazolylindolquinone derivatives against the SKBr3, A4S9 and PV9 cell lines are shown, 
Table 14. Also included, for comparison, are the previously synthesised C(S) methoxy 
[146], [196] compounds and the C(S) amino [305] derivative. An initial striking observation 
is the notable difference in activity between the two methoxy derivatives [146] and [196]. 
The only structural difference between the compounds is the functionality on the thiazole 
ring. Switching the ethyl ester moiety in [146] (R 2 = C02Et) to a methyl group [196] (R 2 = 
CH3) results in a 20 fold increase in activity. The aziridino substituted compounds [194] and 
[197] both showed an impressive increase in activity, in all cell lines. The aziridine 
indolequinone [194] (lCso = 0.1) is 87 times more potent than BE 10988. However, all the 
aziridine containing compounds were similarly active in all three cell lines. Thus, implying 
that topoisomerase II mediated DNA cleavage was not the mechanism of cytotoxicity. Again 
the order of activities were: un substituted aziridine > mono-methyl> amino. 
o 
Results from the analogous "simple' thiazolylindole compounds (Table 10) suggested that 
the activities were dependent upon the nature of the functionality attached to the thiazole 
ring, with hydrogen and methyl groups showing significantly more activity than the ethyl 
ester and primary carboxamide functionalities. An approximate 10 fold increase in activity 
was found in the methyl derivatised thiazolylindole [119] over the primary carboxamide 
derivatised thiazolylindole [119]. Likewise the methyl thiazole derivative [305] showed an 
approximate 10 fold increase in activity over the natural product BE 10988 [43]. 
The thiazolylindolequinone compounds derivatised with a thiazole moiety at the indole C(3) 
position (Table 14) were generally more active than the corresponding indole C(2) thiazole 
derivatised compounds (Table 13). A similar trend was found in the simple indolethiazole 
series. Although a number of compounds were synthesised with major increases in activity 
over BE 10988, serious questions have to be asked about the true cytotoxic nature of these 
compounds, including the original statement that BE 10988 was a potent topo II inhibitor. 
The recognised topo II inhibitor mitoxantrone [304] showed a significant increase in activity 
over all the compounds synthesised and the few compounds that possessed promising 
activities in the SKBr3 and AS49 cell lines were similarly active in the PV9 cell line. 
liS 
Compound 
No. RI R2 IC50{J1M) 
SKBr3 A549 PV9 
[146] OCH3 C02Et 27.8 
[196] OCH3 CH3 1.4 
[194] [:::N- C02Et 0.1 0.41 1.3 
[197] [:::N- CH3 0.12 0.31 0.76 
[195] Me[::N_ C02Et 0.33 1.80 2.0 
[198] Me[::N_ CH3 0.66 1.1 2.3 
[43] NH2 CONH2 7.8 
BE 10988 
[305] NH2 CH3 0.73 
Table 14 
6.2.3. Is the thiazolylindolequinone BE 10988 [43J a topo II inhibitor? 
The cell lines used to determine the in vitro topo 11 activity of the thiazolylindole and 
thiazolylindolequinone compounds are sensitive to the formation of drug induced topo 11 
DNA strand breaks. Total inhibition of topo 11 function has been shown not to result in DNA 
cleavage, however, total inhibition of topo 11 would seriously effect cellular metabolism. 
With the exact nature of the cytotoxic effect of BE 10988 and related analogues appearing 
rather hazy, a method was required to prove precisely whether topo 11 inhibition was 
involved. 129 
The topo II-mediated decatenation of kDNA assay can be used to ascertain precisely whether 
an agent acts as a topo 11 inhibitorl29 kDNA consists of a series of interlinked rings of 
DNA. During incubation with nuclear extracts that contain topo 11, those links become 
separated. Electrophoresis of this decatenated DNA shows that it runs approximately one-
half the distance of the dye front. An effective inhibitor of topo 11 activity will prevent the 
decatenation from occurring, and the electrophoretic pattern will appear the same as for 
kDNA alone. It was found that 10 IlM mitoxantrone [304] completely inhibited the action of 
topo 11 by this assay, in contrast ISO IlM of BE 10988 [43] had no effect on the decatenating 
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activity of topo H. Thus suggesting that the mechanism of action of BE 10988 does not 
involve topo H inhibition. 
6.3. Bioreductive compounds 
Bioreductive drugs are defined as compounds that are selectively toxic to hypoxic tumour 
cells. These bioreductive drugs, can selectively target hypoxic tumour populations that are 
resistant to both radiation and chemotherapy. Bioreductive drugs are initialy activated to 
toxic species under hypoxic conditions by enzymatic metabolism. The ease of bioreduction 
of a given drug will depend upon the ability of the drug to act as a substrate for the 
intracellular reductase(s) and the expression of these enzyme(s) within the particular cell 
type. Further more depending upon whether or not the bioreductive drug is reduced in a one 
or two electron step, the reduction may be reversed by oxygen. In the case of the quinone 
moiety, one electron reduction results in the formation of a semiquinone radical anion which 
will be reoxidised back to a quinone in the presence of oxygen. 
6.3.1. in vitro Activities (ICSOI J1M) of the thiazolylindolequinone analogues in V79 cell 
lines under hypoxia and air 
Selective in vitro toxicity toward hypoxic V79 cells were determined for all compounds 
using the MTT assay. Cells derived from exponentially growing culture were treated with 
varying concentrations of drugs for 3 h at 37°C under hypoxic (N 2) or aerobic conditions. 170 
Then following removal of the drug the cells were allowed to proliferate for 3 days prior to 
MTT assay. The activities are expressed as values of ICSO which are the concentrations 
required to kill SO% of the cells under the conditions of the initial treatment. The ratio of 
ICso(air) vs ICSO(N2) enables quantitative comparison to be made of the 02-dependent 
bioreductive activities of these compounds. The in vitro activities, reported as ICSO values, 
for the C(2) thiazolylindolequinone analogues against these cell lines are shown, Table 15. 
o 
o 
The functionality on the indolequinone C(S) position (R 1) ranged from a simple methoxy 
group to the three, four and six-membered cyclic amines. All the ethyl ester (R 2 = C02Et) 
thiazolylindolequinone analogues were found to be more active under hypoxic (N 2) 
conditions, with airIN2 ratios ranging from S to 14, Figure 12. These results suggested that 
the quinone moieties were reduced by a one electron reduction to a semiquinone radical 
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amon. However, further studies are required to unambiguously confirm the postulate. The 
most active compound was the aziridino derivative [180], however, the most hypoxic 
selective compound was the 2-methyl aziridino derivative [181] which was found to be 14 
times more active against hypoxic (N2) cell lines. The methyl (R2 = CH3) 
thiazolylindolequinone analogues did not show the same levels of activity. The aziridino 
[186] and azetidino compounds were 5 and 4 times more active under hypoxia, again 
suggesting a one electron reduction of the quinone. Whereas the 2-methylaziridinyl [181] 
and mopholinyl [192] derivatives were found to possess similar activities under both hypoxia 
and air, thus suggesting a two electron reduction of the quinone to the hydroquinone species. 
Compound 
No. 
Table 15 
[163] 
[165] 
[180] 
[186] 
[181] 
[187] 
[189] 
[192] 
OCH3 
OCH3 
t::N-
<>-
1\ 
o N-
"--I 
C02Et 
Air 
200 
54 
10.8 
17.4 
112 
30.0 
lOO 
300 
IC50(~M) 
N2 
20 
76 
2.2 
3.4 
7.9 
30.0 
25 
200 
AirIN2 
10.0 
<1 
5.0 
5.0 
14.0 
1.0 
4.0 
1.5 
A rather curious result is found in the case of the methoxy derivatives [163] and [165]. The 
ethyl ester thiazole derivative [163] is significantly more active under hypoxia, whereas the 
methyl thiazole derivative [165] was deactivated under hypoxia. The methoxy compound 
[163] appears to be devoid of functionality capable of alkylating DNA, therefore suggesting a 
different mechanism is responsible for the cytotoxic effect. It could be speCUlated that 
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reduction of the quinone provides hydrogen bonding sites, thus allowing binding of the 
compound to DNA. Indeed this may be the mechanism of action for all the compounds. 
Further studies to unambiguously prove DNA alkylation and strand cleavage for the aziridine 
compounds are required. 
200 • Air 
160 • Hypoxia 
120 
80 
40 
o 
Methoxy Aziridine Methylaziridine 
Substituent R2 
Figure 12: in vitro le 50 ()1M) values, under air and hypoxia, for the thiazolylindolquinone 
C(5) methoxy [163J, aziridinyl [180J and 2-methylaziridinyl [181J derivatives. 
The in vitro activities of the aziridino [194], [197] and the 2-methylaziridino [195], [198] 
thiazolylindolequinone derivatives against the hypoxic (N 2) and air V79 cell lines are shown, 
Table 16. Also included, for comparison, are the previously synthesised C(5) methoxy 
[146], [196] compounds and the C(5) amino [305] derivative. Activities for the known 
bioreductive alkylators MMC [10] and E09 [34] are also provided for comparison. Initial 
observation reveals the poor selectivity for the hypoxic cell lines, with the most selective 
compound [197] being twice as active against the hypoxic cell lines. The poor selectivity 
towards hypoxia in all the compounds suggested that they may be activated by a two electron 
process. The aziridino and 2-methylaziridino compounds were significantly more active than 
the methoxy derivatives and the natural product BE \0988. The aziridino derivative [194] 
was 420 and 340 times more active than the methoxy derivative [146] under air and hypoxia 
respectively. 
o 
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Although the aziridinyl thiazolylindolequinone [197] was approximately 7 times more active 
than the natural compound BE 10988 [43] under hypoxia, the activity must be put into 
perspective with the bioreductive alkylaters MMC [10] and E09 [34]. As can be seen from 
Table 16, the the aziridino thiazolylindolequinone [197] was approximately two and 200 fold 
less active under hypoxic conditions than MMC and E09 respectively. 
Compound 
No. RI R2 IC50(1lM) 
Air N2 AirIN2 
[146] OCH3 C02Et 420 340 1.2 
[196] OCH3 CH3 73 48 1.5 
[194] [>- C0 2Et 1.0 1.0 1.0 
[197] [>- CH3 1.5 0.75 2.0 
[195] MetN_ C02Et 2.0 2.0 1.0 
[198] MetN_ CH3 3.0 3.0 1.0 
[305] NH2 CH3 10.3 6.0 1.7 
[43] NH2 CONH2 6.2 5.1 1.2 
BE 10988 
[10] MMC 0.8 0.4 2 
[34] E09 0.19 0.0038 50.3 
Table 16 
The thiazolylindolequinone derivatives in which the thiazole ring was attached to the indole 
C(3) (Table 16) were generally more active than the corresponding C(2) 
thiazolylindolequinone derivatives (Table 15). However, the C(5) methoxy ethyl ester 
thiazole derivative [146] is significantly less active than the isomeric analogue [163] under 
hypoxia, approximately 17 times less active, whereas, in air it is only two times less active. 
Thus suggesting that the conformation of the thiazole moiety in [146] may inhibit DNA 
binding. The C(2) thiazolylindolequinone derivatives were significantly more selective 
under hypoxia, thus, suggesting they are reduced predominantly by a one electron process. 
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The C(3) thiazolylindolequinone derivatives all showed poor hypoxic cell selectivity, 
suggesting a two electron reduction. Thus the attachment of a thiazole ring at the C(2) 
position on the indolequinone appears to activate reduction of the indolequinone moiety via a 
one electron process, thus forming hypoxia selective agents. This may be a result of altering 
the electropotential of the quinone or a factor of drug conformation, i.e., increasing the 
compounds to act as a substrate for one electron reductase enzymes. 
6.4. Future work, the synthesis of bifunctional thiazolylindolequinone alkylating agents 
Alkylating agents that cause cross linking of DNA are generally more cytotoxic than agents 
that result in monofunctional DNA alkylation. The thiazolylindolequinone analogues 
(Tables 15, 16) contain one site for bioreductive alkylation (the aziridino functionality) and 
so incorporation of functionality onto these molecules which will result in possible 
bifunctional alkylation would be expected to dramatically increase cytoxicity. 
The cyclopropamitosenes have previously been synthesised within these laboratories. As can 
be seen in Table 17 the compounds containing two possible sites for alkylation [33] and 
[309] are significantly more cytotoxic under hypoxia in vitro than the monofunctional agents 
[307] and [308] respectively, i.e ,. incorporation of an aziridine attached to the quinone and a 
carbamoyl group at the indole C(3) position. 
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Compound 
No. RI R2 IC50(1lM) 
Air N2 AirIN2 
[306] OCH3 H 200 200 1.0 
[32] OCH3 CH 20CONH 2 4.8 0.14 34 
[307] ~N- H 7.0 2.0 3.5 
[33] ~N- CH 20CONH 2 0.003 0.003 1.0 
[308] Me~N_ H 90 35 2.5 
[309] Me~N_ CH20CONH2 1.2 0.055 22 
Table 17 
The indole C(3) position is "free" in the thiazolylindolequinone analogues, in which the 
thiazole ring is attached to the indole C(2), therefore the incorporation masked electrophilic 
functionalities could be envisaged to provide species capable of forming DNA cross-links 
upon reductive activation. The compounds [310] and [311] (were RI = OH or OCONH2) 
were envisaged to act as bifunctional alkylating agents. The derivative [311] can be regarded 
as a hybrid of the benzothiazolylindole [141] and the thiazolylindolequinone analogue [186]. 
R1 0 R1 LN S LN 
~ sD ~~ ~ \ ",f 
N C02Et N N Me 
0 0 [311] 
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The C(2) imidazole analogue [312] is also a synthetic possibility, such that the imidazole ring 
may augment drug binding to DNA. The compound [312] can be considered to be a hybrid 
of the thiazolylindolequinone [197] and E09 [31]. All of these compounds can be 
synthesised from the highly functionalised flexible indole [154]. 
R1 0 
.L:N .L:N HN~ ~ \ ~ N C02Et N Me OH 
0 0 [313] 
6.5. Conclusions 
• A number of the "simple" thiazolylindole compounds were found to have greater in vitro 
activity in the SKBr3 cell lines than the natural compound BE 10988 [43], notably [117] 
(Table 10) and the benzothiazolylindole [141] (Table 12). 
• A number of the C(2) thiazolylindolequinone compounds were found to have greater in 
vitro activity in the SKBr3 and A 549 cell lines than the natural compound BE 10988 
[43], notably the C(5) aziridinyl derivatives [180] and [186] (Table 13). However, 
significant activities in the PV9 cell lines indicated that topo 11 inhibition was not a 
consequence of cytotoxicity. 
• A number of the C(3) thiazolylindolequinone compounds were found to have greater in 
vitro activity in the SKBr3 and A 549 cell lines than the natural compound BE 10988 
[43], notably the C(5) aziridinyl derivatives [194], [197] and the 2-methylaziridinyl 
derivatives [195], [198] (Table 14). However, significant activities in the PV9 cell lines 
also indicated that topo II inhibition was not a consequence of cytotoxicity. 
• The "simple" thiazolylindole and thiazolylindolequinone compounds were found to have 
significantly reduced in vitro activity in the SKBr3 cell lines, compared to the known 
topo II inhibitor mitoxantrone [304], thus suggesting inhibition of topo II was not the 
cytotoxic effect. Independent studies into the topo II-mediated decatenation of kDNA 
revealed that the natural compound was not a topo II inhibitor. 
• A number of the C(2) thiazolylindolequinone compounds were found to have increased in 
vitro activity under hypoxia in the V79 cell lines, notably the C(5) 2-methylaziridinyl 
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derivative [181] which was 14 times more active under hypoxia (Table 15). Thus, 
suggesting an oxygen inhibited one electron bioreduction of the quinone moiety. 
• A number of the C(3) thiazolylindolequinone compounds were found to have increased in 
vitro activity in the V79 cell lines than the natural compound BE 10988 [43], notably the 
C(5) aziridinyl derivatives [194], [197] and the C(5) 2-methylaziridinyl derivatives 
[195], [198] (Table 16). However, the in vitro activities were similar under air and 
hypoxia, thus, suggesting a two electron bioreduction of the quinone moiety. 
• The in vitro activities in the V79 cell lines of the most active thiazolylindolequinone 
compounds were less than the common bioreductive agents MMC [10] and E09 [31]. 
However, precedent suggests incorporation of a second alkylation site on the 
thiazolylindolequinone compounds would lead to a significant increase in activity. The 
hypothetical compounds [310], [311], [312] and [313] were suggested as possible 
synthetic targets. 
124 
Chapter 7 
Experimental. 
7.1. General Information 
Solvents and Reagents: Commercially available solvents and reagents were used without 
further purification, except for those detailed below which were purified as described. 'Light 
petroleum' refers to the fraction of petroleum ether boiling between 40°C and 60°C and was 
distilled through a 36 cm Vigreux column before use. Diethyl ether, benzene, mesitylene and 
xylene were dried were necessary by standing over sodium wire for several days. THF was 
distilled from sodium benzophenone ketyl under nitrogen, prior to use. Dichloromethane and 
chloroform were distilled from phosphorus pentoxide, prior to use. Ethyl acetate was distilled 
from potassium carbonate, prior to use. DMF was dried by stirring over calcium hydride for 
15 h, decanted, and distilled under reduced pressure before storing over activated 4A molecular 
sieves under nitrogen. Methanol and ethanol were distilled from magnesium turnings and 
iodine and stored over activated 4A molecular sieves under nitrogen. Aziridine, 2-methyl 
aziridine and eis-dimethyl aziridine were distilled from potassium hydroxide pellets and stored 
over sodium hydroxide pellets under nitrogen in the refrigerator. Unless otherwise stated, all 
reagents were used as supplied. 
Chromatographic Procedures: Analytical thin layer chromatography (TLC) was carried out 
using aluminium backed plates coated with Merck Kieselgel 60 GF254. Flash column 
chromatography was carried out using Merck Kieselgel 60 H silica. Pressure was applied at 
the column head with hand bellows. Size exclusion chromatography was carried out using 
Sephadex LH20® gel, with a 1: 1 solution of methanol and dichloromethane as the eluent. 
Spectroscopic techniques: Infra red (IR) spectra were recorded in the range 4000-600 cm- 1 
using a Nicolet FT -205 spectrometer, with internal calibration. Spectra were recorded as either 
solutions in chloroform, as thin films or as nujol mulls. Thin films and nujol mulls were 
recorded between sodium chloride plates. I H NMR spectra were recorded using Bruker AC-
250 (250 MHz), and Bruker DPX-400 (400 MHz) instruments. 13C spectra were recorded 
using Bruker AC-250 (62.5 MHz), and Bruker DPX-400 (100 MHz) instruments. High and 
low resolution mass spectra were recorded on a Kratos MS80 instrument. 
Other data: Melting points were measured on a Reichert-Kofler hot stage apparatus or on an 
electrothermal digital melting point apparatus. Elemental analyses were carried out on a Perkin 
Elmer 2400 Elemental Analyser. 
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7.2. Synthesis or preparation of general reagents 
Methyl Azidoacetate [205] 
Methyl chloroacetate (50 g, 0.461 mol) was added followed by sodium azide (37.65 g, 0.579 
mol, CAUTION with a plastic spatula) to a stirred mixture of water (50 ml) and acetone (75 
ml). The stirred mixture was heated at reflux for 16 h. The mixture was cooled and evaporated 
under reduced pressure. The yellow mixture was extracted with diethyl ether (3 x 150 ml), 
brine (150 ml), dried (MgS04) and evaporated under reduced pressure to give the title 
compound (44.2 g, 83%) as a pale yellow liquid. Care was taken at all times when handling 
this compound, methyl azidoacetate is potentially explosive. 
Fremy's salt [K20N(S03)2] 
A solution of sodium nitrite (5.8 g, 0.08 mol) in water (15 ml) was cooled in an ice bath, 
crushed ice (approx. 35 g) was added with continuous stirring. A solution of sodium 
metabisulphite (7.3 g, 0.04 mol) in water (15 ml) was added, followed by glacial acetic acid 
(3.5 ml). The mixture was rendered alkaline by adding ammonia (0.88 solution, 2.5 ml), and 
was then stirred continuously in the ice bath during the addition of an ice cold solution of 
potassium permanganate (2.1 g, 0.013 mol) in water (65 m!). The precipate of manganese 
dioxide was filtered off through a bed of Celite. To the cooled violet filtrate was added a 
saturated solution (85 ml) of potassium chloride (33 g / 100 ml of water). The orange 
precipitate was collected by filtration and washed several times with 5% potassium hydroxide, 
then twice with ethanol containing approximately 5% v / v 0.88 ammonia and finally with 
acetone. Air was not drawn through the solid but it was spread on a watch glass and the 
acetone allowed to evaporate over 10-15 min. The product was dried in a desiccator over 
ammonium carbonate and calcium oxide. 
Aziridine 
2-aminoethyl hydrogen sulfate (35.28 g, 0.25 mol) was added to a solution of sodium 
hydroxide (40%, 77 ml). The mixture was gently heated until it just began to boil. Heating 
was resumed and half the volume was collected by distillation, CAUTION aziridine is 
extremely toxic. Potassium hydroxide pellets (31.2g, 0.55 mol) were added and the distillate 
was cooled in a refrigerator for 15 h. The mixture was separated and potassium hydroxide 
pellets (25 g, 0.44 mol) were added. The mixture was left in a refrigerator for a further 3 h. 
The mixture was separated and distilled twice to give the title compound (3.65 g, 34%) as a 
colourless oil. The product was stored over potassium hydroxide pellets in a refrigerator. 
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Thioformamide [125J 
Fonnamide (I g, 22.2 mmol), phosphorus pentasulfide (2.63 g, 5.9 mmol) and diethyl ether 
(20 ml) were heated at reflux for 48 h. The reaction mixture was cooled and evaporated under 
reduced pressure to give the title compound as a yellow oil. 
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7.3. Chapter 2 experimental 
OMe 
Me 
Methyl I-methylindole-3-carboxylate [85] 
Dry DMF (23 ml) was added to potassium hydride (1.17 g, 29.1 mmol), under a nitrogen 
atmosphere, at O°e. A solution of indole-3-carboxylic acid [84] (0.94 g, 5.8 mmol) in DMF 
(13 ml) was added dropwise and the solution stirred at O°C for 5 min then at rt for 45 min. The 
solution was cooled to O°C and methyl iodide (4.15 g, 29.2 mmol) added, the mixture was 
warmed to rt and stirred for a further 45 min. A saturated solution of ammonium chloride (50 
ml) was added and the mixture extracted with diethyl ether (3 x 50 ml). The extracts were 
combined, washed with water (2 x 50 ml), brine (50 mt), dried (MgS04) and evaporated under 
reduced pressure. Flash column chromatography (ethyl acetate elution) gave the title 
compound [85] (1.090 g, 95%) as an off white solid; m.p. 85-87°C; (Found: C, 69.82; H, 
5.80; N, 7.38. C]lH]]N02 requires C, 69.83; H, 5.86; N, 7.40%); vmax. (nujol)lcm- 1 1687, 
1554 and 1232; OH (250 MHz; CDCI3) 3.83 (3H, s, NCH3), 3.91 (3H, s, OCH3), 7.33 (3H, 
m), 7.78 (lH, s) and 8.15 (IH, m); oc(62.5 MHz; CDCb) 33.31, 50.90,107.12,109.77, 
121.58, 122.73, 127.13, 127.24, 135.16, 136.91 and 166.78;mlz 189 (M+, 70%) and 158 
(100); (Found M+, 189.0800. CllHllN02 requires M, 189.07897). 
OH 
Me 
I-Methylindole-3-carboxylic acid [86] 
Methyl l-methylindole-3-carboxylate [85] (0.97 g, 5.18 mmol), THF (14 ml) and sodium 
hydroxide (12 m1, 5% solution) were heated under reflux for 16 h. The reaction mixture was 
cooled and made acidic by the addition of hydrochloric acid (6 M). The mixture was extracted 
with dich10romethane (2 x 50 ml). The extracts were combined, washed with brine (50 ml), 
dried (MgS04) and evaporated under reduced pressure to give the title compound [86] (0.73 
g, 81%) as an off white solid; m.p. 95-97°C; OH (250 MHz; CDCI3) 3.86 (3H, s, NCH3), 
7.30 (2H, m), 7.38 (lH, m), 7.88 (lH, s, H2) and 8.24 (lH, m), carboxylic acid OH 
unobserved. 
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Me 
I-Methylindole-3-carboxamide [87J 
I-Methylindole-3-carboxylic acid [86] (0.2 g, 1.15 mmol), thionyl chloride (2.68 g, 22.4 
mmol) and dichloromethane (10 ml) were heated under reflux for 2 h. The reaction mixture 
was cooled and evaporated under reduced pressure, CAUTION. Dichloromethane (10 ml) 
was added to the crude red oil and the mixture cooled to -78°C. Ammonia gas was bubbled 
into the mixture (approx. 30 ml). The mixture was left to stir at -78°C for 2 h then allowed to 
warm to rt over 12 h. The mixture was evaporated under reduced pressure and flash column 
chromatography (ethyl acetate elution) gave the title compound [87] (0.12 g, 60%) as an off 
white solid; m.p. 178-179°C; (Found M+, 174.0794. ClOHlON20 requires M, 174.0793); 
vrnax (nujol)/cm- I 1604, 1465 and 1377; OH (250 MHz; CDCi]) 3.83 (3H, s, NCH3), 5.77 
(2H, broad, NH2), 7.36 (3H, m), 7.7 (!H, s) and 7.96 (lH, m); Oe (62.9 MHz; CDCI3) 
33.12, 109.56, 109.66, 121.1, 121.24, 122.22, 126.47, 132.56, 136.97 and 167.15; m/z 
174 (M+, 80%), 158 (100),130 (10), and 77 (10). 
Alternative procedure for I-methylindole-3-carboxamide [87] 
Trimethyl aluminium (2M solution in toluene, 7.95 ml, 15.9 mmol) was added dropwise to a 
solution of ammonium chloride (0.85 g, 15.9 mmol) and benzene (15.9 ml) at 5°C under a 
nitrogen atmosphere. The mixture was warmed to rt and stirred for 1 h. A solution of methyl 
l-methylindole-3-carboxylate [85] (1.0 g, 5.3 mmol) in benzene (50 ml) was added and the 
solution stirred at 60°C for 12 h. Hydrochloric acid (2M, 30 ml) was added and the solution 
extracted with ethyl acetate (3 x 50 ml). The extracts were combined, washed with brine (50 
ml), dried (MgS04) and evaporated under reduced pressure. Flash column chromatography 
(ethyl acetate elution) gave the title compound [87] (0.68 g, 74%) as a pale yellow solid, with 
analytical data identical to that previously prepared. 
Alternative procedure for I-methylindole-3-carboxamide [87J 
A solution of CS I (4.31 g, 30.5 mmol) in acetonitrile (10 ml) was added dropwise to a solution 
of I-methylindole [96] (4 g, 30.5 mmol) in acetonitrile (40 ml) at O°C. The mixture was 
stirred at O°C for 30 min then warmed to rt and stirred for a further I h. The precipitate was 
collected by filtration and dissolved in a mixture of acetone (20 ml) and water (6 ml). The 
mixture was made basic (10% potassium hydroxide). The mixture was extracted with 
dichloromethane (3 x 50 ml), the extracts were combined, washed with brine (2 x 50 ml), dried 
(MgS04) and evaporated under reduced pressure. Flash column chromatography (ethyl acetate 
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elution) gave the title compound [87] (3.09 g, 60%) as a colourless solid, with analytical data 
identical to that previously prepared. 
s 
N 
Me 
l-Methylindole-3-thiocarboxamide {97J 
A solution of l-methylindole-3-carboxamide [87] (120 mg, 0.68 mmol), Lawesson's reagent 
[99] (163 mg, 0.4 mmol) and benzene (10 ml) were heated under reflux for I h. The crude 
reaction mixture was evaporated under reduced pressure and flash column chromatography 
(dichloromethane : diethyl ether elution) gave the title compound [97] (120 mg, 60%) as a 
yellow solid; m.p. 125-126°C; (Found M+, 190.2651. CIOHION2S requires M, 190.2646); 
vrnax (nujol)/cm-l 3496,2968 and 1596; 8H (250 MHz; CDCI3) 3.85 (3H, s, NCH3), 7.36 
(5H, m), 7.86 (lH, m) and 8.07 (lH, s); 8e (62.5 MHz; CDCI3) 33.45, 110.58, 116.08, 
119.89, 122.49, 122.88, 123.75, 137.14, 137.69 and 194.88; m/z 190 (M+, 60%),156 
(lOO). 
and l-methylindole-3-nitrile {98J 
eN 
~ V-/ 
Me 
m.p. 61°C; vmax (CH3CI)/cm-1 2218, 1531, 1380, 1249 and 742; 8H (250 MHz, CDCI3) 
3.81 (3H, NCH3), 7.24 (3H, m), 7.49 (lH, s, 2H) and 7.72 (lH, m); 8C (62.5 MHz; 
CDCI3) 33.56,85.01, 110.36, 115.98, 119.63, 122.05, 123.77, 127.67, 135.58 and 135.92. 
Me 
General procedure for the formation of l-methylindole-3-thiocarboxamide {97J 
A solution of l-methylindole-3-carboxamide [87] (30 mg, 0.17 mmol), benzene (5 ml) and 
thionating agent (0.086 mmol, see Table 1) were heated under reflux. The reaction mixture 
was checked by TLC until there appeared to be no more consumption of I-methylindole-3-
130 
---------
carboxamide [97]. The reaction mixture was cooled and evaporated under reduced pressure. 
Flash column chromatography (dichloromethane : diethyl ether elution) gave the title compound 
[97] (for yield see table 1), with analytical data identical to that previously prepared. 
Me 
Ethyl 2-( 1-methylindol-3-yl)thiazole-4-carboxylate [114J 
I-Methylindole-3-thiocarboxamide [97] (100 mg, 0.53 mmol), ethyl bromopyruvate (155 mg, 
0.79 mmol) and ethanol (25 ml) were heated under reflux for 0.5 h. The reaction mixture was 
evaporated under reduced pressure to give a yellow solid. Recrystallisation (methanol: water) 
gave the title compound [114] (100 mg, 66% yield) as pale brown crystals; m.p. 117-118°C; 
(Found: C, 63.07; H, 4.73; N, 9.51. CIsHI4N20S Requires C, 62.94; H, 4.90; N, 9.79%); 
Vrnax (nujol)/cm- I 3050,2930 and 1730; OH (250 MHz; CDCI3) 1.44 (3H, t, J 7.2 Hz, 
OCH2CH3), 3.85 (3H, s, NCH3), 4.43 (2H, q, J 7.12 Hz, OCH2CH3), 7.34 (3H, m), 7.90 
(I H, s), 8.05 (lH, s) and 8.19 (I H, m); Oc (62.5 MHz; CDCI3) 14.32, 23.18, 61.26, 
109.88, 110.06, 120.390, 121.35, 122.75, 124.06, 125.03, 129.96, 137.19, 146.52, 162.32 
and 163.52; m/z 286 (M+, 100%),214 (40), 174 (10), 77 (50), 158 (30) and 120 (12); 
(Found M+, 286.0785. CIsHI4N202S requires M, 286.0776). 
Me 
2-( 1-Methylindol-3-yl)thiazole-4-carboxamide [l15J 
Ethyl 2-(l-methylindol-3-yl)thiazole-4-carboxylate [114] (218 mg, 0.77 mmol), ammonium 
chloride (10.5 mg, 0.19 mmol) and ammonium hydroxide (15 ml, of a 0.88 solution) were 
heated at 100°C in a Young's sealed tube for 48 h. The crude mixture was extracted with ethyl 
acetate (3 x 20 m!), the extracts were combined and washed with brine (20 ml), dried (MgS04) 
and evaporated under reduced pressure. Flash column chromatography (ethyl acetate elution) 
gave the title compound [115] (142 mg, 73%) as a pale brown solid; m.p. 184-185°C; (Found 
M+, 257.0617. C14H12N202S requires M, 257.0617); vrnax (CHCI3)/cm-1 3019, 1680, 1422, 
1216 and 929; OH (250 MHz; CD30D) 3.62 (3H, S, NCH3), 7.12 (3H, m ), 7.54 (lH, s), 
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7.80 (lH, s) and 7.98 (lH, m), amide NH2 unobserved; Oc (62.5 MHz; CD30D) 32.65, 
109.56, 109.67, 120.19, 120.83, 121.08, 122.66, 124.71, 129.58, 137.12, 148.52, 163.44 
and 164.22; m/z 257 (M+, 100%), 174(10), 157(60), 101(20) and 44(18). 
Me 
3-( 4-Methyl-2-thiazolyl)-1-methylindole [116J 
I-Methylindole-3-thiocarboxamide [97] (lIS mg, 0.61 mmol), chloroacetone (ll3 mg, 1.2 
mmol) and ethanol (28 m!) were heated under reflux for 3 h. The reaction mixture was 
evaporated under reduced pressure to give a yellow solid. Flash column chromatography (light 
petroleum: ethyl acetate elution) gave the title compound [116] (60 mg, 43% ) as a pale 
yellow solid; m.p. 74-76°C; (Found M+, 228.0718. CI3HI2N2S requires M, 228.0721); OH 
(250 MHz; CDCI3) 2.52 (3H, s, CH3), 3.34 (3H, s, NCH3), 6.76 (lH, s), 7.35 (3H, m), 
7.56 (I H, s) and 8.19 (I H, m); Oc (62.5 MHz; CDCI3) 15.01, 33.69, 106.14, 109.69, 
110.66, 119.55, 122.38, 123.41, 124.68, 133.79, 137.67, 146.94 and 163.68; m/z 228 
(M+, 100%), 156 (90),114 (20) and 72 (30). 
s~ 
3-(2- Thiazolyl)indole [117J 
A soliution of methyl iodide (3.37 g, 23.7 mmol) in diethyl ether (10 m!) was added over a 5 
min period to magnesium turnings (0.42 g, 17.5 mmol) and a few crystals of iodine, under a 
nitrogen atmosphere. The mixture was heated under reflux for I h. The solvent was removed 
by increasing the nitrogen flow and benzene (20 ml) added. A solution of indole [93] (1.74 g, 
14.8 mmol) in benzene (8 m!) was added and the solution stirred for 10 min. 2-Bromothiazole 
(1.23 g 7.5 mmol) was added and the mixture was heated at reflux for 65 h, under a nitrogen 
atmosphere. Ethyl acetate (60 ml) was added and the mixture washed with a saturated solution 
of ammonium chloride (2 x 20 ml), brine (2 x 20 ml), dried (MgS04) and evaporated under 
reduced pressure. Flash column chromatography (light petroleum: acetone elution) gave the 
title compound [117] (0.896 g, 30% yield) as a pale brown solid; m.p. 134-138°C; (lit., 134-
132 
137°C); (Found M+, 200.0489. C"HsN2S requires M, 200.0482); Yrnax (nujol)/cm-' 1456, 
1377 and 1243; oH (250 MHz; CDCI3) 7.30 (3H, m), 7.44 (lH, m), 7.83 (lH, m), , 7.88 
(lH, m), 8.24 (lH, m) and 8.57 (lH, broad, NH); Oc (62.5 MHz; CDCI3) 111.69, 112.57, 
116.01, 118.52, 120.43, 121.39, 123.12, 124.65, 136.44, 142.37 and 164.43; mlz 200 
(M+, 100%), 142 (30), liS (IS), 100 (10) and 58 (30). 
and l-acetyl-3-(2-thiazolyl)indole [118J (270 mg, 10%) as colourless crysyalline solid; 
m.p. 117.5°C; (lit., 116-1 18°C); (Found M+, 242.0511. C13HION20S requires M, 242.0513); 
Yrnax (nujol)/cm-' 1712, 1450, 1376 and 1248; OH (250 MHz; CDCI3) 2.73 (3H, s, COCH3), 
7.16 (IH, s), 7.42 (2H, m), , 7.92 (lH, m), 8.06 (lH, m), 8.23 (IH, s) and 8.53 (lH, m); 
Oc (62.5 MHz; CDCI3) 24.09 (COCH3), 116.81, 116.97, 117.81, 120.69, 124.38, 124.62, 
126.16, 127.24, 127.44, 136.65, 143.04 and 169.02; mlz 242 (M+, 30%), 200 (100),142 
(20), liS (10), 58 (30) and 43 (10). 
s~ 
3-(2-Thiazolyl)indole [117J 
I-Acetyl-3-(2-thiazolyl)indole [118] (lOO mg, 0.41 mmol), THF (2 ml) and sodium 
hydroxide (I ml, of a 5% solution) were heated at reflux for 16 h. The reaction mixture was 
cooled and made acidic by the addition of hydrochloric acid (6M). The mixture was extracted 
with ethyl acetate (3 x 10 ml), the extracts were combined, washed with brine (20 ml), dried 
(MgS04) and evaporated under reduced pressure. Flash column chromatography (diethyl ether' 
elution) gave the title compound [117] (68 mg, 83%), with analytical data identical to that 
previously reported. 
133 
Me 
1-Methyl-(2-thiazolyl)indole [119] 
3-(2-Thiazolyl)indole [117] (100 mg, 0.49 mmoi) was added to a stirred solution of 
potassium hydroxide (Ill mg, 1.98 mmol) and DMSO (I ml). The solution was stirred at rt 
for 45 min then methyl iodide (141 mg, 1.0 mmol) was added and the mixture stirred for a 
further 45 min. Water (5 ml) was added and the mixture extracted with ethyl acetate (3 x 10 
ml). The extracts were combined, washed with water (3 x 10 ml), brine (10 ml), dried 
(MgS04) and evaporated under reduced pressure. Recrystallisation (hexane) gave the title 
compound [119] (82 mg, 78% yield) as a brown solid; m.p. 69-70°C; (Found M+, 214.0575. 
Cl2HJON2S requires M, 214.0564); vmax (nujol)/cm-1 1552, 1468 and 1376; OH (250 MHz; 
CDCI3) 3.68 (3H, s, NCH3), 7.15 (lH, s), 7.28 (3H, m), 7.65 (lH, s), 7.77 (lH, m) and 
8.23 (lH, s); oe (62.5 MHz; CDCI3) 33.04 (NCH3), 109.75, 110.37, 115.43, 120.67, 
121.10, 122.66, 125.31, 128.96, 137.42, 142.43 and 163.82; m/z 214 (M+, 100%), 156 
(40), 107 (10) and 58 (10). 
Cl 
3-Chloroacetylindole [122] 
Chloroacetyl chloride (11.29 g, 100 mmoi) was added to a srirred solution ofpyridine (7.91 g, 
100 mmol ), indole [93] (11.7 g, 100 mmol) and toluene (250 ml) over I h at 60°C. The 
mixture was stirred for I h, then water (300 ml) and methanol (50 ml) were added. The 
mixture was stirred at 60°C for I h, were upon a brown solid separated. The brown solid was 
removed by filtration, and recrystallisation (ethanol) gave the title compound [122] (13.92 g, 
72% yield) as a pale brown solid; m.p. 230-232°C (lit., 230-232); vrnax (nujol)/cm- 1 1645, 
1459, 1436, 1377 and 751; OH (250 MHz; CD30D) 4.72 (2H, 5, COCH2CI), 7.25 (2H, m), 
7.49 (lH, m) and 8.24 (2H, m), indole NH unobserved; oe (62.5 MHz; CD30D) 45.09 
(COCH2CI), 111.83, 120.95, 120.97, 121.92, 122.94, 122.97, 133.55, 133.76 and 202.37; 
m/z 193 (M+, 30%), 144 (100), 89 (20) and 148 (20). 
134 
Br 
3-Bromoacetylindole [123] 
3-Chloroacetylindole [122] (l g, 5.2 mmol), sodium bromide (5.35 g, 52 mmol) and acetone 
(30 mll were heated under reflux for 24 h. The reaction mixture was filtered through a glass 
sinter and the residue washed with acetone (100 ml), the filtrate was evaporated under reduced 
pressure and recrystallisation (ethyl acetate) gave the title compound [123] (0.78 g, 62%) as a 
brown solid; m.p. 192-194°C; (Found M+, 238.977. CIOH880BrNO requires M, 238.9779; 
Found M+, 236.9787. CIOH878BrNO requires M, 236.9799); OH (250 MHz; CDCb: CD30D) 
4.21 (2H, s, COCH2Br), 7.08 (2H, m), 7.30 (lH, m, Ar), 7.90 (lH, m) and 8.09 (lH, m), 
indole NH unobserved; Oc (62.5 MHz; CDCI3 : CD30D) 31.39 (COCH2Br), 104.32, 11.83, 
114.62,121.56,122.47,123.44,125.01,133.92 and 188.91; mlz 239 (M+, 20%), 237 (10), 
144 (100) and 89 (20). 
3-( 4-Thiazolyl)indole [126J 
3-Bromoacety1indo1e [123] (1.07 g, 4.5 mmol), thioformamide [125] (0.64 g, 9 mmol) and 
ethanol (30 ml) were heated under reflux for 3 h. The reaction mixture was evaporated under 
reduced pressure to give a yellow solid. Flash column chromatography (light petroleum: 
diethy1 ether elution) gave the title compound [126] (0.252 g, 28% yield) as pale yellow solid; 
m.p. 139-140°C; vrnax (CHCb)/cm- i 3066, 1522, 1476, 1423,1225 and 929; oH (250 MHz; 
CDCb) 7.24 (3H, m), 7.42 (lH, d J 1.9 HZ),7.80 (lH, d J 2.7 Hz), 8.04 (lH, m), 8.45 (IH, 
s, NH) and 8.91 (lH, d J 1.9 Hz); Oc (62.5 MHz; CDCI3) 109.66, 111.75, 111.80, 119.36, 
120.18,122.07,124.23,124.40,137.29,151.03 and 152.75. 
135 
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Me 
I-Methyl-3-( 4-thiazolyl)indole [127J 
3-(4-Thiazolyl)indole [126] (50 mg, 0.25 mmol) was added to a stirred solution of potassium 
hydroxide (56 mg, I mmol) and DMSO (I ml). The solution was stirred at rt for 45 min then 
methyl iodide (I41 mg, 1.0 mmol) was added and the mixture stirred for a further 45 min. 
Water (5 ml) was added and the mixture extracted with ethyl acetate (3 x 10 ml). The extracts 
were combined, washed with water (3 x 10 ml), brine (10 ml), dried (MgS04) and evaporated 
under reduced pressure. Flash column chromatography (ethyl acetate elution) gave the title 
compound [127] (44 mg, 83% yield) as a brown solid; m.p. 54-55°C; vrnax (Found M+, 
214.0562. CI2HION20 requires M, 214.0565); (CHCb)/cm- i 3020, 1522, 1421, 1228 and 
929; /lH (250 MHz; CDCI3) 3.69 (3H, s, NCH3), 7.19 (3H, s), 7.26 (\H, d J 1.75 Hz), 
7.55 (lH, s), 7.92 (lH, m) and 8.75 (lH, d J 1.62 Hz); /lc (62.5 MHz; CDCb) 32.86, 
108.94, 109.66, 110.88, 120.07, 120.26, 122.07, 125.48, 128.53, 137.36, 151.65 and 
152.03; m/z 214 (M+, 40%),186 (25),155 (45),113 (40), 70 (30), 51 (lOO) and 31 (85). 
3-(2-Methyl-4-thiazolyl)indole [128J 
A solution of thioacetamide (1.15 g, 15.2 mmol) and ethanol (60 ml) was added dropwise to a 
stirring solution of 3-chloroacetylindole [122] (1.5 g, 7.7 mmo!) in ethanol (lOO ml) at reflux 
and the solution was stirred under reflux for 3 h. The reaction mixture was cooled and sodium 
hydroxide (20% solution, 50 m!) was added. The mixture was extracted with ethyl acetate (2 x 
200 ml) and the extracts were combined and washed with brine (50 ml), dried (MgS04) and 
evaporated under reduced pressure. Flash column chromatography (light petroleum: diethyl 
ether elution) gave the title compound [128] (650 mg, 43% yield) as a pale brown solid; m.p. 
122-124°C; (Found M+, 214.0564. Cl2HlON2S requires M, 214.0559); vrnax (CHCI3)/cm-l 
3448, 1617, 1575, 1482 and 1360; /lH (250 MHz; CDCI3) 2.28 (3H, s, CH3), 7.22 (3H, m), 
7.38 (lH, m), 7.74 (IH, m), 7.99 (lH, m) and 8.45 (lH, broad, NH); /lc (62.5 MHz; 
136 
CDCI3) 19.06 (CH3), 109.57, 111.64, 112.22, 119.82, 120.44, 122.35, 123.96, 125.01, 
136.58 and 150.29; mlz 214 (M+, 100%), 173 (70), 98 (50), 91 (40) and 84 (40). 
Me 
3-(2-Methyl-4-thiazolyl)-1-methylindole [129] 
3-(2-Methyl-4-thiazolyl)indole [128] (200 mg, 0.93 mmo!) was added to a stirred solution of 
potassium hydroxide (209 mg, 3.73 mmol) and DMSO (2 ml). The resultant red solution was 
stirred at rt for 45 min then methyl iodide (246 mg, 1.86 mmol) added and the mixture stirred 
for a further 45 min. Water (5 ml) was added and the mixture extracted with ethyl acetate (3 x 
10 m!). The extracts were combined, washed with water (3 x 10 ml), brine (10 ml), dried 
(MgS04) and evaporated under reduced pressure. Recrystallisation (hexane) gave the title 
compound [129] (160 mg, 75% yield) as a yellow solid; m.p. 120-121°C; (Found: C, 68.48; 
H, 5.24; N, 12.18. CI3H12N2S requires C, 68.39; H, 5.3; N, 12.27%); OH (250 MHz; 
CDCI3) 2.77 (3H, s, CH3), 3.82 (3H, s, NCH3), 7.19 (lH, s), 7.31 (3H, m), 7.96 (lH, s) 
and 8.0 (lH, m); mlz 228 (M+, 100%), 187 (50), 172 (30), 98 (25) and 84 (25); (Found M+, 
228.0707. C13H12N2S requires M, 228.0721). 
N 
H 
Ethyl 4-(indol-3-yl)thiazole-2-carboxylate [130] 
3-Bromoacetylindole [123] (500 mg, 2.1 mmol), ethyl thiooxamate (290 mg, 2.15 mmol) and 
acetonitrile (30 ml) were heated under reflux for 3 h, further ethyl thiooxamate (60 mg, 0.45 
mmo!) was added and the mixture heated under reflux for a further 2 h. The reaction mixture 
was evaporated under reduced pressure to give a yellow solid. Flash column chromatography 
(light petroleum: diethyl ether elution) gave the title compound [130] (417 mg, 74% yield) as 
pale yellow solid; m.p. 170-171 QC; (Found M+, 272.0619. Cl4H 12N202S requires M, 
272.0619); vrnax (nujol)/cm- 1 3683, 3019, 1719, 1522, 1422, 1221 and 929; OH (250 MHz; 
137 
CDCI3) 1.44 (3H, t, J 7.5 Hz, OCH2CH3), 4.42 (2H, q, J 7.1 Hz, OCH2CH3), 7.23 (2H, 
m), 7.47 (lH, s), 7.64 (lH, s), 7.86 (lH, d J 2.71 Hz), 8.09 (lH, m) and 8.98 (lH, s, NH); 
Bc (62.5 MHz; CDCI3) 16.65, 66.02, 115.23, 119.58, 123.12, 123.76, 125.31, 125.58, 
127.21,128.66,128.71,140.91,160.09 and 164.82; m/z 272 (M+, 90%),141 (100) and 29 
(20). 
Me 
Ethyl 4-(1-methylindol-3-yl)thiazole-2-carboxylate [1311 
Dry DMF (1.5 ml) was added to potassium hydride (44 mg, 1.83 mmol), under a nitrogen 
atmosphere, at O°c. A solution of ethyl 4-(indol-3-yl)thiazole-2-carboxylate [130] (100 mg, 
0.37 mmol) in DMF (2 ml) was added dropwise and the solution stirred at O°C for 5 min, then 
at rt for 45 min. The solution was cooled to O°C and methyl iodide (261 mg, 1.84 mmol) 
added, the mixture was warmed to rt and stirred for a further 45 min. A saturated solution of 
ammonium chloride (10 mJ) was added and the mixture extracted with diethyl ether (3 x 20 ml), 
the extracts were combined, washed with water (2 x 20 ml), brine (20 ml), dried (MgS04) and 
evaporated under reduced pressure. Flash column chromatography (diethyl ether elution) gave 
the title compound [131] (95 mg, 90%) as an off white solid; m.p. 131-132°C; (Found M+, 
286.0777. ClsHl4N202S requires M, 285.0776); Vrnax. (nujol)lcm-1 1687, 1554 and 1232; BH 
(250 MHz; CDCI3) 1.44 (3H, t, J 7.4 Hz, OCH2CH3), 4.01 (3H, s, NCH3), 4.42 (2H, q, J 
7.1 Hz, OCH2CH3), 7.25 (3H, m), 7.56 (lH, s), 7.73 (lH, s) and 7.98 (lH, m); Bc (62.9 
MHz; CDCb) 14.24, 32.87, 62.40, 109.73, 111.76, 115.42, 119.64, 120.44, 122.12, 
124.99, 129.37, 137.30, 153.39, 157.08 and 160.21; m/z 286 (M+, 100%), 172 (18),154 
(20) and 29 (20). 
2-(1 ndol-3-yl)thiazole-4-carboxamide [132J 
138 
Ethyl 4-(indol-3-yl)thiazole-2-carboxylate [130] (100 mg, 0.4 mmol), ammonium chloride (5 
mg,O.l mmol) and ammoniumn hydroxide (5 ml, of a 0.88 solution) were heated at 100°C in a 
Young's sealed tube for 48 h. The crude mixture was extracted with ethyl acetate (3 x 10 ml), 
the extracts were combined and washed with brine (15 ml), dried (MgS04) and evaporated 
under reduced pressure. Flash column chromatography (ethyl acetate elution) gave the title 
compound [132] (43 mg, 47%) as a pale brown solid; m.p. 215-216°C; vrnax (nujol)/cm- 1 
3683,3019,1719,1522,1422,1221 and 929; IiH (250 MHz; CD30D: CDCI3) 7.13 (2H, m), 
7.33 (lH, m), 7.36 (lH, s), 7.64 (lH, s) and 7.90 (lH, m), indole NH and amide NH2 
unobserved; lie (62.5 MHz; CD30D : CDCI3) 114.81, 115.34, 119.02, 123.35, 123.79, 
125.64, 125.81, 128.40, 128.72, 140.92, 157.30 and 166.12; mlz 243 (M+ 100%),225 
(30), 173 (50), 141 (40) and 44 (30). 
Me 
4-( 1-Methylindol-3-yl)thiazole-2-carboxamide [133 J 
Ethyl 4-(l-methylindol-3-yl)thiazole-2-carboxylate [132] (233 mg, 0.82 mmol), ammonium 
chloride (20 mg, 0.37mmol) and ammonium hydroxide (10 m1, of a 0.88 solution) were heated 
at 100°C in a Young's sealed tube for 48 h. The crude mixture was extracted with ethyl acetate 
(3 x 10 ml), the extracts were combined and washed with brine (15 ml), dried (MgS04) and 
evaporated under reduced pressure. Flash column chromatography (ethyl acetate elution) gave 
the title compound [133] (120 mg, 58%) as a pale brown solid; m.p. 186-187°C; (Found M+, 
257.0617. C13HIIN30S requires M, 257.0623); vrnax (nujo1)/cm-l 1687,1554 and 1232; IiH 
(250 MHz; CDCI3); m/z 257 (M+, 100%), 187 (20), 172 (15), 155 (15), 128 (10) and 69 
(15). 
~_ . .lMe 
~/-~o 
Me 
Methyl-1-methylindole-2-carboxylate [135J 
Dry DMF (70 ml) was added to potassium hydride (5.542 g, 138 mmol), under a nitrogen 
atmosphere, at O°c. A solution of indole-2-carboxylic acid [134] (4.44 g, 27.5 mmol) in 
DMF (70 ml) was added dropwise. The solution was stirred at O°C for 5 min then stirred at rt 
139 
for 45 min. The solution was cooled to O°C and methyl iodide (19.45 g, 138 mmol) added. 
The mixture was warmed to rt and stirred for a further 45 min. A saturated solution of 
ammonium chloride (150 ml) was added and the mixture extracted with diethyl ether (3 x 150 
ml), the extracts were combined, washed with water (2 x ISO ml), brine (150 ml), dried 
(MgS04) and evaporated under reduced pressure. Recrystallisation (hexane) gave the title 
compound [135] (4.64 g, 90%) as a colourless solid; m.p. 95-97°C; (Found: C, 70.3; H, 
6.06; N, 7.46. CllHllN02 requires C, 69.84; H, 5.82; N, 7.41%); vmax (nujol)/cm- 1 1704, 
1516, 1467, 1253 and 752 ; IiH (250 MHz; CDCb) 3.90 (3H, s, OCH3), 4.07 (3H, s, 
NCH3), 7.12 (lH, m), 7.31 (lH, s), 7.34 (2H, m) and 7.66 (lH, dt, J 7.9,1.0 Hz); lic (62.5 
MHz; CDCb) 31.51, 51.45, 110.16, 110.17, 120.5, 122.55, 124.95, 125.84, 127.61, 
139.92 and 163.32; miz 189 (M+, 100%), 158 (40), 89 (50), 57 (48) and 43 (42); (Found 
M+, 189.0785. CllHllN02 requires M, 189.0789). 
I-Methylindole-2-carboxamide [136J 
Trimethyl aluminium (2M solution in toluene, 19.87 ml, 39.75 mmol) was added dropwise to a 
solution of ammonium chloride (2.125 g, 39.75 mmol) and benzene (39.75 ml) at 5°C, under a 
nitrogen atmosphere. The mixture was warmed to rt and stirred for 1 h. A solution of methyl-
l-methylindole-2-carboxylate [135] (2.5 g, 13.25 mmol) in benzene (125 ml) was added and 
the solution stirred at 60°C for 12 h. Hydrochloric acid (2M, 200 ml) was added and the 
solution extracted with ethyl acetate (3 x ISO ml). The extracts were combined, washed with 
brine (200 ml), dried (MgS04) and evaporated under reduced pressure. Flash column 
chromatography (ethyl acetate elution) gave the title compound [136] (1.32 g, 58% yield) as 
a colourless solid; m.p. 167-169°C; (Found: C, 68.88; H, 5.71; N, 16.13. ClOHlON20 
requires C, 68.97; H, 5.75; N, 16.09%); vmax (nujol)/cm- 1 1652, 1616, 1464 and 1332; IiH 
(250 MHz; CDCb) 4.07 (3H, s, NCH3), 5.91 (2H, broad, NH2), 6.93 (lH, s), 7.16 (lH, 
m), 7.34 (2H, m) and 7.66 (IH, m,); miz 174 (M+, 100%), 158 (40), 130 (40) and 89 (50); 
(Found M+, 174.0776. ClOHlON20 requires M, 174.0793). 
I-Methylindole-2-thiocarboxamide [13 7J 
A solution of l-methylindole-2-carboxamide [136] (300 mg, 1.74 mmol) and Lawesson's 
reagent [99] (351 mg, 0.87 mmol) in benzene (30 ml) were heated under reflux for 1 h. The 
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crude reaction mixture was evaporated under reduced pressure and flash column 
chromatography (light petroleum: diethyl ether elution) gave the title compound [137] (252 
mg, 77% yield) as a yellow solid; m.p. 139-140°C; (Found M+, 190.0545. CI3HI2N2S 
requires M, 190.0565); Vrnax (nujol)/cm-l 1615, 1464, 1377 and 1351; oH (250 MHz; CDCI3) 
4.09 (3H, s, NCH3), 6.71 (lH, s), 7.21 (3H, m), 7.34 (2H, s) and 7.64 (lH, m); OC (62.5 
MHz; CDCI3) 32.23, 103.49, 110.44, 120.97, 122.22, 124.76, 125.57, 138.03, 140.52 and 
193.24; mlz 190 (M+, 90%),157 (100) and 130 (50). 
2-( 4-Methyl-2-thiazolyl)-1-methylindole [138 J 
I-Methylindole-2-thiocarboxamide [137] (79 mg, 0.4 mmo!), chloroacetone (75 mg, 0.81 
mmol), sodium bromide (414 mg, 4.03 mmol) and acetonitrile (5 ml) were heated under reflux 
for 2 h. The reaction mixture was cooled, filtered and washed with dichloromethane (20 m!). 
The filtrate was washed with brine (2 x 20 ml), dried (MgS04) and evaporated under reduced 
pressure to give a yellow solid. Flash column chromatography (light petroleum: diethyl ether 
elution) gave the title compound [138] (68 mg, 71 % yield) as pale yellow solid; m.p. 83-
84°C; (Found M+, 228.0723. C13HI2N2S requires M, 228.0721); vrnax (CHCI3)/cm-1 2957, 
1522,1224 and 884, liH (250 MHz; CDCI3) 2.56 (3H, s, CH3), 4.19 (3H, s, NCH3), 6.87 
(lH, S), 7.14 (lH, s), 7.20 (lH, m), 7.35 (2H, m) and 7.65 (lH, dd, J 7.8, 1.4 Hz); liC 
(62.5 MHz; CDCb) 17.32 (CH3), 31.75 (NCH3), 104.54, 109.85, 113.04, 120.22, 121.07, 
123.16,127.27, 132.76, 139.81, 153.58 and 159.96; m/z 228 (M+, 100%),213 (30),130 
(25), 98 (40) and 44 (15). 
Ethyl 2-( 1-methylindol-2-yl)thiazole-4-carboxylate [139 J 
I-Methylindole-2-thiocarboxamide [137] (lOO mg, 0.53 mmol), ethylbromopyruvate (155 
mg, 0.79 mmol) and ethanol (25 m!) were heated under reflux for 0.5 h. The reaction mixture 
was evaporated under reduced pressure to give a yellow solid. Flash column chromatography 
(light petroleum: ethyl acetate elution) gave the title compound [139] (74 mg, 48% yield) as 
pale yellow solid; m.p. 122-123°C; (Found M+, 286.0771. CI5HI4N202S requires M, 
286.0776); Vrnax (CHCI3)/cm- 1 1733, 1420, 1098 and 668, OH (250 MHz; CDC13) 1.47 (3H, 
t, J 7.15 Hz, CH2CH3), 4.44 (3H, s, NCH3), 4.44 (2H, q, J 7.2 Hz , OCH2CH3), 7.24 (2H, 
141 
m,), 7.37 (2H, m,), 7.61 (lH, m) and 8.29 (lH, s); /lC (62.5 MHz; COCl3) 14.31 
(OCH2CH3), 32.86 (NCH3), 61.45 (OCH2CH3), 110.17, 120.19, 121.07, 124.97, 126.74, 
127.42, 127.53, 138.72, 143.21, 157.98, 161.67 and 187.07; mlz 286 (M+, 100%),214 
(50), 157 (30) and 77 (15). 
2-( 1-Methylindol-2-yl)thiazole-4-carboxylate [140 J 
EthyI2-(l-methylindol-2-yl)thiazole-4-carboxylate [137] (15 mg, 0.057 mmol) was dissolved 
in dichloromethane (I ml) and placed in a Young's tube. The mixture was cooled to _78°C and 
ammonia gas was bubbled into the mixture (approx. 30 ml). The Young's tube was sealed and 
allowed to warm to rt. The mixture was stirred at rt for 4 days. The reaction mixture was 
cooled to _78°C and the Young's tube opened, CAUTION. The mixture was left to warm to 
rt over a 4 h period. Ethyl acetate (20 ml) was added and the mixture was washed with brine (2 
x 20 ml), dried (MgS04) and evaporated under reduced pressure to give a pale brown solid. 
Flash column chromatography (ethyl acetate elution) gave the title compound [140] (11 mg, 
80%) as a pale brown solid; m.p. 190°C; (Found M+, 257.0617. C13HI1N30S requires M, 
257.0617) Vmax (CHCI3)/cm- 1 1686,1420,1216 and 853; /lH (250 MHz; C0300) 4.04 (3H, 
s, NCH3), 7.10 (3H, m), 7.21 (lH, m), 7.43 (IH, m) and 8.03 (lH, m); amide NH2 
unobserved; m/z 257 (M+, 100%), and 213 (40),120 (20) and 77 (10). 
2-(2-Benzothiazolyl)-1-methylindole [141J 
Trimethyl aluminium (2M solution in toluene, 6.76 ml, 13.53 mmol) was added dropwise to 
toluene (25 ml) at O°C, under a nitrogen atmosphere. 2-Aminothiophenol (504 mg, 4.02 
mmol) was added dropwise maintaining the temperature at o°e. The mixture was stirred at O°C 
for 0.5 h then warmed to rt. A solution of methyl-l-methylindole-2-carboxylate [135] (500 
mg, 2.67 mmol) in toluene (10 ml) was added and the solution stirred at 60°C for 14 h. The 
mixture was cooled to O°C and water (5 ml) followed by methanol (50 ml) were added. The 
mixture was filtered and washed with methanol (100 ml) the filtrate was evaporated under 
reduced pressure to give a brown solid. Recrystallisation (diethyl ether) gave the title 
compound [141] (401 mg, 57%) as a pale brown solid; m.p. 135-136°C; (Found M+, 
264.0721. CI6HI2N2S requires M, 264.0721) Vmax (CHCI3)/cm- 1 1549,1424,1345,1312, 
142 
975 and 929; oH (250 MHz; CDCI3) 4.3 (3H, s, NCH3), 7.19 (2H, m), 7.4 (3H, m), 7.54 
(lH, m), 7.67 (lH, dd, J 7.9, 1.0 Hz), 7.9 (lH, dd, J 7.8, 1.3 Hz) and 8.07 (lH, dd, J 8.7, 
1.4 Hz); OC (100 MHz; CDCI3) 32.65, 107.96, 110.51, 120.97, 121.68, 121.96, 123.60, 
124.51, 125.66, 126.65, 127.69, 132.62, 134.90, 140.22, 154.69 and 161.00; m/z 264 
(M+, 90%), 263 (100), 155 (20), 51 (20) and 28 (35). 
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7.4. Chapter 3 experimental 
OBn 
MeO 
~ 
N 
Me 
Methyl 4-benzyloxy-5-methoxy-1-methylindole-2-carboxylate [155 J 
Ory OMF (10 ml) was added to potassium hydride (644 mg, 16.05 mmol), under a nitrogen 
atmosphere, at O°e. A solution of methyl-4-benzyloxy-5-methoxy-2-carboxylate [154] (1.0 
g, 3.21 mmol) in OMF (10 ml) was added drop wise. The solution was stirred at O°C for 5 min 
then stirred at rt for 45 min. The solution was cooled to O°C and methyl iodide (2.27 g, 16.05 
mmol) was added, the mixture was warmed to rt and stirred for a further 45 min. A saturated 
solution of ammonium chloride (30 ml) was added and the mixture extracted with diethyl ether 
(4 x 30 ml), the extracts were combined, washed with water (2 x 30 ml), brine (30 ml), dried 
(MgS04) and evaporated under reduced pressure. Flash column chromatography (light 
petroleum: diethyl ether elution) gave the title compound [155] (0.807 g, 77% yield) as an 
off white solid; m.p. 51-53°C; (Found: C, 70.44; H, 5.72; N, 4.17. CI9H 19N04 requires C, 
70.14; H, 5.89; N, 4.3%); vmax (nujol)/cm- I 1717,1377,1237 and 743; OH (250 MHz; 
COCI3) 3.85 (3H, s, NCH3), 3.86 (3H, s, OCH3), 3.99 (3H, s, C02CH3),5.25 (2H, s, 
OCH2Ar), 7.02 (lH, d, J 9.02 Hz), 7.12 (lH, d, J 8.93 Hz), 7.35 (5H, m) and 7.52 (lH, d, 
J 8.19); OC (62.5 MHz; COCI3) 31.77 (NCH3), 51.56 (C02CH3), 58.57 (OCH3), 75.57 
(OCH2Ar), 105.39, 107.24, 107.38, 115.96, 121.38, 127.85, 128.01, 128.15, 128.35, 
137.07,138.05,145.11 and 162.48; mlz 325 (M+, 20%), 234 (45), 91 (lOO) and 65 (15); 
(Found M+, 325.1325. CI9HI9N04 requires M, 325.1314). 
Alternative procedure for the preparation of 
methyl 4-benzyloxy-5-methoxy-1-methylindole-2-carboxylate [155 J 
Methyl-4-benzyloxy-5-methoxy-2-carboxylate [154] (1.54 g, 4.94 mmol), potassium 
carbonate (4.1 g, 29.6 mmol), acetone (40 ml) and methyl iodide (0.769 g, 5.42 mmol) were 
heated under reflux for 24 h. The reaction mixture was cooled and diethyl ether (100 ml) 
Added. The mixture was washed with water (2 x lOO ml), brine (2 x 100 ml), dried (MgS04) 
and evaporated under reduced pressure. Flash column chromatography (light petroleum: 
diethyl ether elution) gave the title compound [155] (1.21 g, 75%) as a colourless oil, with 
analytical data identical to that previously prepared. 
Alternative procedure for the preparation of 
methyl 4-benzyloxy-5-methoxy-1-methylindole-2-carboxylate [155 J 
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DMSO (20 ml) was added to freshly crushed potassium hydroxide pellets (1.85 g, 33.12 
mmol) at O°C, the mixture was stirred for 10 min then methyl-4-benzyloxy-5-methoxy-2-
carboxylate [154] (2.57 g, 8.28 mmol) was added. The mixture was stirred at O°C for 10 min 
then at rt for 45 min. The solution was cooled to O°C and methyl iodide (9.4 g, 66.24 mmol) 
was added, the mixture was alowed to warm to rt and stirred for a further 45 min. Saturated 
ammonium chloride (100 ml) was added and the mixture extracted with diethyl ether (3 x 50 
ml). The extracts were combined and washed with water (5 x 100 m!), brine (2 x 100 ml), 
dried (MgS04) and evaporated under reduced pressure. Flash column chromatography (light 
petroleum: diethyl ether elution) gave the title compound [155] (2.24 g, 84%) as a pale 
yelow oil, with analytical data identical to that previously prepared. 
OBn 
MeO 
Me 
4-Benzyloxy-5-methoxy-l-methylindole-2-carboxamide [156] 
Ammonium hydroxide (15 ml, of a 0.88 solution) was added to methyl-4-benzyloxy-5-
methoxy-I-methyl-2-carboxylate [155] (410 mg, 1.32 mmol) and ammonium chloride (18 
mg, 0.336 mmol), in a Young's pressure tube. The tube was sealed and stirred at IOQ°C for 48 
h. The crude reaction mixture was evaporated under reduced pressure to give a brown oil. 
Dichloromethane (100 ml) was added and the mixture was washed with brine (2 x 40 ml), 
dried (MgS04) and evaporated under reduced pressure. Flash column chromatography (ethyl 
acetate elution) gave the title compound [156] (264 mg, 68%) as a pale brown solid; m.p. 
148-150°C; (Found: C, 69.29; H, 5.79; N, 8.89. CI8HI8N203S requires C, 69.65; H, 5.85; 
N, 9.03%); Vmax (nujol)/cm- I 1678, 1462, 1377 and 1229; OH (250 MHz; CDCI3) 3.88 
(3H, s, NCH3), 4.01 (3H, s, OCH3), 5.23 (2H, s, OCH2Ar), 5.72 (2H, broad, NH2), 6.83 
(lH, s), 7.05 (lH, d, J 8.99 Hz), 7.09 (lH, d, J 8.92 Hz), 7.33 (4H, m) and 7.50 (lH, m); 
OC (62.5 MHz; CDCI3) 31.72 (N CH3), 58.32 (OCH3), 75.11 (OCH2Ar), 102.30, 105.42, 
114.97, 121.44, 127.28, 127.84, 128.09, 128.31, 130.66, 136.49, 138.02, 145.13 and 
164.19; mlz 310 (M+, 70%), 267 (30), 148 (55), 91 (100) and 65 (30); (Found M+, 
310.1317. CI8HI8N203S requires M, 310.1317). 
Alternative procedure for the preparation of 
4-benzyloxy-5-methoxy-l-methylindole-2-carboxamide [156] 
Ammonium chloride (0.519 g, 9.7 mmol) was added to a solution of trimethyl aluminium 
chloride (2M solution in hexanes, 4.84 ml, 9.7 mmol) and benzene (9.7 ml) at O°C under a 
nitrogen atmosphere. A solution of methyl-4-benzyloxy-5-methoxy-I-methyl-2-carboxylate 
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[155] (I g, 3.22 mmol) in benzene (30 ml) was added dropwise and the mixture stirred at O°C 
for 10 min. The mixture was then stirred at 60°C for 14h. Hydrochloric acid (2M, 50 m!) was 
cautiously added and the mixture extracted with ethyl acetate (3 x 40 ml). The extracts were 
combined and washed with brine (2 x 40 ml), dried (MgS04) and evaporated under reduced 
pressure. Flash column chromatography (light petroleum: diethyl ether elution) gave the title 
compound [156] (366 mg, 38%) as a pale yellow solid, with analytical data identical to that 
previously prepared. 
OBn 
MeO 
~ 
N 
Me 
4-Benzyloxy-5-methoxyindole-2-carboxylic acid [157J 
Methyl-4-benzyloxy-5-methoxy-2-carboxylate [155] (200 mg, 0.65 mmol), THF (4 ml) and 
sodium hydroxide (5% solution, 1.5 m!) were heated at reflux for 16h. The mixture was 
cooled, made acidic, by the addition of dilute hydrochloric acid, then extracted with dichloro-
methane (3 x 10 ml). The extracts were combined, washed with brine (20 ml), dried (MgS04) 
and evaporated under reduced pressure to give a yellow solid. Flash column chromatography 
(ethyl acatate elution) gave the title compound [157] (164 mg, 86%) as a pale yellow solid; 
m.p. 177-179°C; (Found M+, 311.1150. C18H17N04 requires M, 311.1157); vmax 
(CHCI3)/cm- 1 1681, 1520, 1349, 1216 and 752; OH (250 MHz; CDCI3) 3.90 (3H, s, OCH3), 
4.03 (3H, s, NCH3), 5.29 (2H, s, OCH2Ph), 7.03 (lH, d, J 8.5 Hz), 7.14 (lH, d, J 8.5 
Hz), 3.34 (3H, m) and 7.49 (3H, m), carboxylic acid OH unobserved; oC (62.5 MHz; CDCI3 
: CD30D) 31.62, 58.34, 75.07, 105.51, 107.65, 112.96, 115.59, 121.32, 127.65, 128.02, 
128.23, 128.79, 137.07, 137.63, 141.34 and 164.0; mlz 311 (M+, 35%), 267 (15), 220 
(100),206 (25), 91 (75) and 63 (20). 
Alternative procedure for the preparation of 
4-be nzyloxy-5-methoxy-1-methylindole-2-carboxamide [15 6J 
A solution of 4-benzyloxy-5-methoxy-l-methylindole-2-carboxylic acid [157] (55 mg, 0.18 
mmol) and acetyl chloride (326 mg, 4.16 mg) was cooled to O°e. Powdered phosphorus 
pentachloride (40 mg, 0.19 mmol) was added and the mixture stirred at rt for 4 h. The 
resulting yellow solution was evaporated under reduced pressure. Dichloromethane (5 ml) was 
added and the solution was cooled to _78°C, ammonia gas was bubbled into the reaction 
mixture (approx. 30 ml). The reaction mixture was stirred at _78°C for 2 h, then warmed to rt 
over a 12 h period. Dichloromethane (20 ml) was added and the mixture washed with brine (2 
x 10 ml), dried (MgS04) and evaporated under reduced pressure. Flash column 
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chromatography (ethyl acetate elutiuon) gave the title compound [156] (17 mg, 31 %) as a pale 
brown solid, with analytical data identical to that previously prepared. 
OBn 
MeO 
~ 
N 
Me 
4-Benzyloxy-5-methoxy-l-methylindole-2-thiocarboxamide [159 J 
A solution of 4-benzyloxy-5-methoxy-I-methylindole-3-amide [156] (462 mg, 1.49 mmol), 
Lawesson's reagent [99] (356 mg, 0.88 mmol) and toluene (25 ml) were heated under reflux 
for I h. The crude reaction mixture was evaporated under reduced pressure and flash column 
chromatography (dichloromethane : diethyl ether elution) gave the title compound [159] (318 
mg, 65% yield) as a yellow solid; m.p. 176-177°C; (Found: C, 66.50; H, 5.44; N, 8.44. 
C18H18N202S. requires C, 66.24; H, 5.56; N, 8.59%); vmax (nujol)/cm- 1 1642, 1596, 
1523 and 1463; OH (250 MHz; CDCI3) 3.89 (3H, s, NCH3), 4.03 (3H, s, OCH3), 5.21 (2H, 
s, OCH2Ar), 6.77 (lH, s), 7.03 (3H, m), 7.12 (3H, m) and 7.49 (3H, m); OC (62.5 MHz; 
CDCI3) 32.34 (NCH3), 58.21 (OCH3), 75.16 (OCH2Ar), 100.42, 105.63, 115.13, 122.31, 
127.85, 128.13, 128.31, 128.75, 138.07, 138.13, 142.01, 146 and 192; mlz 326 (M+, 
40%), 235 (75), 20 I (30), 148 (20), 91 (100) and 65 (30); (Found M+, 326.1096. 
CI8HI8N202S requires M, 326.1089). 
OBn 
MeO 
eN 
Me 
and 4-benzyloxy-5-methoxy-l-methylindole-2-nitrile [158J; (Found M+, 292.1216. 
CI8HI6N202 requires M, 292.1212); vmax(CHCI3)/cm-1 2224, 1601, 1519, 1215 and 752; 
OH (CDCI3; 250 MHz) 3.84 (3H, s, OCH3), 3.91 (3H, s, NCH3), 5.24 (2H, s, OCH2Ph), 
6.98 (lH, m), 7.10 (2H, m), 7.20 (lH, s), 7.36 (2H, m) and 7.48 (2H, m); OC (CDCI3; 62.5 
MHz) 31.65,75.13,85.41, 105.16, 109.80, 113.50, 116.38, 121.96, 123.43, 128.01, 
128.08, 128.24, 128.53, 134.98, 137.56 and 145.63; mlz 292 (M+, 20%), 201 (40) and 91 
(100). 
Alternative procedure for the preparation of 
4-benzyloxy-5-methoxy-l-methylindole-2-carboxamide [15 6J 
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4-benzyloxy-5-methoxy-l-methylindole-2-nitrile [158] (137 mg, 0.49 mmol), potassium 
hydroxide (101 mg, 0.18 mmol) and tert-butanol (5 ml) were heated under reflux for 30 min. 
Brine (10 m\) was added and the mixture extracted with dichloromethane (3 x 30 ml). The 
extracts were combined washed with brine (2 x \0 ml), dried (MgS04) and evaporated under 
reduced pressure. Flash column chromatography (ethyl acetate elution) gave the title 
compound [156] (126 mg, 86%) as a pale brown solid, with analytical data identical to that 
previously prepared. 
OBn 
MeO 
Me 
2 - (4- B e nzyloxy-5 -m eth oxy-1-methy lindol-2 -y I )thiazole-4 -carboxy lic ac id 
[161J 
4-Benzyloxy-5-methoxy-I-methylindole-3-thioamide [159] (674 mg, 2.06 mmol), 
bromopyruvic acid (725 mg, 4.34 mmol) and ethanol (90 ml) were heated under reflux for 0.5 
h. The crude reaction mixture was evaporated under reduced pressure, to give an oil, water (30 
m\) was added and the mixture extracted with ethyl acetate (3 x 50 rn\), washed with brine (30 
ml), dried (MgS04) and evaporated under reduced pressure. Flash column chromatography 
(dichloromethane : ethyl acetate elution) gave the title compound [161] (509 mg, 62% yield) 
as a pale yellow solid; m.p. 143-145°C; (Found M+, 394.0853. C21H18N204S requires M, 
394.0988); OH (250 MHz; CDCI3) 3.92 (3H, s, NCH3), 4.11 (3H, s, OCH3), 5.26 (2H, s, 
OCH2Ar), 6.99 (\H, s), 7.07 (2H, m), 7.35 (3H, m), 7.50 (2H, m) and 8.24 (lH, s), 
carboxylic acid OH unobserved; OC (62.5 MHz; CDCI3 : CD30D) 31.86 (NCH3), 58.16 
(OCH3), 75.12 (OCH2Ar), 102.8, \05.35, 113.9, 122.9, 127.23, 127.82, 128.08, 128.2, 
132.12,136.7,137.3,140.8,145.2,148.3,162.3 and 164.3; m/z 394 (M+, 5%), 350 (20), 
320 (25), 304 (30),260 (25), 217 (20), 155 (25),113 (20), 91 (100),51 (45) and 44 (lOO); as 
well as the ester [162] (175 mg, 19%). 
OBn 
MeO 
Me 
Ethyl 2 -( 4-benzyloxy-5-methoxy-1-methylindol-2-yl )thiazole-4-carboxylate 
[162J 
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2-(4-Benzyloxy-5-methoxy-I-methylindol-2-yl)thiazole-4-carboxylic acid [161] (471 mg, 
1.19 mmol), ethanol (20 ml) and sulphuric acid (0.5 ml, of a concentrated solution) were 
heated under reflux for 14 h. Brine (20 ml) was added and the mixture extracted with 
dichloromethane (3 x 40 ml). The extracts were combined and washed with brine (30 ml), 
dried (MgS04) and evaporated under reduced pressure. Flash column chromatography 
(dichloromethane: ethyl acetate elution) gave the title compound [162] (428 mg, 85%) as a 
pale yellow solid; m.p. 113-114°C; (Found M+, 422.1257. C23H22N204S requires M, 
422.1300; vmax (CHCI3/cm-l) 1722,1553,1421,1321, 1215 and 757; 8H (250 MHz; 
CDCI3) 1.43 (3H, t, J 7.2 Hz, OCH2CH3), 3.97 (3R, s, NCH3), 4.15 (3H, s, OCH3), 4.42 
(2H, q, J 7.15, OCH2CH3), 5.25 (2H, s, OCH2Ar), 6.96 (lH, s), 7.07 (2H, s), 7.35 (4H, 
m), 7.50 (lH, m) and 8.11 (lH, s); 8C (62.5 MHz; CDCI3) 14.29 (OCH2CH3), 31.86 
(NCH3), 58.27 (OCH3), 61.39 (OCH2CH3), 75.06 (OCH2Ar), 102.91, 105.24, 114.04, 
122.49,126.63,127.83, 128.09, 128.28, 128.74, 131.62, 136.53, 138.03, 145.32, 147.71, 
161.15 and 161.24. m/z 422 (M+, 5%), 332 (70), 317 (45), III (30),97 (40), 83 (50), 69 
(70), 55 (100), 39 (70) and 27 (40). 
o 
MeO 
Ethyl 2-( 5-methoxy-1-methyl-4, 7 -dioxoindol-2-yl)thiazole-4-carboxylate [163] 
Ethyl 2-(4-benzyloxy-5-methoxy-I-methylindol-2-yl)thiazole-4-carboxylate [162] (0.6 g, 
1.42 mmol), ethanol (10 ml) and palladium hydroxide (Pearl man's catalyst) (0.2 g, 0.14 
mmol) were stirred under a hydrogen atmosphere at atmospheric pressure for 48 h. The 
reaction mixture was filtered, washed with dichloromethane (100 ml), the filtrate and washings 
were combined and evaporated under reduced pressure. Acetone (20 ml) and sodium 
dihydrogen phosphate (0.17 M, 20 ml) were added and the mixture stirred at rt for 10 min. 
Fremy's salt (1.9 g, 2.5 mmol) and water (20 ml) were added and the mixture stirred at rt for 
16 h. The mixture was extracted with dichloromethane (3 x 30 ml). The extracts were 
combined, washed with brine (30 ml), dried (Na2S04) and evaporated under reduced 
pressure. Flash column chromatography (dichloromethane : ethyl acetate elution) gave the title 
compound [163] (0.317 g, 64%) as a orange solid; (Found M+, 346.0645. C16H14N205S. 
requires M, 346.0623); 8H (250 MHz; CDCI3) 1.42 (3H, t, J 7.2 Hz, OCH2CH3), 3.8 (3H, 
s, OCH3), 4.39 (3H, 3H, s, NCH3), 4.42 (2H, q, J 7.2 Hz, OCH2CH3), 7.78 (lH, s, H6), 
7.96 (lH, s) and 8.2 (lH, s); 8C (62.5 MHz; CDCI3) 14.24,35.19,56.57,61,59, 108.06, 
110.83,116.12, 121.04, 124.32, 127.40, 127.92, 129.21, 148.17, 160.07, 178.93 and 
179.62; m/z 364 (M+, 10%),97 (40), 81 (50),69 (85), 55 (60),41 (100) and 27 (50). 
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OBn 
MeO 
Me 
2 -( 4-Benzyloxy-5-methoxy-1-methylindol-2-yl)-4-methylthiazole [164 J 
4-Benzyloxy-5-methoxy-I-methylindole-3-thioamide [159] (173 mg, 0.53 mmol), 
bromoacetone (145 mg, 1.06 mmol) and ethanol (20 ml) were heated under reflux for I h. The 
reaction mixture was evaporated under reduced pressure and flash column chromatography 
(dichloromethane : ethyl acetate elution) gave the title compound [164] as a pale yellow solid 
(133 mg, 69%); m.p. 115-117°C; (Found M+, 364.126. C21H20N202S requires M, 
363.1245); vmax (CHCI3/cm-l) 1503, 1415, 1341, 1215, 1003 and 771; OH (250 MHz; 
CDCI3) 2.32 (3H, s, CH3), 3.92 (3H, s, NCH3), 4.01 (3H, s, OCH3), 5.25 (2H, s, 
OCH2Ar), 6.85 (lH, s), 6.94 (lH, s), 7.04 (2H, s), 7.33 (3H, m) and 7.55 (2H, m); OC 
(62.5 MHz; CDCI3) 17.26 (CH3), 31.94 (NCH3), 58.33 (OCH3), 51.96, 75.02 (OCH2Ar), 
101.72, 102.25, 105.07, 113.09, 113.36, 113.75, 117.09, 122.52, 127.7, 128.07, 128.28, 
132.85,136.41,145.26 and 13.46; m/z 311 (M+, 40%),364 (20), 273 (100),230 (20) and 
91 (40). 
o 
MeO 
2-( 5-M ethoxy-1-methyl-4, 7 -dioxoindol-2-yl)-4-methylthiazole [165 J 
2-(4-Benzyloxy-5-methoxy-I-methylindol-2-yl)-4-methylthiazole [164] (0.58 g, 1.60 mmol), 
ethanol (10 ml) and palladium hydroxide (Pearlmans catalyst) (0.223 g, 0.16 mmol) were 
stirred under a hydrogen atmosphere at atmospheric pressure for 48 h. The reaction mixture 
was filtered, washed with dichloromethane (100 ml), the filtrate and washings were combined 
and evaporated under reduced pressure. Acetone (20 ml) and sodium dihydrogen phosphate 
(0.17 M, 20 ml) was added and the mixture stirred at rt for 10 min. Fremy's salt (2.14 g, 8.0 
mmo!) and water (20 m!) were added and the mixture stirred at rt for 16 h. The mixture was 
extracted with dichloromethane (3 x 30 m!). The extracts were combined, washed with brine 
(30 ml), dried (Na2S04) and evaporated under reduced pressure. Flash column 
chromatography (dichloromethane : ethyl acetate elution) gave the title compound [165] (0.272 
g, 59%) as a orange solid; (Found M+, 288.0573. CI4H 12N203S requires M, 288.0567); 
vmax (CHCl3)/cm- 1 1741, 1692, 1569, 1481, 1208 and 741; OH (250 MHz; CDCI3) 2.04 
(3H, s, CH3), 3.85 (3H, s, OCH3), 4.36 (3H, NCH3), 5.75 (lH, s, H6), 6.93 (lH, s) and 
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7.02 (lH, s); BC (62.5 MHz; CDCI3) 17.16,35.03,56.50, 107.92, 109.91, 113.40, 114.14, 
125.01,131.24,154.08,156.91,160.04,178.82 and 179.21. 
OBn 
MeO 
2-( 4-Benzyloxy-S-methoxy-1-methyl-indol-2-yl )thiazole-4-carboxamide [169] 
Ethyl 2-( 4-benzyloxy-5-methoxy-1-methylindol-2-yl)thiazole-4-carboxylate.[162] (385 mg, 
0.91 mmol), ammonium hydroxide (5 ml) and ammonium chloride (12.4 mg, 0.23 mmol) 
were placed in a Young's sealed tube and heated at 100°C for 48 h. The reaction mixture was 
cooled and dichloromethane (30 ml) was added. The mixture was washed with water (2 x 10 
ml), brine (10 ml), dried (MgS04) and evaporated under reduced pressure. Flash column 
chromatography (dichloromethane : ethyl acetate elution) gave the title compound [169] (272 
mg, 79%) as a pale yellow solid; m.p. 193-194°C; (Found M+, 393.1144. C21H19N303S 
requires M, 393.1147); vmax (CHCI3)/cm- 1 1639, 1500, 1459, 1417, 1215 and 757; BC 
(62.5 MHz; CDCI3: CD30D) 35.85, 62.03, 79.09, 106.84, 109.22, 117.92, 125.31, 
127.91, 131.82, 132.07, 132.18, 138.78, 140.38, 141.66, 144.51, 149.21, 153.52,163.41 
and 165.29; miz 393 (M+, 5%), 305 (100),105 (30), 91 (90),77 (35), 65 (25) and 44 (90). 
OBn 
MeO 
2 - (4- B e nzy loxy-5 -me th oxy-1-me thy l-indol-2 -y I )thiazo le-4 -thiocarboxa m ide 
[170] 
2-( 4-Benzyloxy-5-methoxy-1-methyl-indol-2-yl)thiazole-4-carboxamide [169] (265 mg, 0.67 
mmol), Lawesson's reagent [99] (136 mg, 0.34 mmol) and THF (8 ml) were heated under 
reflux for 0.5 h under a nitrogen atmosphere. The reaction mixture was cooled and evaporated 
under reduced pressure. Flash column chromatography (dichloromethane : methanol elution) 
gave the title compound [170] (150 mg, 55%) as a pale yellow solid; m.p. 194-195°C; (Found 
M+, 409.0864. C21H19N302S2 requires M, 409.0919); BH (250 MHz; CDCI3) 3.73 (3H, s, 
OCH3), 3.89 (3H, s, NCH3), 5.15 (2H, OCH2Ph), 6.76 (lH, s), 6.86 (2H, m), 7.13 (3H, 
m), 7.30 (2H, m) and 8.24 (lH, s), thioamide NH2 unobserved; BC (62.5 MHz; CDCI3) 
32.47, 58.64, 66.23, 103.69, 105.69, 109.21, 114.65, 118.93, 122.91, 127.43, 128.35, 
151 
128.57,128.71,131.79,132.03,136.96,138.54,145.79 and 161.21; m/z 409 (M+, 5%), 
318 (15), 284 (60), 241 (20), 109 (10), 91 (60),77 (20), 60 (20) and 44 (100). 
OBn 
~su 
NI-f 
MeO 
N 
Me 
C02Et 
Ethyl 2 -(2- (4-benzyloxy-S-methoxy-1-methylindol-2 -yl)th iazol-4-yl )thiazole-
4-carboxylate [171] 
2-( 4-Benzyloxy-5-methoxy-I-methyl-indol-2-yl)thiazole-4-thiocarboxamide [170] (150 mg, 
0.37 mmol), bromopyruvic acid (92 mg, 0.55 mmol) and ethanol (10 ml) was heated under 
reflux for 1 h. The reaction mixture was cooled and dichloromethane (50 ml) was added. The 
mixture was washed with water (2 x 20 ml), brine (20 ml), dried (MgS04) and evaporated 
under reduced pressure to give a brown oil. Ethanol (20 ml) and a few drops of concentrated 
sulphuric acid were added and the mixture was heated at reflux for 16 h. The reaction mixture 
was cooled and diethyl ether (20 ml) was added. The mixture was washed with brine (2 x 10 
ml), dried (MgS04) and evaporated under reduced pressure to give a brown oil. Flash column 
chromatography (light petroleum: diethyl ether elution) gave the title compound [171] (110 
mg, 60%) as a pale yellow solid; m.p. 132-134°C; (Found M+, 505.1126. C26H23N304S2. 
requires M, 505.1130); Vmax (CHCI3)1cm- 1 1726, 1529, 1421, 1215 and 736; OH (250 MHz; 
CDCI3) 1.45 (3H, t, J 7.2 Hz, OCH2CH3), 3.84 (3H, s, OCH3), 4.10 (3H, s, NCH3), 4.33 
(2H, q, J 7.2 Hz, OCH2CH3), 5.26 (2H, s, OCH2Ar), 7.0 (lH, s), 7.08 (lH, s), 7.36 (4H, 
m), 7.51 (2H, m), 8.12 (lH, s) and 8.20 (lH, s); OC (62.5 MHz; CDCI3) 14.3, 32.14, 
58.18, 61.53, 75.09, 100.91, 102.83, 104.79, 105.15, 114.08, 116.52, 122.54, 127.71, 
127.87, 128.11, 131.43, 136.56, 138.02, 140.85, 145.34, 147.96, 148.61, 161.23 and 
163.29; m/z 505 (M+, 5%), 292 (30), 201 (40) and 91 (lOO). 
OBn 
MeO OH 
4-Benzyloxy-S-methoxyindole-2-methanol [173] 
A solution of methyl-4-benzyloxy-5-methoxyindole-2-carboxylate [154] (4.92 g, 16.62 
mmol) in dry THF (150 ml) was added dropwise to a stirred suspension of lithium aluminium 
hydride (1.225 g, 32.1 mmol) in dry THF (60 ml), such that the mixture achieved gentle 
152 
reflux. After 30 min, water (1.2 ml), sodium hydroxide (15% solution, 1.2 ml) and water (2 
ml), were added to the mixture, and the resultant precipitate removed by filtration (through a 
bed of Celite). The filtrate was dried (MgS04), then evaporated under reduced pressure to give 
the title compound [173] (4.134 g, 93%) as a colourless crystalline solid; m.p. 82-85°C; 
(Found M+, 283.1214. C17H17N03 requires M, 283.1208); Vmax (nujol)/cm- 1 1467 and 
1090; OH (250 MHz; CDCb) 3.89 (3H, s, OCH3), 4.69 (3H, s, CH20H), 5.19 (2H, s, 
OCH2Ar), 6.37 (lH, s), 6.91 (lH, d, J 8.71 Hz), 6.93 (lH, d, J 8.73 Hz), 7.33 (3H, m), 
7.48 (lH, m) and 8.28 (lH, broad, NH), hydroxyl OH unobserved; OC (62.5 MHz; CDCI3) 
58.25 (CH20H), 58.41 (OCH3), 74.98 (OCH2Ar), 97.54, \06.33, 111.77, 123.15, 127.76, 
128.02, 128.28, 128.74, 133.60, 138.14, 138.36 and 144.95; m/z 283 (M+, 20%), 192 
(lOO), 174 (30), 146 (20), 91 (SS). 
OBn 
MeO 
~ 
N 
H 
CHO 
4-Benzyloxy-S-methoxyindole-2-carboxaldehyde [142] 
Manganese dioxide (11.89 g, 136.7 mmol) was added to a stirred solution of 4-benzyloxy-5-
methoxyindole-2-methanol [173] (3.98 g, 14.06 mmol) in dichloromethane (450 ml). The 
suspension was refluxed for 12 h, then the mixture was filtered, and the residue washed with 
dichloromethane (3 x 250 m\). The combined filtrate and washings were evaporated to give an 
oil, which was purified by flash column chromatography (dichloromethane elution) to give the 
title compound [142] (\.98 g, 50%) as a yellow crystalline solid; m.p. 143-144°C; (Found 
M+, 281.1023. C17HlSN03 requires M, 281.1050); vmax (nujol)/cm-1 1665,1453 and 1377; 
OH (250 MHz; CDCI3) 3.92 (3H, s, OCH3), 5.28 (2H, s, OCH2Ar), 7.15 (2H, m), 7.22 
(3H, m), 7.34 (2H, m), 7.47 (lH, m), 8.13 (lH, s, NH) and 9.75 (lH, s, CHO); OC (62.5 
MHz; CDCI3) 58.41 (OCH3), 75.14 (OCH2Ar), 107.48, 112.33, 118.41, 123.39, 127.93, 
128.04, 128.33, 128.74, 135.06, 136.17, 137.76, 145.20 and 183.24 (CHO); m/z 281 (M+, 
40%), 253 (30), 190 (SO), 91 (100) and 65 (IS). 
OBn 
Meo'CQ I ~ 
~ N 
H 
4-Benzyloxy-S-methoxyindole [174J 
153 
Bis(triphenylphosphine)carbonylrodium chloride (l00.3 mg, 0.146 mmol) was suspended in 
dry de gassed mesitylene (6 ml) and warmed to 80°C. After 10 min 1,3-
bis(diphenylphosphino)propane (117 mg, 0.28 mmol) was added. After a further 10 min 4-
benzyloxy-5-methoxyindole-2-carboxaldehyde [142] (500 mg, 1.79 mmol) was added. The 
resultant yellow solution was plunged into a Wood's metal bath at 190°C and refluxed for 2 h. 
The mixture was evaporated under reduced pressure and flash column chromatography (light 
petroleum: diethyl ether elution) gave the title compound [174] (379 mg, 84%) as a pale 
yellow solid; m.p. 81-83°C; (Found M+, 253.1102. C16HlSN02 requires M, 253.1102); OH 
(250 MHz; CDCb) 3.89 (3H, s, OCH3), 5.24 (2H, s, OCH2Ar), 6.55 (!H, s), 6.95 (!H, d, J 
8.68 Hz), 7.04 (2H, m), 7.33 (3H, m), 7.52 (2H, m) and 8.08 (lH, broad, NH); mlz 253 
(M+, 70%), 163 (40), 148 (20), 134 (40), 119 (30), 91 (lOO) and 65 (20). 
o 
N 
Me 
Ethyl 2-(5-( aziridin-l-yl )-I-methyl-4, 7-dioxyindol-2-yl)thiazole-4-carboxylate 
[180J 
Ethyl 2-(5-methoxy-I-methyl-4,7-dioxoindol-2-yl)thiazole-4-carboxylate [163] (25.6 mg, 
0.074 mmol), aziridine (0.5 ml) and methanol (3 ml) were stirred at rt for 16 h. The reaction 
mixture was evaporated under reduced pressure, CAUTION. Flash column chromatography 
(dichloromethane: ethyl acetate elution) followed by size exclusion chromatography (sephadex 
LH 20 gel filtration dichloromethane : methanol elution) gave the title compound [180] (11.2 
mg, 42%) as a red solid; (Found M+, 357.0817. C17H15N304S requires M, 357.0783); 
vmax (CHCI3)1cm-1 1717,1674,1641,1398,1355, 1260 and 756; oH (250 MHz; CDCI3) 
1.42 (3H, t, J 7.2 Hz, OCH2CH3), 2.24 (4H, s, N(CH2)2), 4.4 (3H, s, NCH3), 4.45 (2H, 
q, J 7.2 Hz, OCH2CH3), 5.9 (lH, s, H6), 7.06 (lH, s) and 8.17 (IH, s); OC (100 MHz; 
CDCI3) 14.34,29.19,35.19,61.68, 110.83, 118.20, 125.31, 127.36, 128.41, 131.93, 
141.80, 148.19, 157.39, 162.54 179.01 and 179.74; mlz 357 (M+, 10%),267910),217 
(10), 148 (lOO), 77 (60), 51 (40) and 31 (30). 
o 
~ 
N 
Me 
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Ethyl 2- (1-methyl-S-(2-methylaziridin-1-yl)-4, 7 -dioxoindol-2-yl)thiazole-4-
carboxylate [181] 
As a red solid; (Found M+, 371.0905. C18H17N304S requires M, 371.0939); vmax 
(CHCI3)/cm- 1 1715,1668,1620,1591,1397,1242 and 747; OH (250 MHz; CDCI3) 1.35 
(3H, t, J 7.3 Hz, OCH2CH3), 1.53 (3H, d, J 6.7 Hz, CHCH3), 3.12 (2H, m, NCH2), 3.98 
(lH, m, NCH), 4.35 (3H, s, NCH3), 4.41 (2H, q, J 7.3 Hz, OCH2CH3), 6.01 (lH, s, H6), 
6.97 (lH, s) and 8.09 (lH, s); mlz 371 (M+, 5%), 317 (15),267 (25),217 (20),155 (50), 
51 (100) and 31 (80). 
Ethyl 2- (1-methyl-S-(pyrrolodin-1-yl)-4, 7 -dioxyindol-2 -yl)thiazole-4-
carboxylate [182J 
Ethyl 2-(5-methoxy-1-methyl-4,7-dioxoindol-2-yl)thiazole-4-carboxylate [163] (15 mg, 
0.043 mmol), pyrrolidine (0.5 ml) and methanol (3 m!) were stirred at rt for 16 h. Water (10 
m1) was added and the mixture extracted with dich1oromethane (3 x 10 rnl). The extracts were 
combined, washed with hydrochloric acid (2M, 3 x 10 ml), brine (10 m1), dried (Na2S04) and 
evaporated under reduced pressure. Flash column chromatography (dichloromethane : ethyl 
acetate elution) followed by size exclusion chromatography (sephadex LH 20 gel filtration 
dichlorornethane : methanol elution) gave the title compound [182] (13 rng, 81 %) as a purple 
solid; (Found M+, 385.1103. CI9H19N304S requires M, 385.1096); vmax (CHCI3)/cm- 1 
1725,1667,1613,1545,1385,1272,1205 and 752; OH (250 MHz; CDCI3) 1.42 (3H, t, J 
7.2 Hz, OCH2CH3), 1.65 (4H, rn, (CH2)2), 3.45 (4H, m, N(CH2)2), 4.39 (3H, s, NCH3), 
4.47 (2H, q, J 7.2 Hz, OCH2CH3), 5.61 (!H, s, H6), 6.98 (lH, s) and 8.14 OH, s); m/z 
385 (M+, 25%), 267 (10), 217 (10),155 (25), 113 (20), 70 920), 51 (50) and 28(100). 
o o 
Ethyl 2-( 1-methyl-S (piperidin-1-yl )-4, 7-dioxyindol-2-yl)thiazole-4-carboxylate 
[183J 
155 
As a purple solid; (Found M+, 399.1262. C20H21N304S requires M, 399.1253); vmax 
(CHCI3)/cm- 1 1724,1668,1628,1548,1391,1244 and 757; oH (250 MHz; CDCI3) 1.41 
(3H, t, J 7.2 Hz, OCH2CH3), 1.61 (2H, m, CH2), 1.65 (4H, m, (CH2)2), 2.95 (4H, m, 
N(CH2)2), 4.39 (3H, s, NCH3), 4.44 (2H, q, J 7.2, OCH2CH3), 5.61 (lH, s, H6), 6.99 
(lH, s) and 8.1 (lH, s); OC (100 MHz; CDCI3) 14.67,24.65,29.93,35.32,51.29,61.71, 
109.91, 111.40, 125.19, 127.30, 128.43, 131.55, 148.49, 154.28, 159.60, 161.44, 178.79 
and 179.21; m/z 399 (M+, 100%), 176 (10),155 (IS), \03 (20), 84 (40), 51 (35),41 (40) 
and 28 (50). 
Zl~ 0 
N 
o 
Ethyl 2-( 5-cyclopropylamino-1-methyl-4, 7 -dioxyindol-2-yl)thiazole-4-
carboxylate [184J 
As a purple solid; (Found M+, 371.0938. C18H17N304S requires M, 371.0937); Vmax 
(CHCI3)1cm- 1 1725,1674, 1620, 1593, 1504, 1398, 1257 and 780; OH (400 MHz; CDCI3) 
0.81 (4H, m, (CH2)2), \.36 (3H, t, J 7.2 Hz, OCH2CH3), 2.39 (lH, rn, CH), 4.36 (3H, s, 
NCH3), 4.39 (2H, q, J 7.2 Hz, OCH2CH3), 5.60 (lH, s, H6), 5.87 (lH, br, NH), 6.94 
(lH, s) and 8.09 (lH, s); Oc (lOO MHz; CDCI3) 7.45, 14.68,24.63,35.57,61.96, 100.90, 
110.93, 122.66, 127.35, 127.61, 131.42, 148.52, 149.60, 159.45, 161.44, 178.34 and 
179.42; m/z 371 (M+, 70%), 217 (20), 186 (20), 155 (30), 1 \3 (25),80 (40), 51 (lOO) and 
31 (70). 
o 
o 
~ 
N 
Me 
2-(5- (Aziridin-1-yl)-1-methyl-4, 7 -dioxoindol-2-yl)-4-methylthiazole [186 J 
Ethyl 2-(5-methoxy-1-methyl-4,7-dioxoindol-2-yl)thiazole-4-carboxylate [165] (25.6 mg, 
0.074 mmol), aziridine (0.5 ml) and methanol (3 ml) were stirred at rt for 16 h. The reaction 
mixture was evaporated under reduced pressure, CAUTION. Flash column chromatography 
(dichloromethane : ethyl acetate elution) followed by size exclusion chromatography (sephadex 
LH 20 gel filtration dichloromethane : methanol elution) gave the title compound [186] (11.2 
mg, 42%) as a red solid; (Found M+, 299.0732. C15H\3N302S requires M, 299.0728); 
Vmax (CHCI3)/cm- 1 1676,1640,1587,1480,1351,1203 and 782; oH (250 MHz; CDCI3) 
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2.24 (4H, s, N(CH2)2), 2.50 (3H, s, CH3), 4.35 (3H, s, NCH3), 5.88 (lH, s, H6), 6.97 
(lH, s) and 6.99 (lH, S); OC (62.5 MHz; CDCI3) 17.66,28.11,35.41, 110.31, 114.48, 
118.57, 125.25, 131.49, 133.72, 154.51, 157.61, 157.86, 178.99 and 179.43; mlz 299 
(M+, 100%),272 (20), 244 (10), 215 (10),176 (10), 71 (20) and 45 (15). 
s ~\' 
NACH3 
o Me 
2-( I-M ethyl-5- (2-methylaziridin-I-yl)-4, 7 -dioxoindol-2-yl )-4-methylthiazole 
[187J 
As a red solid; (Found M+, 313.0891. CI6HI5N302S requires M, 313.0885); Vrnax 
(CHCI3)/crn-1 1669, 1594, 1552, 1503, 1393, 1258 and 753; OH (400 MHz; CDCI3) 1.48 
(3H, d, J 6.8 Hz, CHCH3), 2.46 (3H, s, CH3), 3.29 (2H, rn, CH2), 4.16 (\H, rn, CH), 
4.29 (3H, NCH3), 5.81 (lH, s, H6), 6.82 (lH, s) and 6.89 OH, s); OC (100 MHz; CDCI3) 
17.93, 23.71, 36.89, 47.28, 49.32, 110.17, 114.22, 129.23, 132.99, 133.54, 135.70, 
147.10, 154.48, 158.06, 178.04 and 179.31; m/z 313 (M+, 50%), 286 (100),176 (15),142 
(15), 71 (70) and 45 (60). 
I ••• ·LN 
0 
s ~Jl 
N N CH3 
0 Me 
2-(5-(2,3 -cis-Dimethylaziridin-I-yl )-I-methyl-4, 7 -dioxyindol-2 -yl )-4-
methylthiazole [188J 
As a red solid; (Found M+, 327.1039. C17H17N302S requires M, 327.1041); vrnax 
(CHCI3)/crn- 1 1669, 1642, 1586, 1552, 1395 and 783; OH (400 MHz; CDCI3) 1.32 (6H, d, J 
6.6 Hz, (CH3)2), 2.15 (2H, rn, (CH)2), 3.89 (3H, s, CH3), 4.37 (3H, s, NCH3), 5.81 (I H, 
s, H6), 6.95 (lH, s) and 8.11 (\H, s); OC (100 MHz; CDCI3) 13.13,35.49,40.57,52.89, 
111.08, 117.07, 125.14, 127.83, 132.16, 148.20, 158.64, 159.41, 161.85, 179.02 and 
179.62; m/z 327 (M+, > 5%), 270 (10), 70 (20), 57 (15), 41 (100) and 27 (15). 
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o 
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2-(S-(Azetidin-l-yl)-I-methyl-4, 7 -dioxoindol-2-yl)-4-methylthiazole [189] 
As a purple solid; (Found M+, 313.0887. CI6HI5N302S requires M, 313.0885); vmax 
(CHCI3)/cm- 1 1663, 1622, 1576, 1549, 1384, 1258 and 777; liH (400 MHz; CDCI3) 2.11 
(3H, s, CH3), 2.86 (6H, m), 4.73 (3H, s, NCH3), 5.72 (lH, s, H6), 7.24 (lH, s) and 7.63 
(lH, s); liC (62.5 MHz; CDCI3) 17.27, 17.76, 29.71, 34.87, 109.36, 113.49, 122.75, 
128.30,131.93,133.60,148.78,153.91,157.94,177.44 and 179.40; m/z 313 (M+, 100%), 
284 (30), 257 (20), 229 (20), 176 (20), 71 (45),53 (20),45 (35) and 28 (30). 
Q o 
o 
~ 
N 
Me 
2-( I-M ethyl-S -(pyrrolidin-l-yl)-4, 7-dioxoindol-2-yl)-4-methylthiazole [190] 
Ethyl 2-(5-methoxy-I-methyl-4,7-dioxoindol-2-yl)thiazole-4-carboxylate [165] (10 mg, 
0.052 mmot), pyrrolidine (0.5 ml) and methanol (3 ml) were stirred at rt for 16 h. Water (10 
mt) was added and the mixture extracted with dichloromethane (3 x 10 ml). The extracts were 
combined, washed with hydrochloric acid (2M, 3 x 10 ml), brine (10 ml), dried (Na2S04) and 
evaporated under reduced pressure. Flash column chromatography (dichloromethane : ethyl 
acetate elution) followed by size exclusion chromatography (sephadex LH 20 gel filtration 
dichloromethane : methanol elution) gave the title compound [190] (7.1 mg, 63%) as a purple 
solid; (Found M+, 327.1048. C17H17N302S requires M, 327.1042); vmax (CHCI3)/cm- 1 
1663,1606,1541,1383,1274 and 773; liC (100 MHz; CDCI3) 17.61,35.52,51.52,53.76, 
103.40, 110.16, 113.77, 123.79, 132.28, 133.19, 149.32, 154.24, 158.39, 178.18 and 
180.16; m/z 327 (M+, 100%),284 (15), 229 (10), 155 (20), 113 (15),70 (30),51 (40) and 
28 (90). 
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Q o 
2-( 1-Methyl-5 -(piperidin-1-yl)-4, 7 -dioxoindol-2-yl)-4-methylthiazole [191] 
As a purple solid; (Found M+, 341.1204. CI8HI9N302S requires M, 341.1198); vrnax 
(CHCI3)/crn- 1 1663, 1632, 1547,1385, 1244 and 782; DH (250 MHz; CDCI3) 1.69 (6H, rn), 
2.49 (3H, s, CH3), 3.44 (4H, rn, N(CH2)2), 4.35 (3H, s, NCH3), 5.59 (lH, s, H6), 6.88 
(lH, s) and 6.92 (lH, s); DC (lOO MHz; CDCI3) 17.61,24.68,26.20,35.16,51.27,110.0, 
110.42, 113.98, 125.27, 132.18, 132.82, 154.32, 154.34, 158.21, 178.97 and 180.29; mlz 
341 (M+, 100%), 284 (10), 257 (10), 229 (10), 205 (10), 84 (30), 55 (10), 41 (25) and 28 
(30). 
o Me 
2-( 1-Methyl-5-( morpholin-1-yl)-4, 7 -dioxoindol-2-yl)-4-methylthiazole [192] 
As a purple solid; vrnax (CHCI3)/crn- 1 1664, 1629, 1547, 1386 and 778; DH (250 MHz; 
CDCI3) 2.51 (3H, s, CH3), 3.46 (4H, rn, N(CH2)2), 3.85 (4H, rn, O(CH2)2), 4.35 (3H, s, 
NCH3), 5.59 (IH, s, H6), 6.91 (lH, s) and 6.94 (lH, s). 
2-(5- Cyclopropylamino-1-methyl-4, 7 -dioxyindol-2 -yl)-4-methylthiazole [193] 
As a purple solid; (Found M+, 313.0892. CI6HI5N302S requires M, 313.0885); vrnax 
(CHCI3)1crn- 1 1664,1585,1551,1496,1394,1215 and 753; DH (400 MHz; CDCI3) 0.54 
(2H, rn), 0.77 (2H, rn), 2.37 (lH, rn, CH), 2.38 (3H, s, CH3), 4.30 (3H, s, NCH3), 5.56 
(JH, s, H6), 5.85 (lH, br, NH), 6.81 (lH, s) and 6.86 (JH, s); DC (100 MHz; CDCI3) 6.55, 
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16.72, 23.72, 34.52, 99.82, 109.06, 113.13, 121.80, 131.79, 132.85, 148.65, 153.46, 
157.20,177.61 and 180.31; m/z 313 (M+, 100%),296 (30),284 (35), 71 (25) and 51 (50). 
L:N 
o 
Ethyl 2- (5- (aziridin-l-yl)-1-methyl-4, 7 -dioxyindol-3-yl )thiazole-4-carboxylate 
[194J 
Ethyl 2-(5-methoxy-I-methyl-4,7-dioxoindol-3-yl)thiazole-4-carboxylate [146] (15.2 mg, 
0.044 mmol), aziridine (0.5 ml) and methanol (3 m!) were stirred at rt for 16 h. The reaction 
mixture was evaporated under reduced pressure, CAUTION. Flash column chromatography 
(dichloromethane: ethyl acetate elution) followed by size exclusion chromatography (sephadex 
LH 20 gel filtration dichloromethane : methanol elution) gave the title compound [194] (14.3 
mg, 95%) as a red solid; (Found M+, 357.0783. C17HISN304S requires M, 357.0783); 
vmax (CHCI3)/cm- 1 1711,1664,1632,1592,1400,1215 and 755; OH (250 MHz; CDCI3) 
1.35 (3H, t, ] 7.2 Hz, OCH2CH3), 2.21 (4H, s, N(CH2)2), 3.95 (3H, s, NCH3), 4.34 (2H, 
q, ] 7.2 Hz, OCH2CH3), 5.82 (lH, s, H6), 7.75 (lH, s) and 8.09 (lH, s); OC (100 MHz; 
CDCI3) 14.39, 27.86, 36.79, 61.39, 106.79, 117.89, 120.12,127.62, 130.30, 131.20, 
146.66,157.75,160.01,161.60,178.75 and 179.06; m/z 357 (M+, 55%),284 (25), 274 
(30), 217 (20), 155 (IS), 113 (20), 84 (30), 57 (25), 51 (60), 42 (100) and 29 (60). 
Ethyl 2-( l-methyl-5-(2-methylaziridin-l-yl)-4, 7 -dioxoindol-3-yl)thiazole-4-
carboxylate [195J 
As a red solid; (Found M+, 371.0938. C 18H 17N 304S requires M, 371.0939); vmax 
(CHCI3)/cm- 1 1731, 1659, 1632, 1590, 1396, 1210 and 753; OH (400 MHz; CDCI3) 1.36 
(3H, t, ] 7.2 Hz, OCH2CH3), 1.39 (3H, d, ] 6.8 Hz, CHCH3), 2.07 (2H, m, N(CH2)), 
2,28 (I H, m, CH), 4.33 (3H, s, NCH3), 4.39 (2H, q, ] 7.2 Hz, OCH2CH3), 5.89 (lH, s, 
160 
H6), 7.74 (lH, s) and 8.11 (IH, s); BC (100 MHz; CDCI3) 14.78,28.29, 30.10, 37.25, 
57.18,61.81, 107.14, 117.20, 119.73, 120.40, 128.08, 130.32, 131.4, 146.90, 160.30, 
161.93,179.03 and 179.5; m/z 371 (M+, 5%), 229 (15),172(50),127 (60),101 (65),58 
(100) and 44 (55). 
L:N 
o 
2-( 5-(Aziridin-l-yl)-I-methyl-4, 7 -dioxoindol-3-yl)-4-methylthiazole [197] 
2-(5-Methoxy-l-methy 1-4, 7-dioxoindol-2-yl)-4-methylthiazole [196] (10.2 mg, 0.034 
mmol), aziridine (0.5 ml) and methanol (3 ml) were stirred at rt for 16 h. The reaction mixture 
was evaporated under reduced pressure, CAUTION. Flash column chromatography 
(dichloromethane : ethyl acetate elution) followed by size exclusion chromatography (sephadex 
LH 20 gel filtration dichloromethane : methanol elution) gave the title compound [197] (9.3 
mg, 92%) as a red solid; (Found M+, 299.0727. C15H13N302S requires M, 299.0728); BH 
(250 MHz; CDCI3) 2.25 (4H, s, N(CH2)2), 2.47 (3H, s, CH3), 4.01 (3H, s, NCH3), 5.88 
(lH, s, H6), 6.93 (lH, s) and 7.62 (lH, s); BC (100 MHz; CDCI3) 17.08, 27.84, 36.73, 
114.54, 116.72, 119.02, 119.95, 129.96, 130.19, 152.52, 157.88, 158.58, 178.76 and 
176.86; m/z 299 (M+, 100%),288 (30), 272 (25), 259 (10), 244 (10), 230 (10),215 (10), 
203 (10), 174 (10), 161 (5),91 (20) and 42 (30). 
o Me 
2- (I-M ethyl-5- (2 -methylaziridin-l-yl)-4, 7 -dioxoindol-3-yl )-4-methylthiazole 
[198] 
As a red solid; (Found M+, 313.0885. C 16H 15N 302S requires M, 313.0885); vmax 
(CHCI3)/cm-1 1661, 1634, 1589, 1500, 1397, 1216 and 753; BH (400 MHz; CDCI3) 1.38 
(3H, d, J 5.5 Hz, CHCH3), 2.08 (2H, m, N(CH2», 2.23 (lH, m, CH), 2.33 (3H, s, CH3), 
3.96 (3H, s, NCH3), 5.70 (lH, s, H6), 6.83 (IH, s) and 7.52 (lH, s); BC (100 MHz; 
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CDCI3) 15.97, 18.09, 35.12, 36.61, 37.12, 106.97, 114.89, 116.39, 119.20, 130.17, 
130.59, 152.80, 158.21, 160.75, 179.13 and 179.27; mlz 313 (M+, 25%), 267 (30), 217 
(30), 155 (60), 144 (70), 51 (90) and 31 (100). 
o 
4-( S-(Aziridin-I-yl )-I-methyl-4, 7 -dioxoindol-2-yl)-2-methylthiazole [200 J 
4-(5-Methoxy-1-methyl-4, 7-dioxoindol-3-yl)-2-methylthiazole [199] (17.2 mg, 0.059 
mmol), aziridine (0.5 ml) and methanol (3 ml) were stirred at rt for 16 h. The reaction mixture 
was evaporated under reduced pressure, CA UTI 0 N. Flash column chromatography 
(dichloromethane : ethyl acetate elution) followed by size exclusion chromatography (sephadex 
LH 20 gel filtration dichloromethane : methanol elution) gave the title compound [200] (14 
mg, 87%) as a red solid; Vmax (CHCI3)/cm- 1 1636, 1588, 1490, 1389, 1215 and 755; SH 
(250 MHz; CDCI3) 2.24 (4H, s, N(CH2)2), 2.72 (3H, s, CH3), 4.0 (3H, s, NCH3), 5.85 
(lH, s, H6), 7.52 (lH, s) and 8.61 (lH, s); OC (lOO MHz; CDCI3) 19.45,28.17,37.03, 
106.76,117.01,117.40,120.52,130.78,147.13,158.63, 161.17, 165.11, 179.13 and 
179.37. 
4- (I-M ethyl-S- (2 -methylaziridin-I-yl )-4,7 -dioxoindol-2-yl )-2-methylthiazole 
[201] 
As a red solid; (Found M+, 313.0889. C16HI5N302S requires M, 313.0884); vmax 
(CHCI3)/cm- 1 1658, 1633, 1589, 1490, 1387, 1172 and 752; SH (400 MHz; CDCI3) 1.38 
(3H, d, J 5.7 Hz, CHCH3), 2.05 (2H, m, N(CH2)), 2.25 (lH, m, N(CH)), 2.60 (3H, s, 
CH3), 3.93 (3H, s, NCH3), 5.80 (lH, s, H6), 7.37 (!H, s) and 8.60 (lH, s); OC (lOO MHz; 
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CDC(3) IS.11, 19.51,34.50,35.06,36.68,116.34,117.37,120.43, 120.51, 130.63, 
130.96,147.35, 15S.68, 165.14, 179.25 and 179.49; m/z 313 (M+, > 5%),249 (10),125 
(20), 98 (l0), 84 (50), 70 (25), 56 (30), 41 (lOO) and 27 (35). 
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7.5. Chapter 4 experimental 
OBn 
MeO~CHO 
V 
2-Benzyloxy-3-methoxybenzaldehyde [207J 
Potassium hydroxide (16 g, 286 mmol) was added to stirred solution of ortho-vanillin [206] 
(40 g, 264 mmol) in ethanol (240 ml). The solution was stirred for 5 min then benzyl chloride 
(36.04 g 286 mmol) added. The mixture was heated under reflux for 14 h. Water (200 ml) 
was added and the mixture extracted with diethyl ether (3 x 300 ml), the extracts were 
combined, washed with water (2 x lOO ml), potassium hydroxide (5 x 200 ml, of a 2M 
solution), water (2 x 200 ml), brine (200 m!), dried (MgS04) and evaporated under reduced 
pressure. Trituration (hex an e) gave the title compound [207] (47 g, 74%) as an off white 
solid; m.p. 44-46°C; (Found M+, 242.0950. CISHI403 requires M, 242.0943); vmax 
(nujol)/cm- I 1694,1480, 1367 and 1062; OH (250 MHz; CDCI3) 3.95 (3H, s, OCR3), 5.17 
(2H, s, OCR2Ar), 7.13 (2H, m), 7.35 (6H, m) and 10.23 (IH, s, CRO); OC (62.5 MHz; 
CDCI3) 56.05 (OCH3), 76.27 (OCH2Ar), 118.01, 119.02, 124.17, 128.44, 128.52, 128.58, 
130.28, 136.35, 151.29, 153.01 and 190.03; m/z 242 (M+, 7%), 213 (5), 150 (10), 91 (lOO) 
and 65 (10). 
OBn 
MeO 
Methyl 2-azido-3-(2-benzyloxy-3-methoxyphenyl)propenoate [208J 
Sodium metal (6.07 g, 261 mmol) was added to methanol (144 ml), under a nitrogen 
atmosphere. The mixture was cooled to -15°C then a solution of methyl azidoacetate [205] 
(30.4 g, 201 mmo!), 2-benzyloxy-3-methoxybenzaldehyde [207] (15.98 g, 65.52 mmol) in 
methanol (12 ml) was added dropwise. The mixture was stirred at -15°C for 3 h then at 4°C for 
14 h. Water (2 x 300 ml) was cautiously added and the mixture was extracted with ethyl 
acetate (500 ml). The extracts were washed with water (2 x 300 ml) and the aqueous layers 
combined and extracted with ethyl acetate (200 m!). The extracts were combined, washed with 
brine (300 ml), dried (MgS04) and evaporated under reduced pressure. The crude yellow 
solid was recrystallised (diethyl ether) to give (16.2 g) and the mother liquers were purified by 
flash column chromatography (light petroleum: diethyl ether elution) to give (1.4 g), total yield 
of the title compound [208] (17.6 g, 82%), as a yellow solid; m.p. 69-71 cC; vmax (nujol)/cm-
12114,1709 and 1452; OH (250 MHz; CDCI3) 3.89 (3H, s, C02CR3), 3.93 (3H, s, OCR3), 
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5.07 (2H, s, OCH2Ar), 6.93 (lH, d, J 8.19 HZ),7.09 (lH, t, J 8.12 Hz), 7.30 (lH, s), 7.35 
(5H, m) and 7.79 (IH, d, 17.82); OC (62.5 MHz; CDCI3); 52.78 (C02CH3), 55.83 (OCH3), 
75.68 (OCH2Ar), 113.45, 119.58, 121.99, 122.03, 123.93, 125.53, 127.81, 128.14, 
128.75, 137.03, 146.69, 152.62 and 162.03; m/z 311 (M+ -N2, 10%),220 (20), 189 (10), 
91 (100) and 65 (IS). 
OBn 
MeO 
~ 
N 
H 
Methyl 4-benzyloxy-5-methoxyindole-2-carboxylate [154J 
A solution of methyl-2-azido-3-(2-benzyloxy-3-methoxyphenyl)propenoate [208] (5 g, 15.4 
mmol) in xylene (160 m\) was aded dropwise to refluxing xylene (500 ml). After the addition 
was complete the mixture was refluxed for I h. The mixture was evaporated under reduced 
pressure to give an orange solid. Recrystallisation (diethyl ether) gave (1.54 g). Flash column 
chromatography of the mother liquers (light petroleum: diethyl ether elution) gave (1.56 g). 
Total yield of the title compound [154] (3.1 g, 66% yield) as a pale yellow solid; m.p. 117-
120°C (Found M+, 311.1157. CI8H17N04 requires M, 311.1157); vmax (nujo\)/cm- I 1697, 
1453 and 1258; OH (250 MHz; CDCI3) 3.87 (3H, s, OCH3), 3.91 (3H, s, C02CH3), 5.25 
(2H, s, OCH2Ar), 7.02 (lH, s), 7.35 (6H, m), 7.48 (2H, m) and 9.25 (lH, s, NH); OC (62.5 
MHz; CDCI3) 51.96 (C02CH3), 58.47 (OCH3), 75.03 (OCH2Ar), 106.16, 107.13, 116.36, 
123.15, 127.31, 127.85, 128.01, 128.33,128.74,134.16,137.90, 145.14 and 162.45; m/z 
311 (M+, 40%), 220 (100), 188 (90), 91 (85) and 63 (20). 
OS~Ph 
MeO~CHO 
U 
2-BenzenesuIJonyloxy-3-methoxybenzaldehyde [224J 
Benzenesulfonyl chloride (80 g, 450 mmol), ortho-vanillin [206] (68 g, 450 mmol) and 
sodium hydroxide (15% solution, 200 ml) were shaken at rt for I h. The resultant yellow solid 
was collected by filtration and washed with water (200 m\), satutated sodium hydrogen 
carbonate (2 x 200 ml), water (200 ml). Recrystallisation (methanol) gave the title compound 
[224] (95.4 g, 72%) as a pale yellow solid; m.p. 122-123°C; (Found: C, 57.51; H, 4.0. 
CI4H120SS requires C, 57.53; H, 4.14%); oH (250 MHz; CDCI3) 3.53 (3H, s, OCH3), 7.09 
(lH, d, J 8.15 Hz), 7.29 (lH, t, J 7.9 Hz), 7.52 (3H, m), 7.70 (lH, d, J 7.5 Hz), 7.98 (lH, 
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d, J 7.5 Hz) and 10.15 (lH, s, CHO); mlz 230 (M+, 30%),151 (100), 108 (32), 93 (30), 65 
(30),52 (33) and 41 (20). 
OSO,zPh 
MeO~CHO 
U N02 
2-Benzenesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [225] 
2-Benzenesulfonyloxy-3-methoxybenzaldehyde [224] (52.6 g, 180 mmol) was added portion 
wise to fuming nitric acid (526 ml) maintaining the temperature between 5-1 5°C. The mixture 
was stirred for a further 10 min, then poured onto ice (approx. 3 kg). The precipitate was 
collected by filtration and recrystallised (methanol) to give the title compound [225] (20 g, 
33%) as a pale yellow solid; m.p. 143-144°C; (Found M+ 337.0237. C'4H"N07S requires 
M, 337.0259); /lH (250 MHz; CDCI3) 3.53 (3H, s, OCH3), 7.09 OH, d, J 6.7 Hz), 7.34 
(lH, dd, J 8.3 7.1 Hz), 7.52 (lH, dd, J 7.1 1.6 Hz), 7.56 OH, d, J 6.7 Hz), 7.69 OH, m), 
7.90 (2H, dd, J 8.3 1.6 Hz) and 10.16 (IH, s, CHO); /lC (62.5 MHz; CDCI3) 55.78, 117.84, 
119.41,127.92,128.50, 128.97, 132.46, 134.39, 135.27, 140.92, 152.41 and 187.21; m/z 
337 (M+, 10%),294 (10), 179 (10),141 (40), 123 (25), 77 (lOO) and 51 (40). 
4-Nitrobenzylalcohol [226] 
2-Benzyloxy-3-methoxybezaldehyde [207] (5 g, 20.6 mmol) was added to fuming nitric acid 
(50 ml) maintaining the temperature between 5-1 5°C. The reaction mixture was stirred at 10°C 
for 10 min then ice water (150 ml) was aded. The mixture was extracted with diethyl ether (3 x 
100 ml) and the extracts were combined washed with sodium hydrogen carbonate solution (2 x 
100 ml), brine (2 x 100 ml), dried (MgS04) and evaporated under reduced pressure. Flash 
column chromatography (light petroleum: diethyl ether elution) gave the title compound [226] 
(1.92 g, 60%) as a yellow solid; m.p. 94-96°C (Lit., 92-94°C); /lH (250 MHz; CDCI3) 5.53 
(2H, s, OCH2Ph), 7.57 (2H, d, J 6.8 Hz) and 8.26 (2H, d, J 6.8 Hz); IiC (62.5 Hz; CDCI3) 
72.75, 123.58, 129.19, 134.68 and 139.54. 
OH 
Meo~ 
U N02 
2-Methoxy-S-nitrophenol [229] 
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2-Benzenesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [225] (1.86 g, 5.23 mmol), ethanol 
(50 m!) and potassium hydroxide (15% solution, 30 ml) were heated under reflux for 30 min. 
The reaction mixture was cooled and then made acidic by the addition of hydrochloric acid 
(2M). The mixture was extracted with diethyl ether (3 x 50 ml) the extracts were combined, 
washed with brine (2 x 50 ml), dried (MgS04) and evaporated under reduced pressure to give 
the title compound [229] (0.992 g, 96%) as a pale brown solid; m.p. 107-108°C (lit., 104-
106°C); OH (250 MHz; CDCI3) 4.02 (3H, s, OCH3), 5,53 (lH, br, OH), 6.92 (lH, d, J 8.9 
Hz), 7.77 (lH, d, J 2.7 Hz) and 7.85 (lH, dd, J 8.72.7 Hz); oC (62.5 MHz; CDCI3) 56.44, 
109.51,110.0,116.86,117.97,145.43 and 151.84. 
OBn 
Meo~ 
V N02 
3-Benzyloxy-4-methoxynitrobenzene [230] 
2-Methoxy-5-nitrophenol [229] (0.823 g, 4.2 mmo!), ethanol (20 ml) and potassium 
hydroxide (0.25 g, 4.52 mmol) were stirred at rt for 10 min. Benzyl chloride (0.773 g, 4.52 
mmol) was added and the mixture stirred at reflux for 16 h. The reaction mixture was cooled 
and water (50 ml) was added. The mixture was extracted with diethyl ether (3 x 50 ml), the 
extracts were combined, washed with potassium hydroxide (2M, 4 x 50 ml), brine (2 x 50 ml), 
dried (MgS04) and evaporated under reduced pressure. Flash column chromatography 
(diethyl ether elution) gave the title compound [230] (1.15 g, 96%) as a pale yellow solid; 
m.p. 65-67°C; (Found M+, 259.0830. CI4H13N04 requires M, 259.0844); OH (250 MHz; 
CDCI3) 3.97 (3H, s, OCH3), 5.20 (2H, s, CH2Ar), 6.94 (lH, d, J 8.9 Hz), 7.41 (5H, m), 
7.80 (lH, d, J 2.6 Hz) and 7.93 (lH, dd, J 8.9 2.6 Hz); OC (62.5 MHz; CDCI3) 56.37, 
7l.l5, 108.49, 110.09, 118.04, 125.06, 127.49, 128.30, 128.68, 136.06, 142.71 and 
155.29; m/z 259 (M+, 5%), 91 (lOO) and 65 (10). 
OS0.!Ph 
MeO ::::::". C02Me 
(E)-Methyl 3-(2-benzenesuIJonyloxy-3-methoxy-6-nitrophenyl)prop-2-enoate 
[231] 
Sodium hydride (42.7 mg, 1.78 mmol) was added to dry THF (5 ml) under a nitrogen 
atmosphere and the mixture was left to stir for 5 min. Methyl diethyl phosphonoacetate (374 
mg, 1.78 mmol) was added dropwise and the mixture was stirred for 1 h. A solution of 2-
benzenesulfony10xy-3-methoxy-6-nitrobenzaldehyde [225] (300 mg, 0.89 mmol) in THF (15 
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ml) was added dropwise and the mixture left to stir at rt for 2 h. Ammonium chloride solution 
(10 ml) was added and the mixture extracted with ethyl acetate (3 x 20 ml), the extracts were 
combined and washed with brine (4 x 20 ml), dried (MgS04) and evaporated under reduced 
pressure to give a brown solid. Flash column chromatography (light petroleum: diethyl ether 
elution) gave the title compound [231] (297 mg, 85 %) as an off white solid; BH (250 MHz; 
CDCI3) 3.71 (3H, s, OCH3), 3,86 (3H, s, C02CH3), 6.0 (IH, d, J 16.1 Hz), 7.02 (lH, d, J 
9.3 Hz), 7.46 (lH, d, J 16.2 Hz), 7.53 (IH, d, J 7.9 Hz), 7.58 (IH, m), 7.68 (IH, m), 7.88 
(lH, d, J 7.3 Hz) and 8.10 (IH, d, J 9.3 Hz); BC (62.5 MHz; CDCI3) 55.53, 60.27, 115.70, 
129.27, 129.35, 131.79, 132.01, 132.15, 132.93, 133.11, 138.20, 139.79, 144.82, 161.22 
and 169.79. 
(E)-Ethyl 3-(2-benzenesulfonyloxy-3-methoxy-6-nitrophenyl)prop-2-enoate 
[232] 
Sodium hydride (43.6 mg, 1.80 mmol) was added to dry THF (5 ml) under a nitrogen 
atmosphere and the mixture was left to stir for 5 min. Triethyl phosphonoacetate (407 mg, 1.8 
mmol) was added dropwise, the mixture was stirred for I h. A solution of 2-
benzenesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [225] (200 mg, 0.59 mmol) in THF (10 
ml) was added dropwise and the mixture left to stir at rt for 2 h. Ammonium chloride solution 
(10 ml) was added and the mixture extracted with ethyl acetate (3 x 20 ml), the extracts were 
combined and washed with brine (4 x 20 ml), dried (MgS04) and evaporated under reduced 
pressure to give a brown solid. Recrystallisation (diethyl ether) gave the title compound [232] 
(297 mg, 85%) as a colourless solid; m.p. 104-106°C; (Found M+, 407.6678. CI8H 17N08S 
requires M, 407.6675); BH (250 MHz; CDCI3) 1.20 (3H, t, J 7.3 Hz, OCH2CH3), 3.91 (3H, 
s, OCH3), 4.18 (2H, q, J 7.7 Hz, OCH2CH3), 5.98 (IH, d, J 16.3 Hz), 7.0 (IH, d, J 9.3 
Hz), 7.42 (lH, d, J 16.3 Hz), 7.55 (2H, m), 7.58 (lH, m), 7.86 (lH, m) and 8.11 (lH, d, J 
9.3 Hz); m/z 407 (M+, 5%), 361 (25),250 (20),177 (30),141 (30),77 (lOO), 51 (30) and 29 
(80). 
OS0.1Ph 
Mea 
Methyl 4-benzenesulfonyloxy-S-methoxyindole-2-carboxylate [233] 
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Methyl 3-(2-benzenesulfonyloxy-3-methoxy-6-nitrophenyl)propenoate [231] (185 mg, 0.47 
mmol) and triethyl phosphite (383 mg, 2.3 mmol, 0.4 ml) were heated in an oil bath at l70°C 
for 3 h. The reaction mixture was cooled and evaporated under reduced pressure to give a 
viscous brown oil. Flash column chromatography (light petroleum: diethyl ether elution) gave 
the title compound [233] (112 mg, 66%) as a pale browm solid; m.p. 169-l70°C; (Found: C, 
56.4; H, 3.92; N, 3.88. Cl7HI5N06S requires C, 56.50; H, 4.18; 3.88%); oH (250 MHz; 
CDCI3) 3.55 (3H, s, OCH3), 3.91 (3H, s, C02CH3), 6.97 (lH, d, J 8.9 Hz), 7.02 (lH, d, J 
9.5 Hz), 7.31 (lH, d, J 7.9 Hz), 7.50 (2H, m), 7.68 (lH, m), 7.95 (lH, d, J 7.3 Hz) and 
10.34 (lH, s, NH); OC (62.5 MHz; CDCI3) 51.84, 56.94, 105.53, 111.52, 113.41, 128.36, 
128.64,129.13,129.60,129.87,129.93,133.84,136.44, 145.61 and 163.05; m/z 361 (M+, 
10%),220 (100),188 (75),132 (75),132 (150, 77 (40) and 51 (30); (Found M+, 361.0608. 
Cl7HI5N06S requires M, 361.0620). 
OSO:iPh 
MeO 
Ethyl 4-benzenesulfonylloxy-5-methoxyindole-2-carboxylate [234J 
Ethyl 3-(2-benzenesulfonyloxy-3-methoxy-6-nitrophenyl)propenoate [232] (96.6 mg, 0.24 
mmol) and triethyl phosphite (196 mg, 1.18 mmol, 0.2 ml) were heated in an oil bath at l70°C 
for 3 h. The reaction mixture was cooled and evaporated under reduced pressure to give a 
viscous brown oil. Flash column chromatography (light petroleum: diethylether elution) gave 
the title compound [234] (69.4 mg, 79%) as a pale brown solid; m.p. 127-129°C; (Found C, 
57.28; H,4.48; N, 3.72. CI8Hl7N08S requires C, 57.59; H, 4.56; N, 3.73%); OH (250 
MHz; CDCI3) 1.32 (3H, t, J 7.2 Hz, OCH2CH3), 3.44 (3H, s, OCH3), 4.29 (2H, q, J 7.2 
Hz, OCH2CH3), 6.89 (lH, d, J 8.3 Hz), 7.18 (lH, dd, J 8.7 1.2 Hz), 7.43 (2H, m), 7.55 
(lH, m), 7.86 (2H, m) and 9.25 (lH, br, NH); OC (62.5 MHz; CDCI3) 14.26,57.02,61.19, 
105.65, 111.30, 113.50, 121.40, 123.60, 128.53, 128.68, 129.0, 133.26, 133.82, 136.72, 
145.67 and 161.80; m/z 375 (M+, 10%),234 (100), 188 (85), 132 (20),77 (50), 64 (27) and 
51 (30); (Found M+, 375.0770. C18HI7N06S requires M, 375.0776). 
OH 
MeO 
(E )-M ethyl 3-(2-hydroxy-3-methoxy-6-nitrophenyl)prop-2-enoate [235 J 
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Sodium hydride (0.255 g, 10.6 mmol) was added to dry THF (10 ml) under a nitrogen 
atmosphere and the mixture was left to stir for 5 min. Methyl diethyl phosphonoacetate (2.24 
g, 10.6 mmol) was added dropwise and the mixture was stirred for I h, then added to a 
solution of 2-benzenesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [225] (3.27 g, 9.7 mmol) 
in THF (30 ml) and the mixture left to stir at rt for 2 h. Sodium hydride (0.255 g, 10.6 mmol) 
was added and the mixture left to stir for a futher 2 h. Ammonium chloride solution (30 ml) 
was added and the mixture extracted with ethyl acetate (3 x 50 ml), the extracts were combined 
and washed with brine (4 x 50 ml), dried (MgS04) and evaporated under reduced pressure to 
give a yellow solid. Recrystallisation (ethanol) gave the title compound [235] (1.42 g, 58 %) 
as a pale yellow solid; m.p. 123-125°C; vmax (CHCI3)/cm- 1 3400(br) and 1721; OH (250 
MHz; CDCI3) 3.75 (3H, s, C02CH3), 3.96 (3H, s, OCH3), 6.38 (IH, s, OH), 6.66 (IH, d, 
116.2 Hz), 6.81 (lH, d, 1 8.9 Hz), 7.55 (!H, d, 1 8.9 Hz) and 7.73 (!H, d, 1 16.2 Hz); Oc 
(62.5 MHz; CD30D: CDCI3) 51.39, 55.96,109.14,116.04,116.70,124.02,124.86, 
135.96, 142.78, 151.26 and 167.82; m/z 253 (M+, 10%),221 (20),207 (100), 176 (30), 77 
(40),51 (55) and 29 (40). 
OBn 
MeO 
(E)-Methyl 3-(2-benzyloxy-3-metllOxy-6-nitrophenyl)prop-2-enoate [236J 
Methyl 3-(2-hydroxy-3-methoxy-6-nitrophenyl)prop-2-enoate [235] (5.06 g, 20.01 mmol), 
potassium carbonate (3.04 g, 22.01 mmol), benzyl bromide (3.48 g, 20.01 mmol) and THF 
(lOOml) were heated under reflux for 14 h. The reaction mixture was cooled and ammonium 
chloride solution (100 ml) added. The mixture was extracted with diethyl ether (3 x 100 m!), 
the extracts were combined and washed with saturated sodium hydrogen carbonate (3 x 100 
ml), brine (2 x 100 ml), dried (MgS04) and evaporated under reduced pressure to give a 
brown oil. Tritutation (light petroleum) gave an orange solid which was recrystallised (diethyl 
ether) to give the title compound [236] (4.66 g, 68 %) as a pale yellow solid; m.p. 115-116°C; 
(Found: C, 63.1; H, 4.93; N, 4.02. CI8H17N06 requires C, 63.0; H, 5.0; N, 4.1%); vmax 
(CHC1))/cm- 1 1701; OH (250 MHz; CDCI3) 3.79 (3H, s, C02CH3), 3.99 (3H, s, OCH3), 
4.94 (2H, s, OCH2), 6.34 (lH, d, 116.1 Hz), 6.97 (lH, d, 19.0 Hz), 7.34 (5H, m), 7.71 
(lH, d, 1 16.2 Hz) and 7.88 (lH, d, 19.2 Hz); Oc (62.5 MHz; CDCI3) 51.73,56.31,73.82, 
110.90, 121.54, 121.90, 125.76, 126.44, 128.19, 128.30, 128.38, 128.52, 136.02, 141.86, 
157.34 and 166.45; m/z 343 (M+, 3%),266 (5), 91 (100) and 65 (10). 
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OBn 
MeO 
N 
H 
Methyl 4-benzyloxy-S-methoxyindole-2-carboxylate [154J 
Methyl 3-(2-benzyloxy-3-methoxy-6-nitrophenyl)propenoate [236] (4.4 g, 12.8 mmol) and 
triethyl phosphite (10.68 g, 64.1 mmol, 11.15 ml) were heated in an oil bath at 170°C for 3 h. 
The reaction mixture was cooled and evaporated under reduced pressure to give a viscous 
brown oil. Flash column chromatography (light petroleum: diethyl ether elution), gave the title 
compound [154] (2.2g, 54%) as a pale yellow solid, with analytical data identical to that 
previousl y prepared. 
OSo.Me 
MeO~CHO 
U 
2-Methanesulfonyloxy-3-methoxybenzaldehyde [237J 
Methanesulfonyl chloride (17.9 g, 156 mmol, 12.1 ml) was added to a solution of ortho-
vanillin [206] (20 g, 131.4 mmol) in dichloromethane (300 ml) at O°e. The mixture was left 
to stir for 5 min then triethylamine (33.4 g, 330 mmol, 46 ml) was added dropwise and the 
temperature maintained between 0-5°e. The mixture was stirred for a futher 30 min at rt and 
the precipitate was removed by filtration. The filtrate was washed with water (200 ml), 
hydrochloric acid (3 x 200 ml, of a IM solution), saturated sodium hydrogen carbonate (2 x 
200 ml), brine (200 ml), dried (MgS04) and evaporated under reduced pressure to give the title 
compound [237] (28.65 g, 95 %) as an off white solid; m.p. 79-80°C; (Found: C, 47.16; H, 
4.26. C9HlO05S requires C, 46.95; H, 4.38%); vmax (CHCI3)1cm-1 1701; liH (250 MHz; 
CDCI3) 3.36 (3H, s, S02CR3), 3.95 (3H, s, OCR3), 7.28 (lH, dd, J 9.2, 1.7 Hz), 7.37 
(lH, t, J 9.3 Hz), 7.51 (lH, dd, J 9.2, 1.6 Hz) and 10.35 (lH, s, CRO); lie (62.5 MHz; 
CDCI3) 39.29, 56.37, 116.29, 120.09, 127.99, 131.07, 141.09, 152.02 and 188.34; m/z 
230 (M+, 30%), 151 (lOO), 108 (32), 93 (30), 65 (30), 52 (33) and 41 (20). 
OSo.Me 
MeO~CHO 
V N02 
2-M ethanesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [238 J 
170 
2-Methanesulfonyloxy-3-methoxybenzaldehyde [237] (25 g, 107.5 mmol) was added portion 
wise to fuming nitric acid (675 ml) maintaining the temperature between 5-15°C. The mixture 
was stirred for a further 10 min, then poured onto ice (approx. 2 kg) and the precipitate was 
collected by filtration and recrystallised (methanol) to give the title compound [238] (14.82 g, 
50 %) as a pale yellow solid; m.p. 143-144°C; (Found: C, 39.36; H, 3.02; N, 5.02. 
C9H9N07S requires C, 39.28; H, 3.3; N, 5.09%); Vmax (CHCI3)/cm-1 3020, 1719, 1582, 
1525, 1378, 1289, 1168 and 928; OH (250 MHz; CDCI3) 3.34 (3H, s, S02CH3), 4.06 (3H, 
s, OCH3), 7.21 (lH, d, J 9.2 Hz), 8.2 (lH, d, J 8.1 Hz) and 10.28 (lH, s, CHO); Oc (62.9 
MHz; CDCI3) 44.05, 62.11,119.54,130.10,136.18,140.93,141.34,163.28 and 192.04; 
mlz 275 (M+, 10%),196 (20),123 (100),79 (70), 51 (80) and 30 (50). 
OH 
MeO 
(E)-Methyl 3-(2 -hydroxy-3-methoxy-6-nitrophenyl)prop-2-enoate [235 J 
Sodium hydride (0.645 g, 27.27 mmo!) was added to dry THF (40 ml) under a nitrogen 
atmosphere and the mixture was left to stir for 5 min. Methyl diethyl phosphonoacetate (5.73 
g, 27.27 mmol) was added dropwise, the mixture was stirred for 1 h then added to a solution 
of 2-methanesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [238] (5 g, 18.18 mmol) in THF 
(70 m!), and the mixture was left to stir at rt for 2 h. Sodium hydride (0.654 g, 27.27 mmol) 
was added and the mixture left to stir for a futher 2 h. Ammonium chloride (50 ml) was added 
and the mixture extracted with ethyl acetate (3 x lOO ml), the extracts were combined and 
washed with brine (4 x 100 ml), dried (MgS04) and evaporated under reduced pressure to give 
a yellow solid. Recrystallisation (ethanol) gave the title compound [235] (3.34 g, 73%) as a 
pale yellow solid, with analytical data identical to that previously prepared. 
N2 
Et~C)( PO(OEtl2 
Triethyl diazophosphonoacetate [240J 
Triethylphosphonoacetate [242] (2.45 g, 10.95 mmol), caesium carbonate (3.59 g, 10.95 
mmol) and THF (50 ml) were stirred under a nitrogen atmosphere for 30 min. A solution of 
para-toluenesulfonyl azide (2.16 g, 10.9 mmol) in THF (20 ml) was added and the mixture 
stirred under a nitrogen atmosphere for 16 h. The mixture was filtered through a plug of silica 
(diethyl ether elution) to give the title compound [240] (2.22 g, 81%) as a colourless oil; 
vmax(film)/cm- I 2986,2128, 1689, 1437 and 745; OH (250 MHz; CDCI3) 1.23 (3H, t, J 
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7Hz, C02CH2CH3), 1.29 (6H, t, J 6.8 Hz, P(OCH2CH3)2), 4.15 (4H, dq, J 6.8 1.2 Hz, 
P(OCH2CH3)2) and 4.18 (2H, q, J 7 Hz, C02CH2CH3). 
Me 
I 
I N Me OC",.. ... N, ~ NH2 
2-Aminophenyl-N,N-dimethylhydrazone [243 J 
ortho-Nitrobenzaldehyde [221] (I g, 6.6 mmol), N,N-dimethylhydrazine (4.16 g, 69.3 
mmol) and methanol (20 ml) were stirred under reflux for I h. Decolourising charcoal (0.165 
g) and iron(III)chloride (0.022 g, 0.088 mmol) were added and the mixture was left to stir at 
reflux for 16 h. The reaction mixture was cooled, filtered over a bed of celite and evaporated 
under reduced pressure. Flash column chromatography (light petroleum: dichloromethane 
elution) gave the title compound [243] (0.57 g, 50%) as a pale yellow oil; (Found M+, 
163.1101. C9HI3N3 requires M, 163.1109); vmax(film)cm- 1 3456,3313, 1610, 1593, 
1469,1442,1391,1028 and 748; OH (250 MHz; CDCI3) 2.92 (6H, s, N(CH3)2), 5.81 (2H, 
br, NH2), 6.69 (lH, d, J 8.3 Hz), 6.71 (lH, d, J 8.3 Hz), 7.04 (2H, m) and 7.48 (IH, s); 
mJz 163 (M+, 100%), 133 (20), 118 (75), 104 (20), 91 (30),65 (20), 58 (25) and 43 (55). 
Me 
I 
I N Me OC",.. ,.N, ~ ~I PO{OEtl2 
C02Et 
Triethyl (2-aminophenyl-N,N-dimethylhydrazone)-phosphonoacetate [244J 
2-Aminophenyl-N,N-dimethylhydrazone [243] (I g, 5.7 mmol), triethyl 
diazophosphonoacetate [240] (0.715 g, 2.85 mmol), toluene (20 ml) and rhodium(II)acetate 
(0.025 g, 0.057 mmol, 2 mol%) were stirred a reflux for 16 h. The reaction mixture was 
cooled and evaporated under reduced pressure. Flash column chromatography 
(dichloromethane : diethyl ether elution) gave the title compound [244] (0.67 g, 63%) as a 
brown oil; (Found M+, 385.1772. C17H28N30SP requires M, 385.1766); vmax(film)cm-1 
2985,2937, 1709, 1368, 1282, 1022 and 749; OH (250 MHz; CDCI3) 1.26 (3H, t, J 7.2 Hz, 
C02CH2CH3), 1.31 (6H, t, J 8.2 Hz, P(OCH2CH3)2), 2.97 (6H, s, N(CH3)2), 4.09 (4H, 
m, P(OCH2CH3)2), 4.17 (2H, q, J 7.2 Hz, C02CH2CH3), 6.49 (lH, d, J 8.2 Hz), 6.68 
(lH, t, J 8.2 Hz), 7.03 (lH, m), 7.09 (lH, d, 8.2 Hz) and 7.51 (lH, s); OC (62.5 MHz; 
CDCI3) 14.06 (C02CH2CH3), 16.38 (d, J 5.7 Hz, P(OCH2CH3)2), 42.85 (N(CH3)2), 
55.80 (d, J 144 Hz, P(OCH2CH3)2), 61.91 (C02CH2CH3), 63.54 (NHC), 110.49, 116.77, 
172 
119.61, 128.20, 130.96, 138.38 and 168.93; m/z 385 (M+, 30%),326 (30), 203 (40),174 
(30), 144 (45), 131 (50),59 (75) and 28 (lOO). 
OS~Ph 
MeO ~ N02 
(E)- (2 -B e nze ne s ulfo nyloxy-3 -methoxy-6-nitrophe ny 1)-nitro-2 -eth e ne [249 J 
2-Benzenesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [225] (2 g, 5.9 mmol), nitromethane 
(5 ml, 5.63 g, 92 mmol), ammonium acetate (5 g, 64.8 mmol) and glacial acetic acid (15 ml) 
were heated under reflux for 2h. The reaction mixture was cooled and water (40 ml) was 
added, the mixture was then neutrallized by the addition of sodium hydrogen carbonate, 
CAUTION. The mixture was extracted with ethyl acetate (3 x 50 ml). The extracts were 
combined and washed with brine (2 x 30 ml), dried (MgS04) and evaporated under reduced 
pressure to give a dark brown solid. Flash column chromatography (light petroleum: diethyl 
ether elution) gave the title compound [249] (1.06 g, 47%) as a pale orange solid; m.p. 145-
146°C; (Found: C, 47.24; H, 2.83; N, 7.18. CI5HI2N202S requires C, 47.37; 3.18; N, 
7.37%); OH (250 MHz; CDCI3) 3.89 (3H, s, OCH3), 7.12 (lH, d, J 9.40 Hz), 7.59 (IH, d, J 
8.2 Hz), 7.72 (JH, d, J 8.2 Hz), 7.86 (5H, m) and 8.23 (lH, 9.3 Hz); OC (62.5 MHz; 
CDCI3) 56.76, 112.60, 123.65, 125.72, 127.76, 128.34, 129.49, 129.80, 134.81, 136.72, 
140.21, 141.60 and 157.74; mlz 380 (M+, 5%), 163 (10), 141 (50),77 (lOO), 51 (22) and 30 
(14); (Found M+, 380.0309. C15H12N202S reqires M, 380.0314). 
4-Benzenesulfonyloxy-5-methoxyindole [250J 
Iron powder (4.34 g, 77.7 mmol) was added to a mixture of (E)-(2-benzenesulfonyloxy-3-
methoxy-6-nitrophenyl)-nitro-2-ethene [249] (2.17 g, 5.72 mmol), ethanol (50 ml) and glacial 
acetic acid (50 ml) over a 15 min period. The mixture was then heated under reflux for 1 h. 
Water (100 ml) was added and the mixture was extracted with diethyl ether (3 x lOO ml), the 
extracts were combined and washed with a saturated solution of sodium hydrogen carbonate (5 
x 50 ml), brine (100 ml), dried (MgS04) and evaporated under reduced pressure to give a 
brown solid. Flash column chromatography (light petroleum: diethyl ether elution) gave the 
title compound [250] (348 mg, 20%) as a pale yellow solid; m.p. 136°C; (Found: C, 59.79; 
H, 4.33; N, 4.55. CI5H13N03S requires C, 59.4; H, 4.32; N, 4.62%); OH (250 MHz; 
CDCI3) 3.43 (3H, s, OCH3), 6.15 (lH, d, J 3.3 Hz), 6.69 (lH, d, J 8.8 Hz), 7.01 (lH, d, J 
173 
3.2 Hz), 7.14 (2H, m), 7.42 (2H, m), 7.81 (2H, m) and 8.15 (lH, br, NH); liC (62.5 MHz; 
CDCI3) 56.94, 98.79, 109.15, 110.29, 116.03, 123.92, 126.24, 128.25, 128.57, 132.40, 
133.68, 137.08 and 145.12; m/z 303 (M+, 20%), 162 (100), 134 (30), 77 (50),44 (100), 28 
(50) and 20 (50); (Found M+, 303.0528. CI5H13N03S requires M, 303.0565). 
Me0'(x)°SC>.2Ph 
I " ::::... N 
H 
4-Benzenesulfonyloxy-5-methoxyindole [250J 
(E)-(2-Benzenesulfonyloxy-3-methoxy-6-nitrophenyl)-nitro-2-ethene [249] (0.178 g, 0.47 
mmol), silica gel (4.70 g), iron powder (0.39 mg, 7 mmol), glacial acetic acid (3 ml) and 
toluene (5 ml) were heated at reflux under a nitrogen atmosphere for I h. The reaction mixture 
was cooled and water (10 ml) added, the mixture was extracted with diethyl ether (3 x 20 ml), 
the extracts were combined and washed with a saturated solution of sodium hydrogen 
carbonate (5 x IS ml), brine (IS ml), dried (MgS04) and evaporated under reduced pressure. 
Flash column chromatography (light petroleum: diethyl eyther elution) gave the title compound 
[250] (0.13 g, 92%) as a pale yellow solid, with identical data to that prevoiusly prepared. 
PhSC>.20 
MeO 
OH 
(2 - B e nze ne s ulfo n y loxy-3 -m e th oxy-6-nitro ph en y I )-1-hydroxy-2 -nitro ethane 
[251] 
2-Benzenesulfonyloxy-3-methoxy-6-nitrobenzaldehyde [225] (3 g, 8.9 mmol), Potassium 
fluoride (0.240 g, 2.54 mmol) and propan-2-01 (-12 ml) were stirred at rt for 48 h. Water (50 
m!) was added and the mixture extracted with dichloromethane (3 x 70 ml), the extracts were 
combined and washed with brine (50 ml), dried (MgS04) and evaporated under reduced 
pressure to give a pale yellow glass. Recrystallisation (methanol) gave the title compound 
[251] (2.52 g, 71 %) as a pale yellow solid; m.p. 131-133°C; vmax(CHCI3)!cm- 1 1606, 
1582, 1558, 1533, 1380, 1214 and 759; liH (250 MHz; CDCI3) 3.47 (3H, s, OCH3), 4.78 
(lH, dd, J 14.3 2.5 Hz), 5.23 (lH, dd, J 14.4 9.6 Hz), 6.03 (lH, m), 6.98 (lH, d., J 9.1 
Hz), 7.63 (3H, m), 7.76 (2H, m) and 8.04 (lH, d, 9.1 Hz), hydroxyl OH unobserved. 
174 
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OS0.!Ph 
MeO :::::"... N02 
(E)- (2 -B e nze nes u Ifo ny loxy-3 -methoxy-6-nitro ph e n y I )-nitro-2 -ethe ne [249 J 
Methanesulfonyl chloride (0.68 g, 5.97 mmol) was added dropwise to a solution of (2-
benzenesulfonyloxy-3-methoxy-6-nitrophenyl)-I-hydroxy-2-nitroethane [251] (2 g, 5.02 
mmol) in dichloromethane (40 m!) at O°e. The mixture was stirred at O°C for 5 min then 
triethylamine (1.52 g, 15.02 mmol) was added dropwise and the mixture left to stir for 30 min. 
Water (40 ml) was added and the mixture was extracted with dichloromethane (3 x 50 ml), the 
extracts were combined and washed with brine (50 ml), dried (MgS04) and evaporated under 
reduced pressure to give a brown solid. Recrystallisation (ethanol) gave the title compound 
[249] (1.12 g, 59%) as a pale orange solid, with identical data to that prevoiusly prepared. 
MeO 
OH 
Don't know what it is called [252J 
ortho-Vanillin [206] (5 g, 32.8 mmol), methanesulfonyl chloride (4.5 g, 39.8 mmol) and a 
sodium hydroxide (15% solution, 15 ml) were shaken at rt for I h. The reaction mixture was 
filtered and the solid was washed with sodium hydroxide (2M, 50 m!), water (50 ml) then 
recrystallised (methanol) to give the title compound [252] (2.59 g, 34%) as a colourless solid; 
m.p. 147°C; (Found M+, 230.0235. C9HI005S requires M, 230.0249); vmax(CHCI3)1cm-1 
3416 (br), 1585, 1481, 1377, 1216 and 771; OH (250 MHz; CDCI3) 3.46 (lH, dd, J 8.65.0 
Hz), 3.72 (lH, m), 3.89 (3H, s, OCH3), 5.30 (lH, dt, J 5.1 1.2 Hz), 6.95 (lH, dd, 8.1 1.6 
Hz), 7.13 (lH, dd, J 8.1 1.6 Hz) and 7.27 (lH, dd, 8.2 8.0 Hz), hydroxyl OH unobserved; 
OC (62.5 MHz; CDCI3) 51.79, 55.96, 65.37,112.44,119.40,125.59,126.17,138.27 and 
148.41; m/z 230 (M+, 50%),151 (50), 137 (lOO), 77 (30), 51 (40) and 31 (35). 
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7.6. Chapter 5 experimental 
o 
Indole-3-carboxamide [95J 
A solution of CS! (1.2 g, 8.5 mmol) in acetonitrile (2 ml) was added dropwise to a solution of 
indole [93] (I g, 8.5 mmol), and acetonitrile (IS ml) over a 10 min period at O°c. The mixture 
was wanned to rt and stirred for I h. A solution of acetone (8 ml) and water (2 ml) was added 
and the mixture was rendered alkaline by the addition of potassium hydroxide (I 0% solution, 
approx. JO ml). The mixture was extracted with ethyl acetate (3 x 20 ml) and the extracts were 
combined and washed with brine (20 ml), dried (MgS04) and evaporated under reduced 
pressure. Recrystallisation (water) gave the title compound [95] (0.815 g, 61%) as a 
colourless solid; m.p. 191-193°C; (Found M+, 160.0631. C9H8N20 requires M, 160.0630); 
Vmax (CHCI3)/cm- 1 3378, 1660, 1608, 1531,1454,1215,1119 and 747; ()H (250 MHz; 
CDCI3 : CD30D) 7.23 (2H, m), 7.49 (IH, m), 7.84 (IH, s, H2) and 7.97 (lH, m), indole 
NH and amide NH2 unobserved; ()C (62.5 MHz; CD30D) 107.21, 115.26, 124.19, 124.55, 
125.93,129.31,132.55,141.91 and 173.91; m/z 160 (M+, 80%) 144 (100),116 (20) and 89 
(20). 
Indole-3-chloTosulfonylanide [94J 
CS! (2.75 g, 19.4 mmol) was added dropwise to a solution of indole [93] (0.57 g, 4.9 mmol) 
in diethyl ether (30 ml) at O°C. The mixture was stirred at O°C for 30 min then at rt for I h. 
The resultant precipitate was filtered to give the title compound [94] (0.994 g, 78%) as a cream 
solid; m.p. 155-157°C; (Found M+, 259.9821. C9H737CIN203S requires M, 259.9836; 
257.9831. C9H735CIN203S requires M, 257.9864); vmax (nujol)/cm- 1 1678, 1459, 1422 
and 1377; ()H (250 MHz; CD30D) 7.21 (2H, m), 7.49 (lH, m), 8.14 (lH, m) and 8.23 (lH, 
m), indole NH and sulfonyl amide NH unobserved; ()C (62.5 MHz; CD30D) 111.55, 112.92, 
120.95,121.49,122.01,122.75, 126.42,130.32 and 171.61; m/z 260 (M+, 5%) 196 (20), 
142 (100), 91 (30), 80 (40) and 36 (80). 
176 
tert-Butyl indole-I-carboxylate [282J 
Indole [93] (S g, 42.S mmol), di-tert-butyl dicarbonate (ll.lS g, SI mmo!), DMAP (SIS mg, 
4.2S mmol) and acetonitrile (I 15 ml) were stirred at rt for I h. Saturated sodium hydrogen 
carbonate solution (SO ml) was added and the mixture stirred for a further 30 min. The mixture 
was extracted with diethyl ether (2 x SO ml) the extracts were combined washed with brine (2 x 
SO ml), dried (MgS04) and evaporated under reduced pressure. Flash column chromatography 
(light petroleum: diethyl ether elution) gave the title compound [282] (8.89 g, 96%) as a 
colourless oil; (Found M+, 217.1094. C13HISN02 requires M, 217.1103); vmax (film)/cm- I 
173S and 122S; liH (2S0 MHz; CDCI3) 1.69 (9H, s, (CH3)3) 6.S7 (lH, m), 7.23 (2H, m), 
7.60 (2H, m) and 8.13 (lH, m); liC (62.S MHz; CDCI3) 28.16 «CH3)3), 84.72 (C(CH3)3), 
107.29, IIS.19, 120.9S, 122.6S, 124.20, 12S.86, 130.85, 13S.12 and ISO.21; mlz 217 (M+, 
10%), 161 (20), 117 (60), S7 (100),41 (40) and 29 (28). 
o 
tert-Butyl 3-carboxamideindole-I-carboxylate [lOOJ 
CSI (7 g, 40.8 mmol) was added dropwise to a solution of tert-Butyl indole-I-carboxylate 
[282] (8.89 g, 40.8 mmol), and acetonitrile (SO ml) over a 10 min period at O°e. The mixture 
was warmed to rt and stirred for I h. A solution of acetone (40 ml) and water (S m!) was 
added and the solution was rendered alkaline by the addition of potassium hydroxide (10% 
solution, approx. 100 ml). The mixture was extracted with ethyl acetate (3 x SO ml) and the 
extracts were combined and washed with brine (SO ml), dried (MgS04) and evaporated under 
reduced pressure. Recrystallisation (dichloromethane) gave the title compound [100] (6.8S g, 
64%) as a colourless solid; m.p. 163-164°C; (Found M+, 260.1180. CI4HI6N203 requires 
M, 260.1161); Vmax (CHCI3)/cm- 1 1740, 1666, 14S0, 121S, IIS3 and 768; liH (2S0 MHz; 
CDCI3) 1.69 (9H, s, (CH3)3), 5.80 (2H, br, NH2), 7.36 (2H, m), 8.07 (lH, d, J 8.2 Hz), 
8.13 (lH, m) and 8.21 (lH, d, J 8.2 Hz); liC (62.S MHz; CDCI3) 31.61 «CH3)3), 88.90 
(C(CH3)3), 118.86, 12S.14, 127.30, 127.S0, 128.84, 131.49, 132.62, 139.09, IS3.71 and 
171.81; mlz 260 (M+, 10%),204 (20),160 (30),144 (30), S7 (100) and41 (30). 
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s 
tert-Butyl 3 -thiocarboxamideilldole-l-carboxylate [101 J 
rert-Butyl 3-carboxamideindole-l-carboxylate [100] (2 g, 7.69 mmol), Lawesson's reagent 
1.99] (1.55 g, 3.84 mmol) and benzene (20 ml) were heated at refl ux for I h. The reaction 
mixture was cooled and evaporated under reduced pressure to give a yellow solid. Flash 
COlll11l11 c.i1nllllatog.ral'hy (tikhl"nllll"lhalll' : diethyl ethn "llIti(lll) I'.av,' th,' 1;1/ .. .. "III/I("lIld 
[101] (UIl) g, 90%) as a yellow solid; m.p. 98-99°C; (Follnd M+, 276.0922. 
l'I.llIlllN~l)2S Icquile" I\\. 2il1.l)'.l.\2): \'IIIa~ \l'IIU.\)',I\\ I I i·I.'., IS')~; Ui!, I!I) ;1\1,1 
755; OH (250 MHz; CDCI3) 1.68 (9H, S, (CH3)3), 7.34 (2H, m), 7.86 (2H, br, NH2), 8.03 
(IH, d, J 8.2 Hz), 8.19 (11-1, d, J 8.2 I-Iz) and 8.25 (11-1, s); oC (62.5 Ml-lz; CDCI3) 28.02, 
85.27, 115.59, 120.41, 121.06, 124.0, 125.25, 125.98, 128.54, 129.70, 135.83 and 159.92; 
IIl/Z 276 (M+, 5%),142 (20), 84 (65), 57 (30),49 (100),41 (20) and 31 (20). 
HN 
tert-Butyl 3-tlliocarboxilllidateilldole-l-carboxylate [283 J 
tat-Butyl 3-thiocarboxamideindole-l-carboxylate [101] (1.2 g, 4.34 mmol), methyl iodide 
(1.86 g, 13.2mmol) and dichloromethane (10 ml) were stirred at rt for 48 h under a nitrogen 
atmosphere. Dichloromethane (30 ml) was adddcd and the mixture was washed with a 
saturated solution of sodium hydrogen carbonate (2 x 20 ml), brine (2 x 20 ml), dried 
(MgS04) and evaporated under reduced pressure to give the title compoulld [283] (0.93 g, . 
74% crude) as yellow solid which was used in the, next step without further purification. 
CARE the compound is extremely SMELLY, the reaction must be carried out in an efficient 
fume cupboard; m.p. 207-208°C; (Found M+, 290.1087. C ISH 18N 202S requires M, 
290.1056); vmax (CHCI3)/cm-1 1741, 1653, 1451, 1215 and 757; 01-1 (250 Ml-lz; CDCI3) 
1.69 (91-1, s, (CH3)3), 2.46 (3H, s, SCH3), 3.50 (I H, br, NH), 7.34 (21-1, m), 8.07 (11-1, s) 
ang .ll.n (21-1, m); oC (62.5 MHz;CDCI) 12.37 (SCH3), 28.28 «CH3)3),84.88 
(C(CH3)3), 112.51, 115.31, 120.0, 121.85, 123.89,125.39,127.41,135 .. 81, 149.38 and 
166.97; IIl/Z 290 (M+, 5%), 142 (lOO), liS (40), 57 (60) and 27 (20). 
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HCI.HN 
tert-Butyl 3-carbamidinylindole-l-carboxylate hydrochloride [284] 
tert-Butyl 3-thiocarboximidateindole-I-carboxylate [283] (1.13 g, 3.9 mmol), ammonium 
chloride (2.17 g, 4.12 mmol) and methanol (8 ml) Were heated under reflux for 3 h. CARE, 
during the reaction methyl mercaptam is liberated and so a potassium permanganate bubbler 
was attached to the reflux condenser. The reaction mixture was cooled and ethyl acetate (lOO 
ml) was added. The mixture was washed with brine (2 x 30 ml), dried (MgS04) and 
evaporated under reduced preSsure to give a pale brown solid. Recrystallisation (ethanol) gave 
the title compound [284] (0.714 g, 62%) as a pale brown solid; m.p. 207-208°C; OH (250 
MHz; CDCI3) 1.61 (9H, s, C(CH3)3), 7.26 (2H, m), 7.47 (lH, m), 8.03 (!H, m), 8.39 (2H, 
br, NH2), 8.78 (lH, s) and 9.31 (lH, br, NH). 
4-Bromo-2-nitrotoluene [286] 
4-Ammino-2-nitrotoluene [285] (25 g, 164 mmol) was added to water (208 ml) and the 
mixture was heated to reflux. Hydrobromic acid (48%, 83 ml) was added and the mixture was 
stirred at reflux for 20 min. The mixture was cooled to O°C and a solution of sodium nitrate 
(11.29 g, 163.5 mmol) in water (57 ml) was added with rapid stirring, such that the 
temperature did not exceed 5°C. The solution was stirred at O°C for a further IS min then it was 
added dropwise to a solution of copper(J)bromide (27.03 g, 188.4 mmol) in hydrobromic acid 
(48%,55.2 ml) and water (145 ml). The resultant thick suspension was stirred at rt for 30 min 
then at refux for 30 min. The mixture was then left to stand at rt for 16 h. The mixture was 
steam distilled to give the title compound [286] (31.1 g, 88%) as a pale yellow solid; m.p. 44-
45°C; (Found M+, 214.9589. C7H6N02Br requires M, 214.9563); vmax (CHCI3)/cm- 1 
1529; OH (250 MHz; CDCI3) 2.56 (3H, s, CH3), 7.25 (lH, d, J 8.2 Hz), 7.63 (lH, dd, J 8.2 
2.1 Hz) and 8.11 (lH, d, J 8.2Hz); OC (62.5 MHz; CDCI3) 19.2, 119.53,127.37,132.45, 
134.04, 135.86 and 159.92; m/z 217 (MH+, 10%) 215 (10), 198 (40), 90 (30), 78 (30), 63 
(60), 39 (30) and 30 (20). 
179 
6-Bromoindole [287J 
~ Br~l 
H 
4-Bromo-2-nitrotoluene [286] (lOg, 46.2 mmol), DMF (90 ml), N,N-dimethylformamide 
dimethyl acetal 9(16.29 g, 137 mmol) and pyrrolidine (3.24 g, 45.6 mmol) were stirred at 
110°C for 3 h. The reaction mixture was cooled and water (200 ml) was added. The mixture 
was extracted with diethyl ether (3 x 100 ml), the extracts were combined and washed with 
water (5 x 100 ml), brine (lOO ml), dried (MgS04) and evaporated under reduced pressure to 
give a dark red oil. Acetic acid (80%, 300 ml) and was added and the mixture stirred at 75°C. 
Zinc dust (25.8 g, 395 mmol) was added over a 1 h period and the mixture was then stirred at 
85°C for a further 2 h. The mixture was cooled, filtered, the filtrate was washed with diethy 
ether (400 ml) and the washings were combined with the filtrate and washed with satutated 
sodium hydrogen carbonate solution (4 x 200 ml), water (2 x 200 ml), brine (2 x 200 ml), 
dried (MgS04) and evaporated under reduced ptressure. Flash column chromatography (light 
petroleum: dichloromethane elution) gave the title compound [287] (5.03g, 56%) as a gun 
metal solid; m.p. 94-95°C; (Found M+, 194.9697. C8H6NBr requires M, 194.9684); vmax 
(CHCI3)1cm- 1 1522, 1423, 1215 and 929; OH (250 MHz; CDCI3) 6.54 (lH, m), 7.21 (2H, 
m), 7.49 (lH, m) and 8.16 (lH, br, NH); OC (62.5 MHz; CDCI3) 102.73, 114.04, 115.40, 
121.98, 123.12, 123.87, 125.0 and 126.73; mlz 195 (M+, 100%) 116 (90),89 (45), 63 (20), 
51 (30) and 31 (20). 
tert-Butyl 6-bromoindole-l-carboxylate [288J 
6-Bromoindole [287] (2 g, 10.25 mmol), di-tert-butyl dicarbonate (2.46 g, 11.28 mmol), 
DMAP (122 mg, I mmol) and acetonitrile (28 ml) were stirred at rt for I h. Saturated sodium 
hydrogen carbonate solution (20 ml) was added and the mixture stirred for a further 30 min. 
The mixture was extracted with diethyl ether (2 x 20 ml) the extracts were combined washed 
with brine (2 x 20 ml), dried (MgS04) and evaporated under reduced pressure. Flash column 
chromatography (light petroleum: diethyl ether elution) gave the title compound [288] (2.34 
g, 77%) as a colourless solid; m.p. 60-62°C; (Found M+, 295.0208. C13HI4NBr02 requires 
M, 295.0216); Vmax (CHCI3)/cm- 1 1732, 1434, 1377, 1215, and 761; OH (250 MHz; 
CDCI3) 1.69 (9H, s, (CH3)3), 6.54 OH, d, J 3.7 Hz), 7.33 OH, dd, J 8.3 1.7 Hz), 7.41 
180 
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(IH, d, J 8.3 Hz), 7.56 (lH, d, J 3.7) and 8.37 (lH, br); Sc (62.5 MHz; CDCI3) 28.06, 
84.91,106.97,118.01,118.31,121.88,125.79, 126.26, 129.10, 135.87 and 159.42; mlz 
295 (M+, 5%) 239 (15), 195 (20),115 (10), 57 (100), 41 (40) and 29 (20). 
Br 
tert-Butyl 6-bromo-3-carboxamideindole-l-carboxylate [289J 
CSI (2.24 g, 15.84 mmol) was added dropwise to a solution of tert-Butyl 6-bromoindole-l-
carboxylate [288] (2.33 g, 7.92 mmol), and acetonitrile (18 ml) over a to min period at ODC. 
The mixture was warmed to rt and stirred for I h. A solution of acetone (10 m!) and water (2 
ml) was added and the solution was rendered alkaline by the addition of potassium hydroxide 
(10% solution). The mixture was extracted with dichloromethane (3 x 20 ml) and the extracts 
were combined and washed with brine (20 ml), dried (MgS04) and evaporated under reduced 
pressure. Flash column chromatography (light petroleum: dichloromethane elution) gave the 
title compound [289] (1.69 g, 64%) as a colourless solid; m.p. 149-15I DC; (Found M+, 
338.0246. CI4HI5N2Br03 requires M, 338.0266); Vmax (CHCI3)/cm-1 1743,1667,1371, 
1215 and 759; SH (250 MHz; CDCI3) 1.68 (9H, s, (CH3)3), 5.93 (2H, br, NH2), 7.42 (lH, 
dd, J 8.5 1.6 Hz), 7.97 (IH, d, J 8.5 Hz), 8.04 (lH, s) and 8.36 (lH, d, J 1.5 Hz); Sc (62.5 
MHz; CDCI3) 27.73 ((CH3)3), 85.55 (C(CH3)3), 114.92, 118.16, 118.78, 122.43, 126.36, 
126.85, 128.55, 136.20, 148.33 and 166.21; mlz 338 (M+, 5%) 282 (10), 222 (30), 114 
(15), 57 (80), 44 (90) and 28 (100). 
Br 
tert-Butyl 3-thiocarboxamideindole-l-carboxylate [290J 
tert-Butyl 6-bromo-3-carboxamideindole-l-carboxylate [289] (300 mg, 0.88 mmol), 
Lawesson's reagent [99] (179 mg, 0.44 mmol) and benzene (5 ml) were heated at reflux for I 
h. The reaction mixture was cooled and evaporated under reduced pressure to give a yellow 
solid. Flash column chromatography (dichloromethane : diethyl ether elution) gave the title 
compound [290] (153 mg, 49%) as a yellow solid; m.p. 150-151 DC; (Found M+, 354.0013. 
CI4HI5BrN02S requires M, 354.0038); IiH (250 MHz; CDCI3) 1.69 (9H, s, (CH3)3), 7.24 
181 
(2H, br, NH2), 7.46 (lH, dd, J 8.6 1.7 Hz), 8.05 (lH, d, J 8.6 Hz), 8.16 (lH, s) and 8.42 
(lH, d, J 1.7 Hz); m/z 354 (M+, 50%) 220 (80). 155 (30). 141 (45), 114 (45) and 41 (100). 
Br 
tert-Butyl 6-bromo-3-thiocarboximidateindole-1-carboxylate [291J 
tert-Butyl 6-bromo-3-thiocarboxamideindole-l-carboxylate [290] (246 mg, .7 mmol), methyl 
iodide (0.88 g, 6.2 mmol) and dichloromethane (2 ml) were stirred at rt for 48 h under a 
nitrogen atmosphere. Dichloromethane (10 ml) was addded and the mixture was washed with 
a saturated solution of sodium hydrogen carbonate (2 x 10 ml), brine (2 x 10 ml), dried 
(MgS04) and evaporated under reduced pressure to give a yellow gum (237 mg, 91 % crude) 
which was used in the next step without further purification. CARE the compound is 
extremely SMELLY, the reaction must be carried out in an efficient fume cupboard; (Found 
M+, 368.0199. CI5H17BrN202S requires M, 368.0195); vmax (CHCl3)1cm- 1 1742,1653, 
1371, 1215 and 756; OH (250 MHz; CDCI3) 1.68 (9H, s, (CH3)3), 2.43 (3H, s, SCH3), 
7.40 (lH, dd. J 8.4 1.7 Hz), 8.01 (lH, S), 8.09 (lH, d, J 8.5 Hz) and 8.35 (lH, d, J 1.6 
Hz); OC (62.5 MHz; CDCI3) 11.42 (SCH3), 27.21 «CH3)3), 85.11 (C(CH3)3), 117.91, 
119.67,121.61,122.24,124.54.126.33,127.21,128.28, 145.31 and 149.26; m/z 368 (M+, 
5%) 222 (30),141 (20), 114 (20), 57 (100) and 41 (30). 
HCI.HN 
Br 
tert-Butyl 6-bromo-3-carbamidinyindole-1-carboxylate hydrochloride [292J 
lert-Butyl 6-bromo-3-thiocarboximidateindole-I-carboxylate [291] (239 mg, 0.65 mmol), 
ammonium chloride (40 mg, 0.7 mmol) and methanol (5 ml) were heated under reflux for 3 h. 
CARE, during the reaction methyl mercaptam is liberated and so a potassium permanganate 
bubbler was attached to the reflux condenser. The reaction mixture was cooled and ethyl 
acetate (100 ml) was added the mixture was washed with brine (2 x 30 ml), dried (MgS04) and 
evaporated under reduced pressure to give a pale brown solid. Recrystallisation (ethanol) gave 
the title compound [292] (109 g, 45%) as a pale yellow solid; m.p. >300°C; (Found M+, 
372.9832. CI4H17BrCIN302 requires M, 373.0193); vmax (CHCI3)/cm- 1 1746, 1715, 
182 
1428, 1372, 1215 and 759; m/z 368 (M+, 5%) 297 (10), 253 (30), 224 (30), 114 (10), 57 
(100) and 28 (40). 
o 
tert-Butyl 3-acetylindole-l-carboxylate [295J 
3-Acetylindole [294] (l g, 6.3 mmol), di-tert-butyl dicarbonate (1.5 g, 6.9 mmol), DMAP (75 
mg, 0.61 mmol) and acetonitrile (17 ml) were stirred at rt for I h. Saturated sodium hydrogen 
carbonate solution (20 ml) was added and the mixture stirred for a further 30 min. The mixture 
was extracted with diethyl ether (2 x 40 ml) the extracts were combined washed with brine (2 x 
20 ml), dried (MgS04) and evaporated under reduced pressure. Flash column chromatography 
(light petroleum: diethyl ether elution) gave the title compound [295] (1.47 g, 90%) as a 
colourless solid; m.p. 148-149°C; (Found M+, 259.1201. CI5H17N03 requires M, 
259.1208); Vmax (CHCI3)!cm- 1 1740,1664,1546,1450,1371,1215 and 755; OH (250 
MHz; CDCI3) 1.72 (9H, s, (CH3)3), 2.57 (3H, s, CH3), 7.36 (2H, m), 8.10 (lH, m), 8.23 
(lH, s) and 8.37 (IH, m); 8c (62.5 MHz; CDCI3) 27.83 «CH3)3), 28.03, (CH3) 85.31 
(C(CH3)3), 114.86, 120.05, 122.62, 124.28, 125.39, 127.41, 132.31, 135.73, 149.39 and 
196.21; m/z 259 (M+, 5%) 217 (5), 144 (l0), 57 (l0), 41 (lOO) and 28 (20). 
o Br 
tert-Butyl 3-(2-bromoacetyl)indole-l-carboxylate [296J 
tert-Butyl 3-acetylindole-I-carboxylate [295] (500 mg, 1.93 mmol), chloroform (2 ml) and 
ethyl acetate (2 ml) were stirred at 75°C under a nitrogen atmosphere for 20 min. 
Copper(II)bromide (800 mg, 3.7 mmol) was added and the mixture was stirred at 75°C for a 
further 3 h. The mixture was cooled and filtered, washed with ethyl acetate (30 ml), the filtrate 
and washings were combined washed with brine (20 ml), dried (MgS04) and evaporated under 
reduced pressure. Flash column chromatography (light petroleum: dichloromethane elution) 
gave the title compound [296] (293 mg, 45%) as a pale yelow solid; m.p. 142-143°C; (Found 
M+, 337.0302. CI5H 16BrN03 requires M, 337.0314); vmax (CHCI3)/cm- 1 1743, 1665, 
183 
1543, 1450, 1372, 1215 and 756; OH (250 MHz; CDCI3) 1.73 (9H, s, (CH3)3), 4.37 (2H, s, 
CH2Br), 7.39 (2H, m), 8.12 (lH, m), 8.34 (lH, s) and 8.36 (lH, m); OC (62.5 MHz; 
CDCI3) 28.01 «CH3)3), 31.54, (CH2Br) 85.83 (C(CH3)3), 114.98, 116.31, 122.45, 
122.52, 124.59, 125.80, 132.30, 132.81, 159.0 and 186.37; m/z 337 (M+, 5%) 237 (10), 
144 (80),89 (10), 57 (lOO), 41 (50) and 29 (20). 
Br 
tert-Butyl 3-acetyl-6-bromoindole-l-carboxylate [298] 
N,N-Dimethylacetamide (0.8 ml, 8.4 mmol) was added dropwise to solution of phosphorous 
oxychloride (0.78 ml, 8.4 mmol) and chloroform (10 ml) maintaining the temperature below 
100e. The mixture was stirred for 10 min then a solution of 6-bromoindole [287] (500 mg, 
2.56 mmol) in chloroform (10 ml) was added dropwise over a 30 min period, maintaining the 
temperature below 10°C. The mixture was then stirred at reflux for 3h. The mixture was 
cooled and potassium hydroxide (40% solution, 50 ml) was added. The mixture was extracted 
with dichloromethane (3 x 50 ml), the extracts were combined and washed with brine (50 ml), 
dried (MgS04) and evaporated under reduced pressure to give a dark brown solid. A solution 
of di-tert-butyl dicarbonate (408 mg, 2.8 mmol), OMAP (30 mg, 0.24 mmol) and acetonitrile 
(10 ml) was added and the mixture stirred at rt for I h. Saturated sodium hydrogen carbonate 
solution (20 ml) was added and the mixture stirred for a further 30 min. The mixture was 
extracted with diethyl ether (2 x 40 ml) the extracts were combined washed with brine (2 x 20 
m\), dried (MgS04) and evaporated under reduced pressure. Flash column chromatography 
(light petroleum: diethyl ether elution) gave the title compound [298] (345 mg, 40%) as a 
colourless solid; m.p. 150-152°C; (Found M+, 337.0063. C15HI6BrN03 requires M, 
337.0314); vmax (CHCI3)/cm- 1 1745,1668,1432,1215 and 756; OH (250 MHz; COCI3) 
1.72 (9H, s, (CH3)3), 2.56 (3H, s, CH3), 7.46 (lH, dd, J 8.5 1.8 Hz), 8.17 (lH, s), 8.24 
(lH, d, J 8.5 Hz) and 8.36 (lH, d, J 1.8 Hz); OC (62.5 MHz; COCI3) 27.56 (CH3), 27.98 
«CH3)3), 86.01 (C(CH3)3), 118.14, 119.31, 120.93, 123.81, 126.50, 127.59, 132.34, 
142.86, 159.38 and 182.76; m/z 337 (M+, 5%) 203 (20), 159 (30), 144 (60), 57 (100), 41 
(30) and 28 (90). 
184 
o Br 
Br 
tert-Butyl 6-bromo-3-(2-bromoacetyl)indole-l-carboxylate [299] 
tert-Butyl 6-bromo-3-acetylindole-I-carboxylate [298] (254 mg, 0.75 mmol), chloroform (2 
ml) and ethyl acetate (2 m!) were stirred at 75°C under a nitrogen atmosphere for 20 min. 
Copper(II)bromide (311 mg, 1.4 mmol) was added and the mixture was stirred at 75°C for a 
further 3 h. The mixture was cooled and filtered, washed with ethyl acetate (30 m!), the filtrate 
and washings were combined washed with brine (20 ml), dried (MgS04) and evaporated under 
reduced pressure. Flash column chromatography (light petroleum: dichloromethane elution) 
gave the title compound [299] (140 mg, 45%) as a pale yelow solid; m.p. 180-181°C; (Found 
M+, 414.9442. C15H15BQN03 requires M, 414.9442); vmax (CHCI3)1cm- l 1742, 1666, 
1543, 1371, 1215 and 759; OH (250 MHz; CDCI3) 1.73 (9H, s, (CH3)3), 4.33 (2H, s, 
CH2Br), 7.45 (lH, dd, J 8.51.7 Hz), 8.17 (lH, d, J 8.5 Hz), 8.26 (lH, s) and 8.31 (lH, d, 
J 1.7 Hz); OC (62.5 MHz; CDCI3) 28.43 «CH3)3), 31.79 (CH2Br), 86.92 (C(CH3)3), 
117.29, 118.69, 120.11, 124.10, 126.52, 132.82, 136.43, 137.94, 148.75 and 187.36; m/z 
416 (M+, 5%) 317 (10), 224 (20),155 (20), 113 (20), 57 (lOO), 41 (35) and 28 (80). 
2-( I-tert-Butyl(indol-3-yl )carboxylate )-4( 5 )-( 1-(H)-indol-3-yl)imidazole [300] 
tert-Butyl 3-carbamidinylindole-I-carboxylate hydrochloride [284] (92 mg, 0.31 mmol), 3-
bromoacetyindole [123] (75 mg, 0.31 mmo!), potassium carbonate (43 mg, 0.31 mmol) and 
acetonitrile (10 ml) were heated under reflux for 7 h. The reaction mixture was cooled and and 
water (10 ml) added. The mixture was extracted with dichloromethane (2 x 10 ml), the extracts 
were combined, washed with brine (10 ml), dried (MgS04) and evaporated under reduced 
pressure. Flash column chromatography (light petroleum: diethyl ether elution) gave the title 
compound [300] (51 mg, 41 %) as an amber solid; m.p. 112-114°C; (Found M+, 398.1734. 
185 
C24H22N402 requires M, 398.1743); vmax (CHCI3)/cm- 1 2330 (br), 1741, 1427, 1353, 
1215 and 756; oH (250 MHz; CDCI3) 1.55 (9H, s, QCH3)3), 7.17 (4H, m), 7.23 (3H, m), 
7.46 (lH, br, NH), 7.76 (lH, d, J 8.5 Hz), 7.92 (lH, s), 8.09 (lH, dd, J 8.5 2.3 Hz) and 
8.68 (lH, br, NH); OC (62.5 MHz; CDCI3) 27.95, 84.13, 108.42, 111.43, 111.66, 115.04, 
119.63, 120.06, 120.82, 121.85, 122.21, 123.16, 123.56, 124.85, 125.11, 125.17, 127.55, 
135.19, 136.34, 141.15, 149.40 and 161.32; m/z 398 (M+, >5%) 217 (10), 186 (10),155 
(15), 113 (15),70 (10), 56 (50) and 41 (100). 
Br 
2-( 1-tert-Butyl( -6-bromoindol-3-yl )carboxylate )-4( 5)- (1- (H)-indol-3-
yl)imidazole [301] 
tert-Butyl 6-bromo-3-carbamidinyindole-l-carboxylate hydrochloride [292] (56 mg, 0.15 
mmol), 3-bromoacetylindole [123] (36 mg, 0.15 mmol), potassium carbonate (21 mg,0.15 
mmol) and acetonitrile (5 ml) were heated under reflux for 14 h. The reaction mixture was 
cooled and water (10 ml) added. The mixture was extracted with dichloromethane (2 x 10 ml), 
the extracts were combined, washed with brine (10 ml), dried (MgS04) and evaporated under 
reduced pressure. Flash column chromatography (light petroleum: diethyl ether elution) gave 
the title compound [301] (24 mg, 34%) as a pale brown solid, which turned dark brown over 
a few days; m.p. 145-147°C; (Found M+, 478.0823. C24H2181 BrN404 requires M, 
478.0828,476.0848. C24H21 79BrN402 requires 478.0828); vmax (CHCI3)/cm- 1 3230 (br), 
1739,1427,1371,1310,1215 and 756; OH (250 MHz; CDCI3) 1.59 (9H, s, QCH3)3), 7.21 
(4H, m), 7.43 (lH, s), 4.46 (lH, d, J 3.4 Hz), 7.58 (lH, br, NH), 7.87 (lH, s), 7.92 (lH, 
dd, J 8.53.2 Hz), 8.09 (lH, d, J 8.5 Hz), 8.33 (lH, s) and 8.51 (lH, br, NH); m/z 478 
(M+(8IBr), >5%), 479 (M+c79Br), >5), 267 (20), 217 (20),186 (20),155 (40),113 (40), 70 
(25),51 (100) and 31 (60). 
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